

# **in vivo**

**International Journal of Experimental and  
Clinical Pathophysiology and Drug Research**

PRINT ISSN: 0258-851X – ONLINE ISSN: 1791-7549

**Volume 31  
2017**

**INDEX**

## Editorial Board

- I. ABRAHAM**, *The HOPE Center, University of Arizona, Tucson, AZ, USA*
- N.J. AGNANTIS**, *Department of Pathology, University of Ioannina, Ioannina, Greece*
- D. ANDERSON**, *Department of Biomedical Sciences, University of Bradford, Bradford, West Yorkshire, UK*
- V. BARAK**, *Department of Oncology, Hadassah University Hospital, Jerusalem, Israel*
- M.H. BARCELLOS-HOFF**, *Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA*
- K. BEIER**, *Department of Histology, University of Basel, Basel, Switzerland*
- M. BERGQVIST**, *Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala, Sweden*
- R. BJERKVIG**, *Norlux Neuro-Oncology, Department of Biomedicine, University of Bergen, Bergen, Norway*
- W. BOWNE**, *Department of Surgery, Drexel University College of Medicine, Philadelphia, PA, USA*
- M. CARAGLIA**, *Department of Experimental Oncology, National Institute of Tumours Fondazione G. Pascale, Naples, Italy*
- P. CHANDRA**, *Department of Molecular Biology, Frankfurt University, Frankfurt am Main, Germany*
- J.-G. CHUNG**, *Department of Medicine, China Medical College, Taichung, Taiwan, ROC*
- L.A. COHEN**, *Northhampton, MA, USA*
- A.I. CONSTANTINOU**, *Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus*
- T. DALIANIS**, *Department of Pathology-Oncology, Karolinska Institute, Stockholm, Sweden*
- G. DELICONSTANTINOS**, *Department of Experimental Physiology, University of Athens Medical School, Athens, Greece*
- D.T. DENHARDT**, *Division of Life Sciences, Rutgers University, Bridgewater, NJ, USA*
- W. DEN OTTER**, *VUMC - Department of Urology, Amsterdam, The Netherlands*
- K. DE MEIRLEIR**, *Department of Human Physiology and Medicine, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium*
- L. DE RIDDER**, *Department of Anatomy, Embryology and Histology, University of Ghent, Ghent, Belgium*
- E.P. DIAMANDIS**, *Department of Pathology and Laboratory Medicine, University of Toronto, Toronto, Ontario, Canada*
- J.M. DRAKE**, *Division of Medical Oncology, RBHS-Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA*
- T. EFFERTH**, *Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Germany*
- W. ENGSTRÖM**, *Department of Molecular Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden*
- M. ESKELINEN**, *Department of Surgery, University Hospital of Kuopio, Kuopio, Finland*
- J.A. FERNANDEZ-POL**, *Metalloproteomics, LLC, Chesterfield, MO, USA*
- G. FIORENTINI**, *UOC Oncologia, Azienda Ospedaliera Marche Nord, Pesaro, Italy*
- P.B. FISHER**, *Virginia Commonwealth University, School of Medicine, Richmond, VA, USA*
- I. FREITAS**, *Dipartimento di Biologia Animale, University of Pavia, Pavia, Italy*
- M. FRIEDRICH**, *Department of Obstetrics and Gynecology, Klinikum Krefeld, Krefeld, Germany*
- R.E. FRIEDRICH**, *Department of Oral and Maxillofacial Surgery, Eppendorf University Hospital, Hamburg, Germany*
- R. GANAPATHI**, *Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA*
- G. GITSCHE**, *Department of Gynecology and Obstetrics, University of Freiburg Medical Center, Freiburg, Germany*
- V. GORGOULIS**, *Department of Histology-Embryology, Medical School, University of Athens, Greece*
- J.S. GREENBERGER**, *Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA*
- J.W. GREINER**, *National Cancer Institute, NIH, Bethesda, MD, USA*
- D.S. GRIDLEY**, *Department of Radiation Medicine, Radiation Research Laboratories, Loma Linda University and Medical Center, Loma Linda, CA, USA*
- C.J. GRUBBS**, *Department of Nutrition Sciences, University of Alabama, Birmingham, AL, USA*
- F. GUADAGNI**, *IRCCS San Raffaele, Rome, Italy*

- J. HAU**, Department of Comparative Medicine, University of Copenhagen, Denmark
- M. HAUER-JENSEN**, Arkansas Cancer Research Center, University of Arkansas Medical Sciences, Little Rock, AR, USA
- K. HIBI**, Tokai Central Hospital, Kakamigahara, Gifu, Japan
- S.A. IMAM**, Huntington Medical Research Institutes, Gene Therapy Program, Pasadena, CA, USA
- K.S. JEONG**, Department of Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, S. Korea
- M. JHANWAR-UNIYAL**, Department of Neurosurgery, New York Medical College, Valhalla, NY, USA
- I. KISS**, Institute of Preventive Medicine, Medical School, University of Pécs, Pécs, Hungary
- E. KONDO**, Division of Molecular and Cellular Pathology Niigata University Graduate School of Medical and Dental Sciences, Chuo-ku, Niigata, Japan
- M. KOUTSILIERIS**, Department of Experimental Physiology, University of Athens Medical School, Athens, Greece
- G.R.F. KRUEGER**, Department of Anatomy II, Center for Anatomy, The University of Cologne Medical School, Cologne, Germany
- B. KRUSLIN**, Department of Pathology, Ljudevit Jurak University, Sestre milosrdnice University Hospital, Zagreb, Croatia
- N. KYPRIANOU**, Department of Urology, University of Kentucky, Lexington, KY, USA
- S.A. LAMPRECHT**, Division of Clinical Biochemistry, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel
- G. LANDBERG**, Department of Laboratory Medicine, Lund University, Lund, Sweden
- I. LELONG-REBEL**, Lab. de Biophotonique et Pharmacologie, Université de Strasbourg, Illkirch, France
- J. LEROY**, IRCAD, University of Strasbourg, France
- W. LICHTENEGGER**, Charité Campus Virchow-Klinikum, Berlin, Germany
- J. LYKKESFELDT**, Department of Veterinary Disease Biology, University of Copenhagen, Frederiksberg, Denmark
- P. MADARNAS**, Department of Pathology, University of Sherbrooke, Québec, Canada
- H. MAEDA**, BioDynamics Research Foundation, Kumamoto, Japan
- M. MAREEL**, Laboratory of Experimental Cancerology, State University, Ghent, Belgium
- L. MARGOLIS**, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA
- G. MARTORANA**, Policlinico S. Orsola Malpighi, University of Bologna, Bologna, Italy
- J. MOLNÁR**, Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, Szeged, Hungary
- S.L. MOOBERRY**, Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
- N. MOTOHASHI**, Department of Medicinal Chemistry, Meiji Pharmaceutical University, Tokyo, Japan
- R.M. NAGLER**, Department of Oral and Maxillofacial Surgery, Rambam Medical Center, Haifa, Israel
- S. NAKANO**, Graduate School of Health and Nutritional Sciences, Nakamura Gakuen University, Fukuoka, Japan
- M. NAKASHIMA**, Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan
- R. NARAYANAN**, Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
- M.B. NICHOLL**, South Texas Veterans Health Care System, San Antonio, TX, USA
- K. NILSSON**, Tumor Biology Laboratory, Department of Pathology, University Hospital, Uppsala, Sweden
- K.R. NORUM**, Institute for Nutrition Research, University of Oslo, Oslo, Norway
- K. OGAWA**, Department of Surgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
- M. PAGÉ**, Département de Biologie, Division de Biochimie, Université Laval, Québec, Canada
- C. POLYCHRONAKOS**, Department of Paediatrics and Human Genetics, McGill University Health Centre Research Institute, Montreal, QC, Canada
- M.-F. POUPON**, Institut Curie, Section de Recherche, Paris, France
- D. RADES**, Department of Radiation Oncology, University of Lübeck, Lübeck, Germany

- F.M. ROBERTSON**, *Virginia Commonwealth University, Clinical Research Services, Center for Clinical and Translational Research, Richmond Academy of Medicine, Richmond, VA, USA*
- D. RUBELLO**, *Department of Nuclear Medicine, PET Unit, S. Maria della Misericordia Hospital, IOV, Rovigo, Italy*
- C.A. RUBIO**, *Karolinska Institute, Pathology Research Laboratory, Stockholm, Sweden*
- G.R. RUTTEMAN**, *Department of Clinical Sciences of Companion Animals, University of Utrecht, Utrecht, The Netherlands*
- H. SAKAGAMI**, *Department of Dental Pharmacology, Meikai University School of Dentistry, Saitama, Japan*
- G. SAVA**, *Institutes of Biological Research, Fondazione Cellerio-Onlus, Trieste, Italy*
- D. SCHIFFER**, *Neuro-bio-oncology Center, Policlinico di Monza Foundation, University of Turin, Vercelli, Italy*
- L.D. SHULTZ**, *The Jackson Laboratory, Bar Harbor, ME, USA*
- G. SICA**, *Istituto di Istologia ed Embriologia, Universita Cattolica del Sacro Cuore, Roma, Italy*
- J.M. SIEGFRIED**, *Department of Pharmacology, MNPI Center, University of Minnesota, Minneapolis, MN, USA*
- J. SLANSKY**, *Integrated Department of Immunology, School of Medicine, University of Colorado Denver and National Jewish Health, Denver, CO, USA*
- R.M. SNAPKA**, *Department of Radiology, The Ohio State University, Columbus, OH, USA*
- G.-I. SOMA**, *Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan*
- P.P. SORDILLO**, *Department of Medical Oncology and Hematology, Lenox Hill Hospital, New York, NY, USA*
- T.A. SPRINGER**, *Department of Pathology, Harvard Medical School, Boston, MA, USA*
- D.D. SPYROPOULOS**, *Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA*
- K. SYRJÄNEN**, *Biohit Healthcare Oyj, Helsinki, Finland*
- G.C. TORRE**, *Centro Ippocrate, Vico Cosmelli 4, Finale Ligure (SV), Italy*
- B. TRIBUKAIT**, *Department of Medical Radiobiology, Karolinska Hospital, Stockholm, Sweden*
- J. VADGAMA**, *Department of Internal Medicine, Charles E. Drew University of Medicine and Science, Los Angeles, CA, USA*
- J.K. VISHWANATHA**, *Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX, USA*
- W. WANG**, *Research Institute of Healthcare Science, University of Wolverhampton, Wolverhampton, UK*
- N. WATANABE**, *Department of Clinical Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan*
- W. WEBER**, *Clinical Cancer Etiology Unit, Basel, Switzerland*
- L.M. WEINER**, *Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA*
- J.A. WERNER**, *Department of Otolaryngology, Head and Neck Surgery, Marburg, Germany*
- S. YLÄ-HERTTUALA**, *Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, Finland*
- H. YOSHIDA**, *Department of Pathology, Kagoshima University, Kagoshima, Japan*

## Acknowledgements

The following Organisations supported many of the works published in IN VIVO, Volume 31, 2017.

- A. Alfred Taubman Medical Research Institute, Ann Arbor, MI, U.S.A.
- Aarhus University Hospital, European Neuroendocrine Tumor Society (ENETS) Centre of Excellence, Aarhus, Denmark
- Animal Facility, University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, PA, U.S.A.
- Assisted Reproduction Unit, Attikon University Hospital, Athens, Greece
- Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
- Bezmialem Vakif University, Istanbul, Turkey
- Bildungsministerium für Bildung und Forschung (BMBF), Berlin, Germany
- Bio-industry Technology Development Program, Korea Institute of Planning & Evaluation for Technology in Food, Agriculture, Forestry & Fisheries, Anyang, Republic of Korea
- Bio-oriented Technology Research Advancement Institution (BRAIN), National Agriculture and Food Research Organization (NARO), Japan
- BK21 Program for Veterinary Science, Seoul National University, Seoul, Republic of Korea
- Bower Foundation, Ridgeland, MS, U.S.A.
- Breast Cancer Action Fund, London, U.K.
- Center for Molecular Imaging and the Tumor Imaging Core, Department of Radiology, University of Michigan, Ann Arbor, MI, U.S.A.
- Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.
- Cheng Hsin General Hospital, Taipei, Taiwan, R.O.C.
- Chosun University, Gwangju, Republic of Korea
- Chugai Pharmaceutical Co., Ltd, Tokyo, Japan
- Clinical Medicine Research Institute, Chosun University Hospital, Gwangju, Republic of Korea
- Clinical Trial and Research Center of Excellence, Ministry of Health and Welfare, Taipei, Taiwan, R.O.C.
- Council for Science, Technology and Innovation (CSTI), Tokyo, Japan
- Cross-ministerial Strategic Innovation Promotion Program (SIP), Japan
- Department of Aging Regulation, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
- Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
- Department of Hematology, KEM Hospital, Mumbai, India
- Department of Histology-Embryology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
- Department of Molecular Target Medicine Screening, Aichi Medical University School of Medicine, Aichi, Japan
- Department of Pathology, University Clinical Centre Maribor, Maribor, Slovenia
- Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS, U.S.A.
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Berlin, Germany
- Diabetic Nephropathy Treatment Study Group, Japan
- Edanz Group, Tokyo, Japan
- Editage, Tokyo, Japan
- Enago, Tokyo, Japan
- Eskisehir Osmangazi University, Eskisehir, Turkey
- Faculty Hospital Plzen, Pilsen, Czech Republic
- Fanconi Anemia Research Fund, Eugene, OR, U.S.A.
- Frankel Cardiovascular Center, Ann Arbor, MI, U.S.A.
- Fundaçao para a Ciéncia e a Tecnologia (FCT), Ministério da Ciéncia e Ensino Superior, Portugal
- Grants-in-Aid for Scientific Research (KAKENHI), Japan
- Society for the Promotion of Science, Tokyo, Japan
- Grants-in-Aid for Scientific Research, Ministry of Education, Culture, Sports, Science and Technology(MEXT) of Japan, Tokyo, Japan
- Hallym University, Chuncheon, Republic of Korea
- Hangzhou Health Science and Technology Fund, Zhejiang Province, P.R. China
- Harold Amos Medical Faculty Development Program, Indianapolis, IN, U.S.A.
- Hellenic Endocrine Society, Athens, Greece
- Hirosaki Chuo Hospital, Hirosaki, Japan
- Hirosaki University Graduate School of Medicine, Hirosaki, Japan
- Imamura Clinic, Kagoshima, Japan
- Indian Council of Medical Research, New Delhi, India
- Industrial Technology Innovation Program, Ministry of Trade, Industry & Energy, Sejong, Republic of Korea
- Ipsen, Paris, France
- Itsukaichi Naika Clinic, Itsukaichi, Japan

Japan Society for the Promotion of Science(JSPS), Tokyo, Japan	Research Council of Lithuania, Lithuania
Kanagawa Cancer Center, Yokohama, Japan	Research Grant for Young Researchers, Kitasato University, Tokyo, Japan
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, R.O.C.	Research Institute for Veterinary Science, Seoul National University, Seoul, Republic of Korea
Kensei Hospital, Tokyo, Japan	Research Project of Charles University, Prague, Czech Republic
Kitasato University Medical Center, Kitamoto, Japan	Rigshospitalet, Denmark
Latvia, Lithuania and Taiwan Cooperation Project	Robert Wood Johnson Foundation (RWJF), Princeton, NJ, U.S.A.
Maxwell International, Inc, Chiba, Japan	Saiseikai Nakatsu Hospital, Osaka, Japan
Medical Research Core Facilities Center, Office of Research & Development, China Medical University, Taichung, Taiwan, R.O.C.	Scientific Communication srl., Naples, Italy
Ministry of Human Capacities, Budapest, Hungary	Section of Pediatric Surgery, University of Michigan, Ann Arbor, MI, U.S.A.
Ministry of Science and Higher Education, Warsaw, Poland	Shimizu Clinic, Japan
Ministry of Science and ICT (MSIT), Gwacheon, Republic of Korea	Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, R.O.C.
Ministry of Science and Technology (MOST), Taipei, Taiwan, R.O.C.	Solid Tumor Oncology Program, University of Michigan C.S. Mott Children's Hospital, Ann Arbor, MI, U.S.A.
National Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia	State Serum Institute, Denmark
National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, U.S.A.	Stem Cell Research Center, K-STEMCELL Co., Ltd, Seoul, Republic of Korea
National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, U.S.A.	Stiftungsfonds BIOX, Germany
National Sustainability Program I (NPU I), Ministry of Education Youth and Sports of the Czech Republic, Prague, Czech Republic	Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
Next-Generation BioGreen 21 Program, Rural Development Administration, Republic of Korea	Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
Novartis International AG, Basel, Switzerland	Taiwan Ministry of Health and Welfare (MOHW), Taipei, Taiwan, R.O.C.
Novo Nordic Foundation, Bagsvaerd, Denmark	Takeda Science Foundation, Japan
Physiology Phenotyping Core (PPC), University of Michigan, Ann Arbor, MI, U.S.A.	Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan, R.O.C.
Postdoc Fellowships of Excellence – Siemens, State Scholarships Foundation (IKY), Athens, Greece	THORAX Research Center for Intensive and Emergency Thoracic Medicine, Athens, Greece
Programa Operacional Competitividade e Internacionalização (POCI), COMPETE2020, Lisboa, Portugal	Tissue-bank of China Medical University Hospital, Taichung, Taiwan, R.O.C.
Programa Operacional Factores de Competitividade and the European Union (FEDER), COMPETE2020, Lisboa, Portugal	Tsugaru General Hospital, Goshogawara, Japan
Research Agency, Republic of Slovenia	Tumour and Angiogenesis Research Group, Greece
Research Council (CNCS)- Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI), Romania	University of Pécs, Pécs, Hungary
	Vevo 2100 Imaging System, FUJIFILM VisualSonics, Inc., Toronto, ON, Canada
	Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
	Wilhelm-Sander-Foundation, Munich, Germany

## Contents, Volume 31, 2017

### **Number 1**

#### *Reviews*

- Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies. A. NOGUEIRA, M.J. PIRES, P.A. OLIVEIRA (*Vila Real; Bragança, Portugal*) ..... 1

- Prevalence of *EGFR* Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review. C. PERISANIDIS (*Vienna, Austria*) ..... 23

- Clinical Factors Associated with Treatment Outcomes following Whole-brain Irradiation in Patients with Prostate Cancer. L. DZIGGEL, S.E. SCHILD, T. VENINGA, A. BAJROVIC, D. RADES (*Lübeck; Hamburg, Germany; Scottsdale, AZ, USA; Tilburg, the Netherlands*) ..... 35

#### *Experimental Studies*

- Effectiveness of Analogs of the GS-Nitroxide, JP4-039, as Total Body Irradiation Mitigators. M.W. EPPERLY, J.R. SACHER, T. KRAINZ, X. ZHANG, P. WIPF, M. LIANG, R. FISHER, S. LI, H. WANG, J.S. GREENBERGER (*Pittsburgh, PA, USA*) ..... 39

- Active and Passive Immunization Against *Staphylococcus aureus* Periprosthetic Osteomyelitis in Rats. N.H. SØE, N.V. JENSEN, A.L. JENSEN, J. KOCH, S.S. POULSEN, G.B. PIER, H.K. JOHANSEN (*Hellerup; Copenhagen; Hørsholm, Denmark; Boston, MA, USA*) ..... 45

- Gene Expression Analysis of Cultured Rat-Endothelial Cells after Nd:YAG Laser Irradiation by Affymetrix GeneChip Array. Y. MASUDA, S. YOKOSE, H. SAKAGAMI (*Saitama, Japan*) ..... 51

- Wound Healing Delay in the ZDSD Rat. M.A. SUCKOW, T.A. GOBBETT, R.G. PETERSON (*St. Paul, MN; Indianapolis, IN, USA*) ..... 55

- Pulsed Electromagnetic Field Stimulation Promotes Anti-cell Proliferative Activity in Doxorubicin-treated Mouse Osteosarcoma Cells. Y. MURAMATSU, T. MATSUI, M. DEIE, K. SATO (*Aichi, Japan*) ..... 61

- Influence of Periostin on Synoviocytes in Knee Osteoarthritis. Y. TAJIKA, T. MOUE, S. ISHIKAWA, K. ASANO, T. OKUMO, H. TAKAGI, T. HISAMITSU (*Tokyo; Kanagawa, Japan*) ..... 69

- Influence of IL13 on Periostin Secretion by Synoviocytes in Osteoarthritis. T. MOUE, Y. TAJIKA, S. ISHIKAWA, Y. KANADA, T. OKUMO, K. ASANO, T. HISAMITSU (*Tokyo, Japan*) ..... 79

- Influence of Mechanical Force on Bone Matrix Proteins in Ovariectomised Mice and Osteoblast-like MC3T3-E1 Cells. M. ZHANG, S. ISHIKAWA, T. INAGAWA, H. IKEMOTO, S. GUO, M. SUNAGAWA, T. HISAMITSU (*Tokyo, Japan*) ..... 87

- Salivary Samples for the Diagnosis of *Pemphigus vulgaris* Using the BIOCHIP Approach: a Pilot Study. I. RUSSO, A. SAPONERI, A. MICHELOTTO, M. ALAIBAC (*Padua, Italy*) ..... 97

**Clinical Studies**

PET Probe-Guided Surgery in Patients with Breast Cancer: Proposal for a Methodological Approach. P. ORSARIA, A. CHIARAVALLOTTI, A. FIORENTINI, C. PISTOLESE, G. VANNI, A.V. GRANAI, D. VARVARAS, R. DANIELI, O. SCHILLACI, G. PETRELLA, O.C. BUONOMO ( <i>Rome, Italy</i> ) .....	101
Evaluation of Long-term Outcomes of Correction of Severe Blepharoptosis with Advancement of External <i>Levator</i> Muscle Complex: Descriptive Statistical Analysis of the Results. A. INNOCENTI, F. MORI, D. MELITA, E. DREASSI, F. CIANCIO, M. INNOCENTI ( <i>Florence; Foggia, Italy</i> ) .....	111
Outcomes After Radio(chemo)therapy for Non-Metastatic Bile Duct Cancer. L. BOLM, L. KAESMANN, T. BARTSCHT, S.E. SCHILD, D. RADES ( <i>Lübeck, Germany; Scottsdale, AZ, USA</i> ) .....	117
High-dose Parenteral Thiamine in Treatment of Wernicke's Encephalopathy: Case Series and Review of the Literature. A. NISHIMOTO, J. USERY, J.C. WINTON, J. TWILLA ( <i>Memphis, TN, USA</i> ) .....	121
Effects of Therapy with Maraviroc on the Carotid <i>Intima Media</i> Thickness in HIV-1/HCV Co-infected Patients. P. MAGGI, G. BRUNO, F. PERILLI, A. SARACINO, A. VOLPE, C. SANTORO, N. LADISA, G. ANGARANO ( <i>Bari, Italy</i> ) .....	125
Primary Vaginal Melanoma, A Rare and Aggressive Entity. A Case Report and Review of the Literature. E. KALAMPOKAS, T. KALAMPOKAS, C. DAMASKOS ( <i>Aberdeen, UK; Athens, Greece</i> ) .....	133
Clozapine Associated with Autoimmune Reaction, Fever and Low Level Cardiotoxicity – A Case Report. C. GERASIMOU, G.P. VITALI, G.D. VAVOUGIOS, C. PAPAGEORGIOU, A. DOUZENIS, S.I. KOKORIS, I. LIAPPAS, E. RIZOS ( <i>Athens; Larissa, Greece</i> ) .....	141
Effect of Calcitriol on FGF23 Level in Healthy Adults and its Dependence on Phosphate Level. E. GEORGIADOU, H. MARKETOU, G. TROVAS, I. DONTAS, N. PAPAIOANNOU, K. MAKRIS, A. GALANOS, A.G. PAPAVASSILIOU ( <i>Athens, Greece</i> ) .....	145
Outcomes in Patients with pT1-T2, pN0-N1 Breast Cancer After Conservative Surgery and Whole-breast Radiotherapy. M. TRIGNANI, C. DI CARLO, C. CEFALOGLI, M. NUZZO, L.A. URSINI, L. CARAVATTA, F. PERROTTI, M. DI NICOLA, A. PAMIO, D. GENOVESI ( <i>Chieti, Italy</i> ) .....	151

**Number 2***Experimental Studies*

Induction of TGF- $\beta$ by Irradiation or Chemotherapy in Fanconi Anemia (FA) Mouse Bone Marrow Is Modulated by Small Molecule Radiation Mitigators JP4-039 and MMS350. M.W. EPPERLY, B.-H. RHIEU, D. FRANICOLA, T. DIXON, S. CAO, X. ZHANG, D. SHIELDS, H. WANG, P. WIPF, J.S. GREENBERGER ( <i>Pittsburgh, PA, USA</i> ) .....	159
A Modified Method for Purifying Gallbladder Epithelial Cells Using Fluorescence-activated Cell Sorting. H. IMAMURA, T. ADACHI, A. KITASATO, Y. SAKAI, S. ONO, T. HARA, K. NATSUDA, A. SOYAMA, M. HIDAKA, M. TAKATSUKI, T. KUROKI, S. EGUCHI ( <i>Nagasaki; Omura, Japan</i> ) .....	169

Assessment of Radiobiological $\alpha/\beta$ Ratio in Lung Cancer and Fibroblast Cell Lines Using Viability Assays. I.V. KARAGOUNIS, E.K. SKOURTI, M.V. LIOUSIA, M.I. KOUKOURAKIS ( <i>Alexandroupolis, Greece</i> ) ...	175
Increased Numbers of CD4 $^{+}$ CD25 $^{+}$ and CD8 $^{+}$ CD25 $^{+}$ T-Cells in Peripheral Blood of Patients with Rheumatoid Arthritis with Parvovirus B19 Infection. M. NACIUTE, G. MACIUNAITE, D. MIELIAUSKAITE, R. RUGIENE, A. ZINKEVICIENE, M. MAURICAS, M. MUROVSKA, I. GIRKONTAITE ( <i>Vilnius, Lithuania; Riga, Latvia</i> ) .....	181
Chemopreventive Action by Ethanol-extracted Brazilian Green Propolis on Post-initiation Phase of Inflammation-associated Rat Colon Tumorigenesis. K. DOI, M. FUJIOKA, Y. SOKUZA, M. OHNISHI, M. GI, M. TAKESHITA, K. KUMADA, A. KAKEHASHI, H. WANIBUCHI ( <i>Osaka, Japan</i> ) .....	187
Bevacizumab Modulation of the Interaction Between the MCF-7 Cell Line and the Chick Embryo Chorioallantoic Membrane. Ș. COMŞA, R. POPESCU, Ș. AVRAM, R.A. CEAUŞU, A.M. CÎMPEAN, M. RAICA ( <i>Timișoara, Romania</i> ) .....	199
Effects of Caspase 9 Gene Polymorphism in Patients with Prostate Cancer. S.G. YILMAZ, F. YENCILEK, A. YILDIRIM, E. YENCILEK, T. ISBIR ( <i>Istanbul, Turkey</i> ) .....	205
The Effect of Geraniol on Liver Regeneration After Hepatectomy in Rats. M. CANBEK, M. UYANOGLU, S. CANBEK, E. CEYHAN, A. OZEN, B. DURMUS, O. TURGAK ( <i>Eskisehir, Turkey</i> ) ...	209
Centrosome Aberration Frequency and Disease Association in B-Acute Lymphoblastic Leukemia. L.S. KERKETTA, K. GHOSH, A. NADKARNI, M. MADKAIKAR, B.R. VUNDINTI ( <i>Mumbai, India</i> ).....	215
<b>Clinical Studies</b>	
Prevalence of Neurotropic Viruses in Malignant Glioma and Their Onco-Modulatory Potential. T. STROJNIK, D. DUH, T.T. LAH ( <i>Maribor; Ljubljana, Slovenia</i> ) .....	221
Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing IVF/ICSI: A Prospective Randomized Study. C. SIRISTATIDIS, G. SALAMALEKIS, K. DAFOPOULOS, G. BASIOS, P. VOGIATZI, N. PAPANTONIOU ( <i>Athens; Larissa, Greece</i> ) .....	231
Chemoradiation Including Paclitaxel for Locally Recurrent Muscle-invasive Bladder Cancer in Elderly Patients. L. KÄSMANN, L. MANIG, S. JANSSEN, D. RADES ( <i>Lübeck, Germany</i> ).....	239
Polymorphisms of Platelet Glycoprotein Receptors and Cell Adhesion Molecules in Fetuses with Fetal Growth Restriction and Their Mothers As Detected with Pyrosequencing. M. SIMOU, E. KOUSKOUNI, N. VITORATOS, E. ECONOMOU, G. CREATSAS ( <i>Athens, Greece</i> ) .....	243
Improvement of Perioperative Outcomes in Major Gynecological and Gynecologic-Oncological Surgery with Hemostatic Gelatin-Thrombin Matrix. R. WATROWSKI, C. JÄGER, J. FORSTER ( <i>Freiburg, Germany</i> ) .....	251

Lack of Definite Association of Vitamin D Deficiency with Diabetic Neuropathy. Investigation in Greek and in Bangladeshi Patients. T. ZAMBELIS, G. PAPADAKIS, P. KOKOTIS, V. VILLIOTOU, N. DOGKAS, N. KARANDREAS ( <i>Athens; Piraeus, Greece</i> ) .....	259
Sclerotherapy for Orbital Lymphangioma – Case Series and Literature Review. K.C. PATEL, G. KALANTZIS, N. EL-HINDY, B.Y. CHANG ( <i>Huddersfield; Leeds, UK</i> ) .....	263
<b>Number 3</b>	
<i>Reviews</i>	
The Use of Proteomics in Assisted Reproduction. I. KOSTERIA, A.K. ANAGNOSTOPOULOS, C. KANAKA-GANTENBEIN, G.P. CHROUSOS, G.T. TSANGARIS ( <i>Athens, Greece</i> ) .....	267
Factors Associated with Microalbuminuria Remission in Patients with Type 2 Diabetes: Importance of Early Intervention for Microalbuminuric Patients (TSUGARU STUDY). N. NAKAMURA, I. NARITA, T. FUJITA, R. MURAKAMI, M. SHIMADA, M. NAKAMURA, H. OSAWA, H. YAMABE, K. OKUMURA ( <i>Aomori, Japan</i> ) .....	285
Laparoscopic Splenectomy for Benign Hematological Disorders in Adults: A Systematic Review. D. MORIS, N. DIMITRIOU, J. GRINIATSOS ( <i>Columbus, OH, USA; Athens, Greece</i> ) .....	291
The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice. L. HOLUBEC, J. POLIVKA, L. LISNEROVA, T. KUBIKOVA, M. SAFANDA ( <i>Pilsen; Prague, Czech Republic</i> ) .....	303
Tailoring the ‘Perfect Fit’ for Renal Transplant Recipients with End-stage Polycystic Kidney Disease: Indications and Timing of Native Nephrectomy. C. ARGYROU, D. MORIS, S. VERNADAKIS ( <i>Athens, Greece; Columbus, OH, USA</i> ) .....	307
<i>Experimental Studies</i>	
Reduced Competitive Repopulation Capacity of Multipotential Hematopoietic Stem Cells in the Bone Marrow of Friend Virus-infected Fv2-resistant Mice. M.W. EPPERLY, X. ZHANG, R. FISHER, W. HOU, D. FRANICOLA, D. SHIELDS, M. QUICKEL, P. HANKEY-GIBLIN, H. WANG, J.S. GREENBERGER ( <i>Pittsburgh; University Park; Hershey, PA, USA</i> ) .....	313
Functional Roles of Netrin-1 in Osteoblast Differentiation. T. SATO, S. KOKABU, Y. ENOKI, N. HAYASHI, M. MATSUMOTO, M. NAKAHIRA, M. SUGASAWA, T. YODA ( <i>Saitama; Kitakyushu, Japan</i> ) .....	321
Automated Multichamber Time-lapse Videography for Long-term <i>In Vivo</i> Observation of Migrating Cells. H. BUHLER, R. ADAMIETZ, T. ABELN, D. DIAZ-CARBALLO, P. NGUEMGO-KOUAM, T. HERO, I.A. ADAMIETZ ( <i>Herne; Bochum, Germany</i> ) .....	329
Bone Regeneration of Hydroxyapatite with Granular Form or Porous Scaffold in Canine Alveolar Sockets. S.J. JANG, S.E. KIM, T.S. HAN, J.S. SON, S.S. KANG, S.H. CHOI ( <i>Cheongju; Gwangju; Daegu, Republic of Korea</i> ) .....	335

Vitamin C Improves Therapeutic Effects of Adipose-derived Stem Cell Transplantation in Mouse Tendonitis Model. K.-K. KANG, E.-J. LEE, Y.-D. KIM, M.-J. CHUNG, J.-Y. KIM, S.-Y. KIM, S.-K. HWANG, K.-S. JEONG ( <i>Daegu, Republic of Korea</i> ) .....	343
Anti-inflammatory Effects of Oct4/Sox2-overexpressing Human Adipose Tissue-derived Mesenchymal Stem Cells. Q. LI, S.-M. HAN, W.-J. SONG, S.-C. PARK, M.-O. RYU, H.-Y. YOUN ( <i>Seoul, Republic of Korea</i> ) .....	349
The Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor Shrinkage. S. TURGUT, M. ILHAN, S. TURAN, O. KARAMAN, I. YAYLIM, O. KUCUKHUSEYIN, E. TASAN ( <i>Istanbul, Turkey</i> ) .....	357
Partial Deletions of Y-Chromosome in Infertile Men with Non-obstructive Azoospermia and Oligoasthenoteratozoospermia in a Turkish Population. C.C. BEYAZ, S. GUNES, K. ONEM, T. KULAC, R. ASCI ( <i>Samsun, Turkey</i> ) .....	365
Effect of Hydrogen Dioxide Treatment on the Osteogenic Potential of Duck-beak Bone-derived Natural Bioceramic Microparticles. J.-H. KIM, M.-H. PARK, S.J. JANG, S.J. SON, J.Y. LEE, J.S. SON, S.E. KIM, S.S. KANG, S.H. CHOI ( <i>Jeonju; Cheongju; Daegu; Gwangju, Republic of Korea</i> ) .....	373
<b>Clinical Studies</b>	
Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA. J. ONATSU, M. TAINA, P. MUSTONEN, M. HEDMAN, A. MUURONEN, O. ARPONEN, M. KORHONEN, P. JÄKÄLÄ, R. VANNINEN, K. PULKKI ( <i>Kuopio; Jyväskylä, Finland</i> ) .....	381
Magnetic Resonance Imaging Assessment of Lipomatous Soft-tissue Tumors. A. CORAN, P. ORTOLAN, S. ATTAR, E. ALBERIOLI, E. PERISSINOTTO, A.L. TOSI, M.C. MONTESCO, C.R. ROSSI, S. TROPEA, M. RASTRELLI, R. STRAMARE ( <i>Padua, Italy</i> ) .....	387
Survival and Predictors of Death for Patients with Bronchopulmonary Carcinoid at a Danish Tertiary NET Centre. L.S. KORNERUP, G. DAM, H. GRONBEK ( <i>Aarhus, Denmark</i> ) .....	397
Correlation Between Expression of the Cancer/Testis Antigen KKLC-1 and <i>Helicobacter pylori</i> Infection in Gastric Cancer. T. FUKUYAMA, N. FUTAWATARI, Y. ICHIKI, A. SHIDA, T. YAMAZAKI, Y. NISHI, H. NONOGUCHI, Y. TAKAHASHI, H. YAMAZAKI, N. KOBAYASHI ( <i>Kitamoto; Sagamihara; Kitakyushu, Japan</i> ) .....	403
Clinical Implication of the Width of Subserosal Invasion in T3N0 Gastric Cancer. K. NAKAMURA, M. TOMIOKU, K. NABESHIMA, E. NOMURA ( <i>Isehara; Hachioji, Japan</i> ) .....	409
Multiparametric MRI Apparent Diffusion Coefficient (ADC) Accuracy in Diagnosing Clinically Significant Prostate Cancer. P. PEPE, D. D'URSO, A. GARUFI, G. PRIOLO, M. PENNISI, G. RUSSO, M.G. SABINI, L.M. VALASTRO, A. GALIA, F. FRAGGETTA ( <i>Catania; Cefalù; Catania, Italy</i> ) .....	415
Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases. T. YOSHIMOTO, Y. MORINE, S. IMURA, T. IKEMOTO, S. IWASHI, Y. SAITO, S. YAMADA, D. ISHIKAWA, H. TERAOKU, M. YOSHIKAWA, J. HIGASHIJIMA, C. TAKASU, M. SHIMADA ( <i>Tokushima, Japan</i> ) .....	419

Angiotensin-converting Enzyme Inhibition Improves the Effectiveness of Transcutaneous Carbon Dioxide Treatment. B. NEMETH, I. KISS, T. JENCSIK, I. PETER, Z. KRESKA, T. KOSZEGI, A. MISETA, P. KUSTAN, I. BONCZ, A. LACZO, Z. AJTAY ( <i>Pecs; Harkany, Hungary</i> ) .....	425
Partial Cystectomy for Atypical Isolated Recurrence of Ovarian Adenocarcinoma – A Case Report and Literature Review. N. BACALBASA, I. BALESCU ( <i>Bucharest, Romania</i> ) .....	429
A New Prognostic Instrument Specifically Designed for Patients Irradiated for Recurrent Carcinoma of the Bladder. L. MANIG, S. JANSSEN, S.E. SCHILD, D. RADES ( <i>Lübeck, Germany; Scottsdale, AZ, USA</i> ) .....	435
Thrombotic Microangiopathy Following Chemotherapy with S-1 and Cisplatin in a Patient with Gastric Cancer: A Case Report. J. MUTO, H. KISHIMOTO, Y. KAIZUKA, M. KINJO, H. HIGASHI, F. KISHIHARA ( <i>Kitakyushu, Japan</i> ) .....	439
IT-based Psychosocial Distress Screening in Patients with Sarcoma and Parental Caregivers via Disease-specific Online Social Media Communities. F. POHLIG, U. LENZE, H.M.L. MUHLHOFER, F.W. LENZE, J. SCHAUWECKER, C. KNEBEL, T. ZIMMERMANN, P. HERSCHBACH ( <i>Munich; Traunstein; Hannover, Germany</i> ) .....	443
Surgical Management of Non-small Cell Lung Cancer with Solitary Hematogenous Metastases. G. KARAGKIOUZIS, E. SPARTALIS, D. MORIS, D. PATSOURAS, A. ATHANASIOU, I. KARATHANASIS, A. VERVENIOTIS, F. KONSTANTINOU, I.A. KOUERINIS, K. POTARIS, D. DIMITROULIS, P. TOMOS ( <i>Athens, Greece; Columbus, OH, USA</i> ) .....	451
Definitive Intensity-modulated Radiation Therapy in Elderly Patients with Locally Advanced Oropharyngeal Cancer. F. DE FELICE, A. GALDIERI, G. ABATE, N. BULZONETTI, D. MUSIO, V. TOMBOLINI ( <i>Rome, Italy</i> ) .....	455
Testicular Dose During Prophylaxis of Heterotopic Ossification with Radiation Therapy. W.F. MOURAD, J.K. MA, S. PACKIANATHAN, W. YAN, S.G. SHAABAN, E.M. MARCHAN, L.E. ABDALLAH, R. HE, P.N. MOBIT, C. YANG, S. VIJAYAKUMAR ( <i>Jackson, MS; Augusta, GA; Mobile, AL, USA</i> ) .....	461
Prevalence of Congenital Cytomegalovirus Infection Assessed Through Viral Genome Detection in Dried Blood Spots in Children with Autism Spectrum Disorders. I. GENTILE, E. ZAPPULO, M.P. RICCIO, S. BINDA, L. BUBBA, L. PELLEGRINELLI, D. SCOGNAMIGLIO, F. OPERTO, L. MARGARI, G. BORGIA, C. BRAVACCIO ( <i>Naples; Milan; Bari, Italy</i> ) .....	467
Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures. A. HATA, N. KATAKAMI, S. NANJO, C. OKUDA, R. KAJI, Y. IMAI ( <i>Kobe, Japan</i> ) .....	475
Ewing's Sarcoma Family Tumors in the Jaws: Case Report, Immunohistochemical Analysis and Literature Review. A.R. CASAROTO, M.B. DA SILVA SAMPIERI, C.T. SOARES, P.S. DA SILVA SANTOS, R.Y. FARIA YAEDU, J.H. DAMANTE, V.S. LARA ( <i>Bauru, SP, Brazil</i> ) .....	481

Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer. J. WATANABE, Y. ITO, T. SAEKI, N. MASUDA, T. TAKANO, S. TAKAO, K. NAKAGAMI, K. TSUGAWA, S. NAKAGAWA, K. KANATANI, T. NAKAYAMA ( <i>Shizuoka; Tokyo; Saitama; Osaka; Hyogo; Kanagawa, Japan</i> ).....	493
--	-----

## **Number 4**

### *Reviews*

Solid Pseudopapillary Tumor of the Pancreas: A Single-center Experience and Review of the Literature. E.A. ANTONIOU, C. DAMASKOS, N. GARMPIS, C. SALAKOS, G.-A. MARGONIS, K. KONTZOGLOU, S. LAHANIS, E. SPARTALIS, D. PATSOURAS, S. KYKALOS, A. GARMPI, N. ANDREATOS, T.M. PAWLIK, G. KOURAKLIS ( <i>Athens, Greece; Baltimore, MD, USA; London, UK</i> ).....	501
Mitochondrial Membrane Dynamics and Inherited Optic Neuropathies. E. BAGLI, A.K. ZIKOU, N. AGNANTIS, G. KITSOS ( <i>Ioannina, Greece</i> ).....	511
K-ras Mutations as the Earliest Driving Force in a Subset of Colorectal Carcinomas. N. MARGETIS, M. KOULOUKOUPA, K. PAVLOU, S. VRAKAS, T. MARIOLIS-SAPSAKOS ( <i>Athens; Piraeus, Greece</i> ).....	527

### *Experimental Studies*

Enhancement of Wound Healing by the Traditional Chinese Medicine Herbal Mixture <i>Sophora flavescens</i> in a Rat Model of Perianal Ulceration. X. XU, X. LI, L. ZHANG, Z. LIU, Y. PAN, D. CHEN, D. BIN, Q. DENG, Y. SUN, R.M. HOFFMAN, Z. YANG, H. YUAN ( <i>Hangzhou; Changsha; Nanjing, PR China; San Diego, CA, USA</i> ) .....	543
Resveratrol Attenuates Nicotine-mediated Oxidative Injury by Inducing Manganese Superoxide Dismutase in Renal Proximal Tubule Cells. S. HALL, M. DIXIT, I. ARANY ( <i>Jackson, MS, USA</i> ) .....	551
Cerebral Perfusion After Repair of Congenital Diaphragmatic Hernia with Common Carotid Artery Occlusion After ECMO Therapy. C. HENZLER, F.G. ZÖLLNER, M. WEIS, F. ZIMMER, S.O. SCHOENBERG, K. ZAHN, T. SCHAIABLE, K.W. NEFF ( <i>Mannheim, Germany</i> ).....	557
Clinical Significance of <i>INHBA</i> Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy. Y. KATAYAMA, T. OSHIMA, K. SAKAMAKI, T. AOYAMA, T. SATO, K. MASUDO, M. SHIOZAWA, T. YOSHIKAWA, Y. RINO, T. IMADA, M. MASUDA ( <i>Yokohama, Japan</i> ) .....	565
Improvement Effect of Dewaxed Brown Rice on Constipation in Antibiotic-treated Mice. H. INAGAWA, T. SAIKA, N. NISHIYAMA, T. NISIZAWA, C. KOHCHI, M. UENOBE, G.-I. SOMA ( <i>Kagawa; Niigata; Aichi, Japan</i> ) .....	573
Microbicidal Effects of Stored Aqueous Ozone Solution Generated by Nano-bubble Technology. M. SEKI, T. ISHIKAWA, H. TERADA, M. NASHIMOTO ( <i>Niigata, Japan</i> ) .....	579

The Contribution of Matrix Metalloproteinase-8 Promoter Polymorphism to Oral Cancer Susceptibility. Y.-W. HUNG, C.-W. TSAI, C.-N. WU, L.-C. SHIH, Y.-Y. CHEN, Y.-F. LIU, H.-S. HUNG, M.-Y. SHEN, W.-S. CHANG, D.-T. BAU ( <i>Taichung, Taiwan, ROC</i> ) .....	585
Evaluation of Biological Activity of Mastic Extracts Based on Chemotherapeutic Indices. R. SUZUKI, H. SAKAGAMI, S. AMANO, K. FUKUCHI, K. SUNAGA, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, Y. SHIRATAKI, M. TOMOMURA, Y. MASUDA, S. YOKOSE, A. TOMOMURA, H. WATANABE, M. OKAWARA, Y. MATAHIRA ( <i>Sakado; Tokyo; Kawasaki; Fuji, Japan</i> ).....	591
Transcriptome Analysis of Skin from SMP30/GNL Knockout Mice Reveals the Effect of Ascorbic Acid Deficiency on Skin and Hair. K. WAKAME, K.-I. KOMATSU, A. NAKATA, K. SATO, A. TAKAGURI, H. MASUTOMI, T. NAGASHIMA, H. UCHIYAMA ( <i>Sapporo; Tokyo; Atsugi, Japan</i> ) .....	599
A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells. A. FEDERICO, V. CONTI, G. RUSSOMANNO, M. DALLIO, M. MASARONE, P. STIUSO, C. TUCCILLO, M. CARAGLIA, V. MANZO, M. PERSICO, A. FILIPPELLI, C. LOGUERCIO ( <i>Naples; Salerno, Italy</i> ) .....	609
Grid-climbing Behaviour as a Pain Measure for Cancer-induced Bone Pain and Neuropathic Pain. S. FALK, S. GALLEGOS-PEDERSEN, N.C. PETERSEN ( <i>Copenhagen, Denmark</i> ) .....	619
MicroRNA-1 and MicroRNA-21 Individually Regulate Cellular Growth of Non-malignant and Malignant Renal Cells. H.S AHREND, A. KAUL, S. ZIEGLER, L.-O. BRANDENBURG, U. ZIMMERMANN, A. MUSTEA, M. BURCHARDT, P. ZIEGLER, M.B. STOPE ( <i>Greifswald; Aachen, Germany</i> ) .....	625
The Contribution of <i>MMP-7</i> Promoter Polymorphisms in Renal Cell Carcinoma. C.-H. LIAO, W.-S. CHANG, P.-S. HU, H.-C. WU, S.-W. HSU, Y.-F. LIU, S.-P. LIU, H.-S. HUNG, D.-T. BAU, C.-W. TSAI ( <i>Taichung; Taipei; Changhua, Taiwan, ROC</i> ).....	631
Cortisol Levels and Gastrointestinal Disorders After Stressful Surgery in Rabbits. S.J. JANG, S.S. KANG, S.J. SON, J.Y. LEE, G. KIM, S.H. CHOI ( <i>Cheongju; Gwangju, Republic of Korea</i> ).....	637
Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis. E. TSIAMBAS, N.S. MASTRONIKOLIS, A.Y. LEFAS, S.N. GEORGIANNOS, V. RAGOS, P.P. FOTIADES, N. TSOUKALAS, N. KAVANTZAS, A. KARAMERIS, D. PESCHOS, E. PATSOURIS, K. SYRIGOS ( <i>Athens; Patras; Ioannina, Greece; Southampton; London; Leicester, UK</i> ).....	641
Adipose Tissue Graft Improves Early but not Late Stages of Nerve Regeneration. V. BLOANCĂ, A.R. CEAUŞU, A.A. JITARIU, A. BARMAYOUN, R. MOŞ, Z. CRĂINICEANU, T. BRATU ( <i>Timișoara, Romania</i> ) .....	649
Elevated IL-4 and IFN-γ Levels in Muscle Tissue of Patients with Dermatomyositis. M. GİRİŞ, H. DURMUŞ, B. YETİMLER, H. TAŞLI, Y. PARMAK, E. TÜZÜN ( <i>Istanbul, Turkey</i> ).....	657

*Clinical Studies*

Breast Cancer Prognosis for Young Patients. M. OWRANG, R.L. COPELAND JR, L.J. RICKS-SANTI, M. GASKINS, D. BEYENE, R.L. DEWITTY JR, Y.M. KANAAN ( <i>Washington, DC; Hampton, VA, USA</i> ).....	661
Corrupted Colonic Crypts Bordering Regenerating Mucosal Ulcers in Ulcerative Colitis. C.A. RUBIO ( <i>Stockholm, Sweden</i> ).....	669
Increased Resistance of Skin Flora to Antimicrobial Prophylaxis in Patients Undergoing Hip Revision Arthroplasty. H.M.L. MÜHLHOFER, L. DEISS, P. MAYER-KUCKUK, F. POHLIG, N. HARRASSER, U. LENZE, H. GOLLWITZER, C. SUREN, P. PRODINGER, R. VON EISENHART-ROTHE, J. SCHAUWECKER ( <i>Munich, Germany</i> ) .....	673
A Head to Head Comparison Between SurgiMend® – Fetal Bovine Acellular Dermal Matrix and Tutomesh® – A Bovine Pericardium Collagen Membrane in Breast Reconstruction in 45 Cases. C. EICHLER, J. EFREMOVA, K. BRUNNERT, C.M. KURBACHER, O. GLUZ, J. PUPPE, M. WARM ( <i>Cologne; Osnabrueck; Bonn; Moenchengladbach, Germany</i> ).....	677
Which Is the Safer Anastomotic Method for Colon Surgery? – Ten-year Results. M. KOSUGE, K. ETO, R. HASHIZUME, M. TAKEDA, K. TOMORI, K. NEKI, N. MITSUMORI, K. YANAGI ( <i>Tokyo, Japan</i> ) .....	683
A Survival Score Based on Symptoms and Performance Status for Patients with High-grade Gliomas Receiving Radiochemotherapy. P.C. PHUONG, L.V. NAM, S.E. SCHILD, D. RADES, M.T. KHOA ( <i>Hanoi, Vietnam; Scottsdale, AZ, USA; Lübeck, Germany</i> ).....	689
Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection. I. GENTILE, A.R. BUONOMO, R. SCOTTO, E. ZAPPULO, C. CARRIERO, M. PICCIRILLO, F. IZZO, M. RIZZO, D. CERASUOLO, G. BORGIA, E. CAVALCANTI ( <i>Naples, Italy</i> ).....	695
Primary Gastric ALK-negative EBV-negative Anaplastic Large Cell Lymphoma Presenting with Iron Deficiency Anemia. W. ZHANG, S. BURTON, S. WU, X. QIAN, M.N. RAJEH, K. SCHROEDER, M. SHULDBERG, A. MERANDO, J.-P. LAI ( <i>St. Louis, MO; Gainesville, FL, USA</i> ) .....	701
Rare Case of Cecal Signet Ring Cell Carcinoma with Distal Intramural Spread. K. ONO, M. MURAKAMI, M. WATANABE, A. FUJIMORI, K. OTSUKA, T. AOKI, T. YAMOCHI-ONIZUKA, M. TAKIMOTO ( <i>Tokyo, Japan</i> ) .....	705
Reticulocyte Hemoglobin Content Helps Avoid Iron Overload in Hemodialysis Patients: A Retrospective Observational Study. D. CAPONE, M. CATALDI, M. VINIGUERRA, T. MOSCA, S. BARRETTA, A. RAGOSTA, A. SORRENTINO, A. VECCHIONE, L. BARRETTA, G. TARANTINO ( <i>Naples; Pozzuoli, Italy</i> ) ...	709
Increased Copy Number Variation of mtDNA in an Array-based Digital PCR Assay Predicts Ulcerative Colitis-associated Colorectal Cancer. T. TANAKA, T. KOBUNAI, Y. YAMAMOTO, K. MURONO, K. OTANI, K. YASUDA, T. NISHIKAWA, T. KIYOMATSU, K. KAWAI, K. HATA, H. NOZAWA, S. ISHIHARA, T. WATANABE ( <i>Tokyo, Japan</i> ).....	713

---

Debulking Surgery for High-grade Serous Endometrial Cancer with Disseminated Peritoneal Lesions. N. BACALBASA, I. BALESCU, A. FILIPESCU ( <i>Bucharest, Romania</i> ).....	719
Clinical Predictors for Neutrophil-to-Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment. P.-H. LE, K.-H. LIANG, M.-L. CHANG, C.-W. HSU, Y.-C. CHEN, C.-L. LIN, W.-R. LIN, M.-W. LAI, C.-T. YEH ( <i>Taoyuan, Taiwan, ROC</i> ).....	723
Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine. A. PLOQUIN, S. TRUANT, G. PIESSEN, P. VUAGNAT, C. BALDINI, S. CATTAN, M. HEBBAR ( <i>Lille, France</i> ).....	731
Combined Use of Mammography and FNA Eliminates Pitfalls in the Management of Metaplastic Breast Carcinoma. D.I. TSILIMIGRAS, I. NTANASIS-STATHOPOULOS, D. SCHIZAS, A. BAKOPOULOS, D. MORIS, G.-M. STANC, A. TENTOLOURIS, S. NASSAR, C. SALLA ( <i>Athens, Greece; Columbus, OH, USA</i> ).....	737
Factors Impacting the Overall Survival of Patients Irradiated for Invasive Carcinoma of the Urinary Bladder. D. RADES, L. MANIG, S. JANSSEN, S.E. SCHILD ( <i>Lübeck, Germany; Scottsdale, AZ, USA</i> ).....	741
A New Prognostic Tool for Patients Undergoing Radiotherapy plus Upfront Transurethral Resection for Bladder Cancer. L. MANIG, S. JANSSEN, S.E. SCHILD, D. RADES ( <i>Lübeck, Germany; Scottsdale, AZ, USA</i> ) .....	745
Correlation Between Infection Status of Epstein-Barr Virus and $^{18}\text{F}$ -Fluorodeoxyglucose Uptake in Patients with Advanced Gastric Cancer. S.J. NA, H.L. PARK, J.H. O, S.Y. LEE, K.Y. SONG, S.H. KIM ( <i>Seoul, Republic of Korea</i> ).....	749
Predictive Factors for Prolonged Urination Disorder After Permanent $^{125}\text{I}$ Brachytherapy for Localized Prostate Cancer. H. MORI, T. FUKUMORI, K. DAIZUMOTO, M. TSUDA, Y. KUSUHARA, T. FUKAWA, Y. YAMAMOTO, K. YAMAGUCHI, M. TAKAHASHI, A. KUBO, T. KAWANAKA, S. FURUTANI, H. IKUSHIMA, H.-O. KANAYAMA ( <i>Tokushima, Japan</i> ) .....	755
Hepatic Epithelioid Hemangioendothelioma – a Rare Tumor and Diagnostic Dilemma. V. TRESKA, O. DAUM, M. SVAJDLER, V. LISKA, J. FERDA, J. BAXA ( <i>Pilsen, Czech Republic</i> ) .....	763
Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma. Y. KOBARI, T. KONDO, T. TAKAGI, K. OMAE, H. NAKAZAWA, K. TANABE ( <i>Tokyo, Japan</i> ) .....	769
Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects. E. BARGAGLI, V. BONTI, K. FERRARI, E. ROSI, A. BINDI, M. BARTOLUCCI, M. CHIARA, L. VOLTOLINI ( <i>Florence, Italy</i> ) .....	773

**Number 5***Experimental Studies*

Tissue-directed Implantation Using Ultrasound Visualization for Development of Biologically Relevant Metastatic Tumor Xenografts. R.A. VAN NOORD, T. THOMAS, M. KROOK, S. CHUKKAPALLI, M.J. HOENERHOFF, J.R. DILLMAN, E.R. LAWLOR, V.P. OPIPARI, E.A. NEWMAN ( <i>Ann Arbor, MI, USA</i> ) .....	779
Netrin-4 Promotes Differentiation and Migration of Osteoblasts. Y. ENOKI, T. SATO, S. KOKABU, N. HAYASHI, T. IWATA, M. YAMATO, M. USUI, M. MATSUMOTO, T. TOMODA, W. ARIYOSHI, T. NISHIHARA, T. YODA ( <i>Saitama; Fukuoka; Tokyo, Japan</i> ) .....	793
Melatonin Synergizes the Chemotherapeutic Effect of Cisplatin in Ovarian Cancer Cells Independently of MT1 Melatonin Receptors. A. ZEMŁA, I. GRZEGOREK, P. DZIĘGIEL, K. JABŁOŃSKA ( <i>Wrocław, Poland</i> ) .....	801
Pharmacokinetics of Morphine in Rats with Adjuvant-induced Arthritis. Y. KIMURA, M. SHIBATA, M. TAMADA, N. OZAKI, K. ARAI ( <i>Kanazawa; Eiheiji, Japan</i> ) .....	811
Expression of Cyclooxygenase-2, Nitric Oxide Synthase 2 and Heme Oxygenase-1 mRNA Induced by Bis-Eugenol in RAW264.7 Cells and their Antioxidant Activity Determined Using the Induction Period Method. Y. MURAKAMI, A. KAWATA, S. FUJISAWA ( <i>Sakado, Japan</i> ) .....	819
RUNX3 as a Potential Predictor of Metastasis in Human Pancreatic Cancer. E. ROSSI, C. BAGALÀ, F. INZANI, E. LEONCINI, C. BRUNELLI, P. LANZA, M. BASSO, G.C. MATTIUCCI, A. CASSANO, G. RINDI, C. BARONE, G. SCHINZARI ( <i>Rome, Italy</i> ) .....	833
Phe354Leu Polymorphism of <i>LKB1</i> is a Potential Prognostic Factor for Cytogenetically Normal Acute Myeloid Leukemia. M.-Y. YANG, H.-H. HSIAO, Y.-C. LIU, C.-M. HSU, S.-F. LIN, P.-M. LIN ( <i>Tao-Yuan; Kaohsiung; Chiayi, Taiwan, ROC</i> ) .....	841
Cytocompatibility of Direct Laser Interference-patterned Titanium Surfaces for Implants. P. HARTJEN, O. NADA, T.G. SILVA, C. PRECHT, A. HENNIGSEN, M.G. HOLTHAUS, N. GULOW, R.E. FRIEDRICH, H. HANKEN, M. HEILAND, C. ZWAHR, R. SMEETS, O. JUNG ( <i>Hamburg; Bremen; Berlin; Dresden, Germany</i> ) .....	849
The Immunoreactivity of PI3K/AKT Pathway After Prenatal Hypoxic Damage. H. WANG, Y. CHUNG, S.-K. YU, Y. JUN ( <i>Gwang-ju, Republic of Korea</i> ) .....	855
Comparing the Organs and Vasculature of the Head and Neck in Five Murine Species. M.J. KIM, Y.Y. KIM, J.R. CHAO, H.S. PARK, J. CHANG, D. OH, J.J. LEE, T.C. KANG, J.-G. SUH, J.H. LEE ( <i>Chuncheon; Dongtan, Republic of Korea; Washington, DC, USA</i> ) .....	861
<i>SCARB1</i> Gene Polymorphisms and HDL Subfractions in Coronary Artery Disease. H. AYHAN, U. GORMUS, S. ISBIR, S.G. YILMAZ, T. ISBIR ( <i>Istanbul, Turkey</i> ) .....	873
<i>Antrodia Cinnamomea</i> Reduces Carbon Tetrachloride-induced Hepatotoxicity In Male Wister Rats. Y.-L. SHIH, M.-F. WU, C.-H. LEE, M.-Y. YEH, J. CHOU, J.-Y. LIU, H.-F. LU, Y.-P. HUANG, N.-C. LIAO, J.-G. CHUNG ( <i>Taipei; New Taipei; HouLong; Taichung, Taiwan, ROC</i> ) .....	877

Differential Expression of Aquaporins in Experimental Models of Acute Lung Injury. A.G. VASSILIOU, N. MANITSOPOULOS, M. KARDARA, N.A. MANIATIS, S.E. ORFANOS, A. KOTANIDOU ( <i>Athens, Greece</i> ) .....	885
Osteochondral Repair Using Porous Three-dimensional Nanocomposite Scaffolds in a Rabbit Model. B. ŻYLIŃSKA, E. STODOLAK-ZYCH, A. SOBCZYŃSKA-RAK, T. SZPONDER, P. SILMANOWICZ, M. ŁAŃCUT, Ł. JAROSZ, P. RÓŻAŃSKI, I. POLKOWSKA ( <i>Lublin; Cracow, Poland</i> ).....	895
5-Aminolevulinic-acid-mediated Photodynamic Diagnosis Enhances the Detection of Peritoneal Metastases in Biliary Tract Cancer in Mice. T. KUSHIBIKI, T. NOJI, Y. EBIHARA, K. HONTANI, M. ONO, S. KUWABARA, T. NAKAMURA, T. TSUCHIKAWA, K. OKAMURA, M. ISHIZUKA, S. HIRANO ( <i>Sapporo; Tokyo, Japan</i> ) .....	905
<b>Clinical Studies</b>	
Treatment of Squamous Cell Carcinoma of the Esophagus Synchronously Associated with Head and Neck Cancer. M. MORITA, A. EGASHIRA, Y. NAKAJI, M. KAGAWA, M. SUGIYAMA, D. YOSHIDA, M. OTA, M. IKEBE, M. MASUDA, Y. INOUE, N. KUNITAKE, Y. TOH ( <i>Fukuoka, Japan</i> ) .....	909
Comparison of the Grip Strength Using the Martin-Vigorimeter and the JAMAR-Dynamometer: Establishment of Normal Values. S. NEUMANN, S. KWISDA, C. KRETTEK, R. GAULKE ( <i>Hannover; Hamburg, Germany; Zurich, Switzerland</i> ).....	917
Parathyroid Carcinoma in Patients that Have Undergone Surgery for Primary Hyperparathyroidism. P. LIBANSKÝ, S. ADAMEK, P. BROULNK, M. FIALOVÁ, J. KUBINYI, R. LISCHKE, O. NAŇKA, P. PAFKO, J. XEDÝ, V. BOBEK ( <i>Prague; Olomouc; Labem, Czech Republic; Wroclaw, Poland</i> ).....	925
Efficacy of N-acetylcysteine, D-mannose and <i>Morinda citrifolia</i> to Treat Recurrent Cystitis in Breast Cancer Survivors. D. MARCHIORI, P.P. ZANELLO ( <i>Bologna; Parma, Italy</i> ) .....	931
Prospective Analysis of a Sterile, Semi-automated Tissue Biopsy Homogenization Method in the Diagnosis of Prosthetic Joint Infections. C. SUREN, N. HARRASSER, F. POHLIG, I.J. BANKE, U. LENZE, F. LENZE, C. KNEBEL, R. VON EISENHART-ROTHE, J. SCHAUWECKER, H.M.L. MáHLHOFER ( <i>Munich, Germany</i> ).....	937
Risk Factors for Transumbilical Wound Complications in Laparoscopic Gastric and Colorectal Surgery. K. TOMIOKA, M. MURAKAMI, A. FUJIMORI, M. WATANABE, T. KOIZUMI, S. GOTO, K. OTSUKA, T. AOKI ( <i>Tokyo, Japan</i> ) .....	943
Impact of Time Factors on Outcome in Patients with Head and Neck Cancer Treated with Definitive Radio(Chemo)Therapy. S. DAHLKE, D. STEINMANN, H. CHRISTIANSEN, M. DURISIN, A. ECKARDT, G. WEGENER, M. BREMER, A. MEYER ( <i>Hannover, Germany</i> ).....	949
Rotating Gamma System Irradiation: A Promising Treatment for Low-grade Brainstem Gliomas. P.C. PHUONG, N.Q. HUNG, T.B. NGOC, D. RADES, M.T. KHOA ( <i>Hanoi; Thai Nguyen, Vietnam; Lübeck, Germany</i> ) .....	957
Predictive Factors of Late-onset Rectal Mucosal Changes After Radiotherapy of Prostate Cancer. E. IPPOLITO, A. GUIDO, G. MACCHIA, F. DEODATO, L. GIACCHERINI, A. FAROLI, A. ARCELLI, D. CUCCHI, L. FRAZZONI, S. CILLA, M. BUWENGE, G. MANTINI, A.R. ALITTO, M. NUZZO, V. VALENTINI, M. INGROSSO, A.G. MORGANTI, L. FUCCIO ( <i>Rome; Bologna; Campobasso; Rome, Italy</i> ).....	961

Influenza Among Breast Cancer Survivors in South Korea: A Nationwide Population-Based Study. J. HEO, M. CHUN, Y.-T. OH, O.K. NOH, L. KIM ( <i>Suwon; Seoul, Republic of Korea</i> ) .....	967
Rectosigmoidian Involvement in Advanced-stage Ovarian Cancer – Intraoperative Decisions. N. BACALBASA, I. BALESCU, S. DIMA ( <i>Bucharest, Romania</i> ) .....	973
Successful Resection and Vascular Ligation of a Large Hepatic Artery Aneurysm – A Case Report and Literature Review. N. BACALBASA, I. BREZAN, C. ANGHEL, I. BARBU, M. PAUTOV, I. BALESCU, V. BRASOVEANU ( <i>Bucharest, Romania</i> ).....	979
Management of a Fulminant Upper Gastrointestinal Bleeding Exteriorized Through Hemobilia Due to Arteriobiliary Fistula Between the Common Bile Duct and a Right Hepatic Artery Aneurysm – A Case Report. N. BACALBASA, I. BREZAN, C. ANGHEL, I. BARBU, M. PAUTOV, I. BALESCU, V. BRASOVEANU ( <i>Bucharest, Romania</i> ) .....	983
Mouse Hemokinin-1 Decapeptide Subjected to a Brain-specific Post-translational Modification. G. DELICONSTANTINOS, S. BARTON, M. SOLOVIEV, N. PAGE ( <i>London, UK</i> ) .....	991
Ileocecal Obstruction Due to Endometriosis – A Case Report and Literature Review. N. BACALBASA, I. BALESCU, A. FILIPESCU ( <i>Bucharest, Romania</i> ).....	999
Elevated Serum AA/EPA Ratio as a Predictor of Skeletal Muscle Depletion in Cachexic Patients with Advanced Gastro-intestinal Cancers. M. KITAGAWA, S. HAJI, T. AMAGAI ( <i>Nishinomiya; Osaka, Japan</i> )...	1003
Lymph Node Size on Computed Tomography Images Is a Predictive Indicator for Lymph Node Metastasis in Patients with Colorectal Neuroendocrine Tumors. T. TANAKA, H. NOZAWA, K. KAWAI, K. HATA, T. KIYOMATSU, T. NISHIKAWA, K. OTANI, K. SASAKI, K. MURONO, T. WATANABE ( <i>Tokyo, Japan</i> ) .....	1011
Gastric Tube Reconstruction with Superdrainage Using Indocyanine Green Fluorescence During Esophagectomy. H. KITAGAWA, T. NAMIKAWA, J. IWABU, K. HANAZAKI ( <i>Nankoku, Japan</i> ) .....	1019
Endobronchial Carcinoid Tumor Totally Occluding the Left Main Bronchus Without Producing Symptoms of Bronchial Obstruction. D.I. TSILIMIGRAS, D. MORIS, I. NTANASIS-STATHOPOULOS, D. PATRINI, N. PANAGIOTOPoulos ( <i>Athens, Greece; Columbus, OH, USA; London, UK</i> ) .....	1023
Influence of Diabetes on Circulating Apoptotic Microparticles in Patients with Chronic Hepatitis C. J. ZUWALA-JAGIELLO, M. PAZGAN-SIMON, E. MURAWSKA-CIALOWICZ, K. SIMON ( <i>Wroclaw, Poland</i> ) .....	1027
Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer. T. MAEKURA, M. NAITO, M. TAHARA, N. IKEGAMI, Y. KIMURA, S. SONOBE, T. KOBAYASHI, T. TSUJI, S. MINOMO, A. TAMIYA, S. ATAGI ( <i>Osaka, Japan</i> ) .....	1035
Multiple Sclerosis and Subsequent Human Immunodeficiency Virus Infection: A Case with the Rare Comorbidity, Focus on Novel Treatment Issues and Review of the Literature. C. SKARLIS, M. GONTIKA, S. KATSAVOS, G. VELONAKIS, P. TOULAS, M. ANAGNOSTOULI ( <i>Athens, Greece</i> )....	1041

**Number 6***Reviews*

- Ghrelin and Obesity: Identifying Gaps and Dispelling Myths. A Reappraisal. M.C. MAKRIS, A. ALEXANDROU, E.G. PAPATSOUTSOS, G. MALIETZIS, D.I. TSILIMIGRAS, A.D. GUERRON, D. MORIS (*Athens, Greece; Buer, Germany; London, UK; Durham, NC, USA*) ..... 1047

*Experimental Studies*

- Role for Neutrophil Extracellular Traps (NETs) and Platelet Aggregation in Early Sepsis-induced Hepatic Dysfunction. K. SAKURAI, T. MIYASHITA, M. OKAZAKI, T. YAMAGUCHI, Y. OHBATAKE, S. NAKANUMA, K. OKAMOTO, S. SAKAI, J. KINOSHITA, I. MAKINO, K. NAKAMURA, H. HAYASHI, K. OYAMA, H. TAJIMA, H. TAKAMURA, I. NINOMIYA, S. FUSHIDA, K. HARADA, J.W. HARMON, T. OHTA (*Kanazawa, Japan; Baltimore, MD, USA*) ..... 1051

- The Contribution of MMP-8 Promoter Genotypes to Childhood Leukemia. J.-S. PEI, W.-S. CHANG, P.-C. HSU, Y.-W. HUNG, S.-P. CHENG, C.-W. TSAI, D.-T. BAU, C.-L. GONG (*Taoyuan; Taichung, Taiwan, ROC*) ..... 1059

- Clinical Significance of Tensin 4 Gene Expression in Patients with Gastric Cancer. S. SAWAZAKI, T. OSHIMA, K. SAKAMAKI, T. AOYAMA, T. SATO, M. SHIOZAWA, T. YOSHIKAWA, Y. RINO, T. IMADA, M. MASUDA (*Yokohama, Japan*) ..... 1065

- Implementation of Humane Endpoints in a Urinary Bladder Carcinogenesis Study in Rats. M. OLIVEIRA, E. NASCIMENTO-GONHALVES, J. SILVA, P.A. OLIVEIRA, R. FERREIRA, L. ANTUNES, R. ARANTES-RODRIGUES, A.I. FAUSTINO-ROCHA (*Vila Real; Aveiro, Lisbon, Portugal*) ..... 1073

- Three-dimensional Laser Scanning Confocal Analysis of Conjunctival Microcysts in Glaucomatous Patients Before and After Trabeculectomy. S. DI STASO, L. AGNIFILI, A. DI GREGORIO, H. CLIMASTONE, E. GALASSI, V. FASANELLA, M. CIANCAGLINI (*L'Aquila; Chieti, Italy*) ..... 1081

- Re-evaluation of Culture Condition of PC12 and SH-SY5Y Cells Based on Growth Rate and Amino Acid Consumption. H. SAKAGAMI, R. SUZUKI, Y. SHIRATAKI, S. IWAMA, M. NAKAGAWA, H. SUZUKI, K. TANAKA, N. TAMURA, H. TAKESHIMA (*Saitama, Japan*) ..... 1089

- Corpus luteum Regression Induced by Prostaglandin F2 $\alpha$  in Microminipigs During the Normal Estrous Cycle.* M. NOGUCHI, M. HIRATA, H. KAWAGUCHI, A. TANIMOTO (*Sagamihara; Korimoto; Sakuragaoka, Japan*) ..... 1097

- Fisetin Induces Apoptosis of HSC3 Human Oral Cancer Cells Through Endoplasmic Reticulum Stress and Dysfunction of Mitochondria-mediated Signaling Pathways. Y.-L. SHIH, F.-M. HUNG, C.-H. LEE, M.-Y. YEH, M.-H. LEE, H.-F. LU, Y.-L. CHEN, J.-Y. LIU, J.-G. CHUNG (*Taipei; New Taipei; Miaoli County; Changhua; Hsinchu; Taichung, Taiwan, ROC*) ..... 1103

- Mesenchymal Stem Cells Contribute to Improvement of Renal Function in a Canine Kidney Injury Model. S.-J. LEE, M.-O. RYU, M.-S. SEO, S.-B. PARK, J.-O. AHN, S.-M. HAN, K.-S. KANG, D.-H. BHANG, H.-Y. YOUN (*Seoul; Daegu; Republic of Korea*) ..... 1115

- Regional Immunoreactivity of Pax6 in the Neurogenic Zone After Chronic Prenatal Hypoxia. K. SO, Y. CHUNG, S.-K. YU, Y. JUN (*Gwangju, Republic of Korea*) ..... 1125

FT-IR Spectroscopy Study in Early Diagnosis of Skin Cancer. M. KYRIAKIDOU, J. ANASTASSOPOULOU, A. TSAKIRIS, M. KOUTI, T. THEOPHANIDES ( <i>Athens, Greece</i> ) .....	1131
The Human Mesenchymal Stem Cells and the Chick Embryo Chorioallantoic Membrane: The Key and the Lock in Revealing Vasculogenesis. Ş. COMŞA, R.A. CEAUŞU, R. POPESCU, A.M. CIMPEAN, M. RAICA ( <i>Timișoara, Romania</i> ) .....	1139
Beneficial Effect of Bis(Hinokitiolato)Zn Complex on High-fat Dietinduced Lipid Accumulation in Mouse Liver and Kidney. Y. NAITO, Y. YOSHIKAWA, K. YOSHIZAWA, A. TAKENOUCHE, H. YASUI ( <i>Kyoto; Kobe; Nishinomiya, Japan</i> ) .....	1145
<b>Clinical Studies</b>	
Clinical Impact of Rest Dual-Energy Computed Tomography Myocardial Perfusion in Patients with Coronary Artery Disease. S. BAUMANN, M. RUTSCH, T. BECHER, P. KRYEZIU, H. HAUBENREISSER, N. VOGLER, C.A. SCHOENIKE, M. BORGGREFE, S.O. SCHOENBERG, I. AKIN, T. HENZLER, D. LOSSNITZER ( <i>Mannheim, Germany</i> ) .....	1153
Endo-extralaryngeal Lateralofixation of the Vocal Folds in Patients with Bilateral Vocal Fold Immobility. S. WIEGAND, A. TEYMOORTASH, H. HANSCHMANN ( <i>Leipzig; Marburg; Frankfurt am Main, Germany</i> ) .....	1159
Balneotherapy in Psoriasis Rehabilitation. I. PETER, A. JAGICZA, Z. AJTAY, I. BONCZ, I. KISS, K. SZENDI, P. KUSTAN, B. NEMETH ( <i>Harkany; Pecs, Hungary</i> ) .....	1163
Angiomyolipoma of the Liver: A Rare Benign Tumor Treated with a Laparoscopic Approach for the First Time. C. DAMASKOS, N. GARMPIS, A. GARMPI, A. NONNI, S. SAKELLARIOU, G.-A. MARGONIS, E. SPARTALIS, D. SCHIZAS, N. ANDREATOS, E. MAGKOUTI, A. GRIVAS, K. KONTZOGLOU, M.J. WEISS, E.A. ANTONIOU ( <i>Athens, Greece; Baltimore, MD, USA</i> ) .....	1169
Profiling Neutrophil-to-Lymphocyte Ratio Changes in Response to Nucleoside Analog Therapy for Chronic Hepatitis B Infection. M. MARALLAG, A. PATEL, M. CHOI, M.N. WONG, A.B. SEETHARAM ( <i>Phoenix; Tempe, AZ, USA</i> ) .....	1175
Prognostic Value of Procalcitonin, CRP, Serum Amyloid A, Lactate and IL-6 Markers in Liver Transplant Patients Admitted to ED with Suspected Infection. A. GUR, H. OGUZTURK, A. KOSE, M.G. TURTAY, V. ERSAN, Y. BAYINDIR, V. INCE, S. GURBUZ, N. YUCEL ( <i>Van; Malatya, Turkey</i> ) .....	1179
Cancer Patients' Knowledge and Acceptance of Physical Activities for Rehabilitation. J. BUNTZEL, I. KUSTERER, Y. RUDOLPH, T. KUBIN, O. MICKE, J. HUBNER ( <i>Nordhausen; Kirchheim unter Teck; Berlin; Traunstein; Bielefeld; Jena, Germany</i> ) .....	1187
Pulmonary Embolism in a Young Immunocompetent Adult Infected with Cytomegalovirus. Are Novel Oral Anticoagulants an Efficient Alternative? I. BOUNTOURIS, D. MORIS, D.I. TSILIMIGRAS, G. LAOUTARIS, G. KRITIKOU, V.-V. PALLA, G. KARAOLANIS ( <i>Athens, Greece; Columbus, OH, USA</i> ) .....	1193
Circulating Tumor Cells as an Auxiliary Diagnostic Tool in Surgery. K. KOLOSTOVA, A. RZECHONEK, J. SCHUTZNER, R. GRILL, R. LISCHKE, P. HLADIK, J. SIMONEK, V. BOBEK ( <i>Prague; Labem, Czech Republic; Wroclaw, Poland</i> ) .....	1197

---

Functional Abnormalities and Thyroid Nodules in Patients with End-stage Renal Disease. V. CUNA, V. MENGHI, G. COMAI, M. CAPPUCCILLI, G. CIANCIOLI, C. RAIMONDI, F. GRAMMATICO, G. DONATI, O. BARALDI, I. CAPELLI, G. LA MANNA ( <i>Bologna, Italy</i> ) .....	1203
Five-year Survival After Surgical Removal and Gamma Knife Stereotactic Radiosurgery for a Cerebellar Metastasis from an Esophagogastric Junction Cancer: A Case Report and Literature Review. Y. KANAZAWA, I. FUJITA, D. KAKINUMA, Y. AOKI, H. KANNO, H. ARAI, K. MATSUNO, T. SHIMODA, T. MATSUTANI, N. HAGIWARA, T. NOMURA, T. YAMADA, S. KATO, Z. NAITO, H. TAKASAKI, E. UCHIDA ( <i>Tokyo; Kamisu, Japan</i> ) .....	1209
Effect of Preoperative Bacteriuria and Pyuria on Intravesical Recurrence in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy. H. FUKUSHIMA, M. KOBAYASHI, K. KAWANO, S. MORIMOTO ( <i>Tsuchiura, Japan</i> ) .....	1215
Fibrotic Lung Toxicity Induced by Hydroxycarbamide. E. BARGAGLI, M. PALAZZI, F. PERRI, E. TORRICELLI, E. ROSI, A. BINDI, M. PISTOLESI, L. VOLTOLINI ( <i>Florence, Italy</i> ) .....	1221
Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction. H. YAMAZAKI, H. IWASAKI, T. YAMASHITA, T. YOSHIDA, N. SUGANUMA, T. YAMANAKA, K. MASUDO, H. NAKAYAMA, K. KOHAGURA, Y. RINO, M. MASUDA ( <i>Yokohama, Japan</i> ) .....	1225
Comparison of the Viability and Yield of Adipose-Derived Stem Cells (ASCs) from Different Donor Areas. A. TSEKOURAS, D. MANTAS, D.I. TSILIMIGRAS, D. MORIS, M. KONTOS, G.C. ZOGRAFOS (Athens, Greece; Columbus, OH, USA) .....	1229
Index .....	1235

## Subject Index

(Figures refer to page numbers)

- 5-Aminolevulinic acid, photodynamic diagnosis, biliary tract cancer, 905  
 AA/EPA ratio, cachexia, sarcopenia, cancer, fatty acids, n-6/n-3, 1003  
 ABCB1, morphine, inflammation, adjuvant-induced arthritis, uDP-glucuronosyltransferase, 811  
 Acellular dermal matrix, breast cancer, ADM, tutomesh, surgiMend, reconstruction, 677  
 Acetabular fracture, radiation therapy (RT), heterotopic ossification (HO), megavoltage photon, split-beam technique, testicular dose, radiation prophylaxis, indomethacin, 461  
 Acute kidney injury, canine umbilical cord blood-mesenchymal stem cells, dog, 1115  
 Acute myeloid leukemia, liver kinase B1, *LKB1*, AML, phe354Leu polymorphism, cytogenetically normal, 841  
 Adipose-derived stem cell, tendonitis, vitamin C, SMP30-KO mouse, stem cell therapy, 343  
 Adipose-derived stem cells, fat grafting, viability, yield, donor areas, 1229  
 Adjuvant chemotherapy, inhibin beta A, gastric cancer, 565  
 Adjuvant chemotherapy, tensin 4, *TNS4*, gastric cancer, S-1, prognostic factor, 1065  
 Adjuvant radiotherapy, breast cancer, pT1-T2, pN0-N1, conservative surgery, 151  
 Adjuvant-induced arthritis, morphine, inflammation, uDP-glucuronosyltransferase, ABCB1, 811  
 ADM, breast cancer, acellular dermal matrix, tutomesh, surgiMend, reconstruction, 677  
 Admission, influenza, breast cancer, pulmonary disease, 967  
 Adrenal metastasis, brain metastasis, non-small cell lung cancer, surgery, 451  
 Adults, laparoscopic splenectomy, laparoscopy, splenectomy, hematological holds disorders, hematology, review, 291  
 AdV, glioblastoma, oncogenic viruses, neurotropic viruses, serum biomarkers, HSV, VZV, EBV, HCMV, HHV-6, hEV, TBEV, 221  
 Advanced stage ovarian cancer, rectosigmoidian loop, resection, peritonectomy, 973  
 Adverse events, brain stem gliomas, radiosurgery, rotating gamma system, treatment outcomes, 957  
 Affymetrix GeneChip Array, endothelial cell, nd:YAG laser, 51  
 AFG3L2, mitochondrial membrane dynamics, optic neuropathy, OPA1, MFN, DRP1, SPG7, YME1L, MFF, OPA3, SLC25A46, ATAD3A, review, 511  
 AFP, cirrhosis, HCV, PIVKA-II, HCC, 695  
 African-American, breast cancer, prognosis, 661  
 Age, childhood, gender, genotype, leukemia, *MMP-8*, polymorphism, 1059  
 AIF, fisetin, mitochondria, DNA damage, ENDO G, HSC3 cells, 1103  
 Akt, prenatal hypoxia, neurogenesis, pAkt, PI3K, 855  
 Alcohol, thiamine, vitamin B1, wernicke's encephalopathy, 121  
 ALK-negative, stomach, anaplastic large cell lymphoma, eBV-negative, 701  
 ALT, IL6, monoterpenoid alcohol, RT-PCR, tNF $\alpha$ , 209  
 Alveolar socket, bone regeneration, hydroxyapatite, dog, 335  
 Amino acid consumption, nerve cell, culture condition, growth, amyloid peptide, 1089  
 AML, liver kinase B1, *LKB1*, acute myeloid leukemia, phe354Leu polymorphism, cytogenetically normal, 841  
 Amyloid peptide, nerve cell, culture condition, growth, amino acid consumption, 1089  
 Anaplastic large cell lymphoma, stomach, aALK-negative, eBV-negative, 701  
 Anemia and iron supplementation, reticulocyte hemoglobin content, hemodialysis, 709  
 Aneurysm resection, hepatic artery aneurysm, portal embolization, 979  
 Aneurysm resection, right hepatic artery aneurysm, percutaneous arterial embolization, arteriobiliary fistula, portal vein resection and reconstruction with cadaveric allograft, 983  
 Angiogenesis, bevacizumab, breast cancer, chorioallantoic membrane, mesenchymal stem cells, 199  
 Angiogenesis, chorioallantoic membrane, mesenchymal stem cells, pericyte-like, vasculogenesis, 1139  
 Angiomyolipoma, liver, epithelioid, tumor, laparoscopic surgery, 1169  
 Animal model, zn complex, morphological analysis, ectopic fat deposition, 1145  
 Animal models, BBN, rodents, animal welfare, 1073  
 Animal welfare, BBN, animal models, rodents, 1073  
 Anti-HER2 therapy, breast cancer, HER2, trastuzumab emtansine (T-DM1), japanese patients, 493  
 Anti-HIV, mastic, fractionation, ethyl acetate extraction, antibacterial, anti-HSV, tumor specificity, CYP3A4 inhibition, 591  
 Anti-HSV, mastic, fractionation, ethyl acetate extraction, antibacterial, anti-HIV, tumor specificity, CYP3A4 inhibition, 591

- Anti-tachykinin antibodies, mouse hemokinin-1, substance P, tachykinins, n-terminal acetylation, RP-HPLC, mALDI-ToF, 991
- Antibacterial, mastic, fractionation, ethyl acetate extraction, anti-HIV, anti-HSV, tumor specificity, CYP3A4 inhibition, 591
- Antibiotics, brown rice, lipopolysaccharide, constipation, 573
- Antimicrobial prophylaxis, prosthetic joint infection, coagulase-negative *Staphylococci*, 673
- Antioxidants, eugenol-related compounds, RAW264.7 cells, COX-2, NOS2, HO-1, theoretical parameters, 819
- Antiretroviral therapy, multiple sclerosis, HIV, ATRIPLA®, neuroinflammation, 1041
- Antrodia cinnamomea*, carbon tetrachloride, hepatotoxicity, wistar rats, hepatic fibrosis, 877
- Apoptotic microparticles, chronic hepatitis C, inflammation, diabetes, 1027
- Apparent diffusion coefficient (ADC), multiparametric MRI and prostate cancer, diffusion-weighted imaging (DWI), 415
- Appetite, ghrelin, obesity, hormone levels, diet, bariatric surgery, review, 1047
- Aquaporins, ARDS, inflammation, 885
- ARDS, aquaporins, inflammation, 885
- Arteriobiliary fistula, right hepatic artery aneurysm, percutaneous arterial embolization, aneurysm resection, portal vein resection and reconstruction with cadaveric allograft, 983
- Ascorbic acid deficiency, vitamin C, RNA sequencing, skin, hair growth, 599
- Assisted reproduction, proteomics, IVF, ICSI, fertility, sperm, oocyte, embryo, offspring health, epigenetics, review, 267
- ATAD3A, mitochondrial membrane dynamics, optic neuropathy, OPA1, MFN, DRP1, AFG3L2, SPG7, YME1L, MFF, OPA3, SLC25A46, review, 511
- Atheromasic plaques, CCR5, maraviroc, HIV, HCV, 125
- ATRIPLA®, multiple sclerosis, HIV, antiretroviral therapy, neuroinflammation, 1041
- Atypical, neuroendocrine tumors, bronchial neuroendocrine tumors, carcinoid, typical, ki67 index, 397
- B-ALL, chromosomal abnormalities, centrosome aberrations, hyperdiploidy, polyploidy, prognosis, 215
- B1/b3, non-obstructive azoospermia, oligoasthenoteratozoospermia, male infertility, Y chromosome deletion, gr/gr, b2/b3, 365
- B2/b3, non-obstructive azoospermia, oligoasthenoteratozoospermia, male infertility, Y chromosome deletion, gr/gr, b1/b3, 365
- Bacteriuria, pyuria, upper tract urothelial carcinoma, radical nephroureterectomy, intravesical recurrence, 1215
- Balneotherapy, psoriasis, rehabilitation, 1163
- Bangladeshi, diabetic neuropathy, vitamin D, Greek, 259
- Bariatric surgery, ghrelin, obesity, appetite, hormone levels, diet, review, 1047
- Basal cell carcinoma (BCC), skin cancer, melanoma (MM), nevous (NEV), infrared spectroscopy, diagnostic bands, 1131
- BBN, animal models, rodents, animal welfare, 1073
- Benign polyp, *k-ras* mutation, normal mucosa, biomarker, colorectal cancer, earliest mutation, review, 527
- Bevacizumab, angiogenesis, breast cancer, chorioallantoic membrane, mesenchymal stem cells, 199
- Biliary epithelial cell, isolation, fluorescence-activated cell sorting, mouse gallbladder, 169
- Biliary tract cancer, 5-aminolevulinic acid, photodynamic diagnosis, 905
- BIOCHIP-based indirect immunofluorescence technique, *Pemphigus vulgaris*, saliva, desmoglein 1, desmoglein 3, 97
- Biomarker, *k-ras* mutation, normal mucosa, benign polyp, colorectal cancer, earliest mutation, review, 527
- Biomaterial, cartilage, rabbit, osteochondral defect, tissue regeneration, femoral trochlea, poly-L/D-lactide, 895
- Bladder cancer, radiotherapy, transurethral resection, overall survival, prognostic tool, 745
- Blepharoptosis, ptosis, ptosis surgery outcome, eyelid surgery, eyelid ptosis correction, 111
- Blood vessels, comparative anatomy, rodentia, neck dissection, neck anatomy, 861
- Bone regeneration, alveolar socket, hydroxyapatite, dog, 335
- Bone, duck-beak, osteogenic, potential, hydrogen dioxide, 373
- Brachytherapy, lower urinary tract symptoms, prostate cancer, 755
- Brain metastasis, adrenal metastasis, non-small cell lung cancer, surgery, 451
- Brain metastasis, esophagogastric junction cancer, gastric cancer, stereotactic radiosurgery, gamma knife, long-term survival, 1209
- Brain stem gliomas, radiosurgery, rotating gamma system, treatment outcomes, adverse events, 957
- Breast cancer, acellular dermal matrix, ADM, tutomesh, surgiMend, reconstruction, 677
- Breast cancer, angiogenesis, bevacizumab, chorioallantoic membrane, mesenchymal stem cells, 199
- Breast cancer, cystitis, vaginal atrophy, n-acetylcysteine, d-mannose, 931
- Breast cancer, HER2, trastuzumab emtansine (T-DM1), anti-HER2 therapy, japanese patients, 493
- Breast cancer, influenza, pulmonary disease, admission, 967
- Breast cancer, metaplastic carcinoma, fine-needle aspiration cytology, case report, 737

- Breast cancer, nodal staging, sentinel node, positron-emission tomography (PET) probe, radio-guided surgery, 101
- Breast cancer, prognosis, african–American, 661
- Breast cancer, pT1-T2, pN0-N1, adjuvant radiotherapy, conservative surgery, 151
- Bronchial neuroendocrine tumors, neuroendocrine tumors, carcinoid, typical, atypical, ki67 index, 397
- Brown rice, lipopolysaccharide, antibiotics, constipation, 573
- CA19-9, pancreas, prognostic factor, liver metastasis, 429
- CA19-9, pancreas, prognostic factor, liver metastasis, 731
- Cachexia, sarcopenia, cancer, fatty acids, n-6/n-3, AA/EPA ratio, 1003
- Calcitriol, phosphorus, FGF23, sevelamer hydrochloride, healthy adults, 145
- Cancer-induced bone pain, pain behaviour, chronic pain, neuropathic pain, grid climbing, 619
- Cancer, cachexia, sarcopenia, fatty acids, n-6/n-3, AA/EPA ratio, 1003
- Cancer, cardiovascular disease, end-stage renal disease, hypothyroidism, thyroid abnormalities, thyroid nodules, waiting list for renal transplant, 1203
- Cancer, sports, physical activity, screening, 1187
- Cancer/testis antigen, KK-LC-1, gastric cancer, *Helicobacter pylori*, carcinogen, 403
- Canine umbilical cord blood-mesenchymal stem cells, acute kidney injury, dog, 1115
- Carbon tetrachloride, *Antrodia cinnamomea*, hepatotoxicity, wistar rats, hepatic fibrosis, 877
- Carcinogen, KK-LC-1, cancer/testis antigen, gastric cancer, *Helicobacter pylori*, 403
- Carcinogenesis, ulcerative colitis, mtDNA, digital PCR, 713
- Carcinoid, neuroendocrine tumors, bronchial neuroendocrine tumors, typical, atypical, ki67 index, 397
- Carcinoma of the urinary bladder, definitive treatment, irradiation, overall survival, independent predictive factors, 741
- Carcinoma, lung, epidermal growth factor receptor, chromosome, gene, tissue microarray, 641
- Cardioembolic, suPAR, ischemic stroke, inflammation, mortality, 381
- Cardiotoxicity, fever, clozapine, schizophrenia, case report, 141
- Cardiovascular disease, cancer, end-stage renal disease, hypothyroidism, thyroid abnormalities, thyroid nodules, waiting list for renal transplant, 1203
- Cartilage, biomaterial, rabbit, osteochondral defect, tissue regeneration, femoral trochlea, poly-L/D-lactide, 895
- Case report, breast cancer, metaplastic carcinoma, fine-needle aspiration cytology, 737
- Case report, cardiotoxicity, fever, clozapine, schizophrenia, 141
- Case report, hydroxycarbamide, hydroxyurea, lung toxicity, interstitial pneumonitis, 1221
- Caspase 9, prostate cancer, rs1052576, polymorphism, 205
- CCR5, maraviroc, HIV, HCV, atheromasic plaques, 125
- CD4<sup>+</sup>CD25<sup>+</sup>, parvovirus B19, rheumatoid arthritis, treg, CD8<sup>+</sup>CD25<sup>+</sup>, 181
- CD8<sup>+</sup>CD25<sup>+</sup>, parvovirus B19, rheumatoid arthritis, treg, CD4<sup>+</sup>CD25<sup>+</sup>, 181
- Cecum, signet ring cell carcinoma, distal intramural spread, 705
- Cell proliferation, PEMF, doxorubicin, osteosarcoma, synergistic effect, 61
- Cellular motility, time-lapse videography, environmental chamber, live cell imaging, migrating cells, 329
- Central nervous system, disease progression, programmed cell death 1 ligand 1, renal cell carcinoma, 769
- Centrosome aberrations, B-ALL, chromosomal abnormalities, hyperdiploidy, polyploidy, prognosis, 215
- Cerebral perfusion, congenital diaphragmatic hernia, pulsed arterial spin labeling, extracorporeal membrane oxygenation therapy, common carotid artery occlusion, 557
- Chemoradiation, muscle-invasive bladder cancer, local recurrence, paclitaxel, outcomes, toxicities, 239
- Chemotherapy drugs, tGF-β, total body irradiation, Fanconi anemia, mouse bone marrow, molecular radiation, mitigators, JP4-039, MMS350, 159
- Chemotherapy, melatonin, cisplatin, ovarian cancer, MT1 melatonin receptor, 801
- Childhood, age, gender, genotype, leukemia, MMP-8, polymorphism, 1059
- Chorioallantoic membrane, angiogenesis, bevacizumab, breast cancer, mesenchymal stem cells, 199
- Chorioallantoic membrane, angiogenesis, mesenchymal stem cells, pericyte-like, vasculogenesis, 1139
- Chromosomal abnormalities, B-ALL, centrosome aberrations, hyperdiploidy, polyploidy, prognosis, 215
- Chromosome, lung, carcinoma, epidermal growth factor receptor, gene, tissue microarray, 641
- Chronic hepatitis B, neutrophil-to-lymphocyte ratio, cirrhosis, nucleoside analog therapy, 1175
- Chronic hepatitis B, neutrophil-to-lymphocyte ratio, peginterferon, 723
- Chronic hepatitis C, apoptotic microparticles, inflammation, diabetes, 1027
- Chronic pain, pain behaviour, neuropathic pain, cancer-induced bone pain, grid climbing, 619
- Cirrhosis, chronic hepatitis B, neutrophil-to-lymphocyte ratio, nucleoside analog therapy, 1175

- Cirrhosis, HCV, PIVKA-II, AFP, HCC, 695
- Cisplatin, melatonin, ovarian cancer, chemotherapy, MT1 melatonin receptor, 801
- Cisplatin, thrombotic microangiopathy, thrombotic thrombocytopenic purpura, S-1, 439
- Clinical symptoms, high-grade gliomas, radiochemotherapy, temozolomide, performance status, survival score, 689
- Clomiphene citrate, controlled ovarian hyperstimulation, poor responders, recombinant FSH, mild stimulation, 231
- Clozapine, cardiotoxicity, fever, schizophrenia, case report, 141
- CMV, pulmonary, embolism, immunocompetent, nOACs, 1193
- Coagulase-negative *Staphylococci*, prosthetic joint infection, antimicrobial prophylaxis, 673
- Colectomy specimens, colon, mucosal ulcers, ulcerative colitis crypts, 669
- Colon cancer, ethanol-extracted propolis, rat, dimethylhydrazine, dextran sodium sulfate, inflammation, oxidative stress, 187
- Colon, colectomy specimens, mucosal ulcers, ulcerative colitis crypts, 669
- Colonic resection, triangulating anastomosis, functional end-to-end anastomosis, 683
- Colorectal cancer, *k-ras* mutation, normal mucosa, benign polyp, biomarker, earliest mutation, review, 527
- Colorectal liver metastases, MDN, prognostic factor, 419
- Colorectal, neuroendocrine carcinoma, lymph node metastasis, 1011
- Common carotid artery occlusion, congenital diaphragmatic hernia, pulsed arterial spin labeling, extracorporeal membrane oxygenation therapy, cerebral perfusion, 557
- Comparative anatomy, blood vessels, rodentia, neck dissection, neck anatomy, 861
- Comparison, JAMAR, martin, grip strength, conversion factor, 917
- Competitive repopulation assay, friend virus, hematopoietic stem cells, 313
- Complication, transumbilical, wound, 943
- Compound *Sophora flavescens*, topical treatment, cytokine, perianal ulceration, 543
- Concurrent radiochemotherapy, non-metastatic bile duct cancer, radiotherapy, local control, metastases-free survival, overall survival, 117
- Confocal microscopy, open angle glaucoma, trans-scleral aqueous humor outflow, trabeculectomy, conjunctival microcysts, three-dimensional analysis, 1081
- Congenital diaphragmatic hernia, pulsed arterial spin labeling, extracorporeal membrane oxygenation therapy, common carotid artery occlusion, cerebral perfusion, 557
- Congenital infection, cytomegalovirus, nervous system, 467
- Conjunctival microcysts, confocal microscopy, open angle glaucoma, trans-scleral aqueous humor outflow, trabeculectomy, three-dimensional analysis, 1081
- Conservative surgery, breast cancer, pT1-T2, pN0-N1, adjuvant radiotherapy, 151
- Constipation, brown rice, lipopolysaccharide, antibiotics, 573
- Controlled ovarian hyperstimulation, poor responders, recombinant FSH, mild stimulation, clomiphene citrate, 231
- Conversion factor, JAMAR, martin, grip strength, comparison, 917
- Coronary artery disease, coronary CT angiography, myocardial perfusion imaging, dual-energy CT, myocardial ischemia, 1153
- Coronary artery disease, HDL subfractions, SCARB1, polymorphism, 873
- Coronary CT angiography, coronary artery disease, myocardial perfusion imaging, dual-energy CT, myocardial ischemia, 1153
- Cortisol, gastrointestinal disorder, surgery, stress, rabbits, 637
- COX-2, eugenol-related compounds, antioxidants, RAW264.7 cells, NOS2, HO-1, theoretical parameters, 819
- Crowdsourcing, psychosocial distress, psycho-oncology, facebook, osteosarcoma, ewing's sarcoma, 443
- CRP, liver transplantation, emergency department, PCT, lactate, SAA, IL-6, 1179
- CTC, surgery, metaCell, pancreatic cancer, lung cancer, liquid biopsy, 1197
- Culture condition, nerve cell, growth, amino acid consumption, amyloid peptide, 1089
- CYP3A4 inhibition, mastic, fractionation, ethyl acetate extraction, antibacterial, anti-HIV, anti-HSV, tumor specificity, 591
- Cystitis, breast cancer, vaginal atrophy, n-acetylcysteine, d-mannose, 931
- Cytocompatibility, direct laser interference, titanium implants, 849
- Cytogenetically normal, liver kinase B1, *LKB1*, acute myeloid leukemia, AML, phe354Leu polymorphism, 841
- Cytokine, compound *Sophora flavescens*, topical treatment, perianal ulceration, 543
- Cytomegalovirus, congenital infection, nervous system, 467
- D-mannose, breast cancer, cystitis, vaginal atrophy, n-acetylcysteine, 931
- Debulking surgery, endometrial cancer, peritoneal carcinomatosis, 719
- Definitive treatment, carcinoma of the urinary bladder, irradiation, overall survival, independent predictive factors, 741

- Dermatomyositis, interleukin-4, interleukin-17, interferon-gamma, ELISA, 657
- Desmoglein 1, *Pemphigus vulgaris*, saliva, desmoglein 3, bIOCHIP-based indirect immunofluorescence technique, 97
- Desmoglein 3, *Pemphigus vulgaris*, saliva, desmoglein 1, bIOCHIP-based indirect immunofluorescence technique, 97
- Dexamethasone, knee osteoarthritis, matrix metalloproteinase, periostin, 69
- Dextran sodium sulfate, ethanol-extracted propolis, rat, colon cancer, dimethylhydrazine, inflammation, oxidative stress, 187
- Diabetes, chronic hepatitis C, apoptotic microparticles, inflammation, 1027
- Diabetes, obesity, wound healing, zucker diabetic sprague dawley, rat, 55
- Diabetic nephropathy, microalbuminuria, urinary albumin excretion (UAE), 285
- Diabetic neuropathy, vitamin D, Greek, bangladeshi, 259
- Diagnostic bands, skin cancer, basal cell carcinoma (BCC), melanoma (MM), nevous (NEV), infrared spectroscopy, 1131
- Diagnostic dilemma, hepatic epithelioid haemangioendothelioma, treatment options, 763
- Diet, ghrelin, obesity, appetite, hormone levels, bariatric surgery, review, 1047
- Differentiation, netrin-1, osteoblast, 321
- Differentiation, netrin-4, osteoblast, migration, 793
- Diffusion-weighted imaging (DWI), multiparametric MRI and prostate cancer, apparent diffusion coefficient (ADC), 415
- Digital PCR, ulcerative colitis, carcinogenesis, mtDNA, 713
- Dimethylhydrazine, ethanol-extracted propolis, rat, colon cancer, dextran sodium sulfate, inflammation, oxidative stress, 187
- Direct laser interference, titanium implants, cytocompatibility, 849
- Disease progression, central nervous system, programmed cell death 1 ligand 1, renal cell carcinoma, 769
- Disease, rats, mice, kidneys, renal function, review, 1
- Disinfectant, nano-bubble water, ozone, 579
- Distal intramural spread, cecum, signet ring cell carcinoma, 705
- DNA damage, fisetin, mitochondria, AIF, ENDO G, HSC3 cells, 1103
- Dog, acute kidney injury, canine umbilical cord blood-mesenchymal stem cells, 1115
- Dog, alveolar socket, bone regeneration, hydroxyapatite, 335
- Donor areas, fat grafting, adipose-derived stem cells, viability, yield, 1229
- Doxorubicin, PEMF, osteosarcoma, cell proliferation, synergistic effect, 61
- DRP1, mitochondrial membrane dynamics, optic neuropathy, OPA1, MFN, AFG3L2, SPG7, YME1L, MFF, OPA3, SLC25A46, ATAD3A, review, 511
- Dual-energy CT, coronary CT angiography, coronary artery disease, myocardial perfusion imaging, myocardial ischemia, 1153
- Duck-beak, bone, osteogenic, potential, hydrogen dioxide, 373
- Dyspnea, laterofixation, vocal fold immobility, vocal fold paralysis, recurrent laryngeal nerve paralysis, 1159
- Earliest mutation, *k-ras* mutation, normal mucosa, benign polyp, biomarker, colorectal cancer, review, 527
- EBV-negative, stomach, anaplastic large cell lymphoma, aLK-negative, 701
- EBV, glioblastoma, oncogenic viruses, neurotropic viruses, serum biomarkers, HSV, VZV, HCMV, HHV-6, adV, hEV, TBEV, 221
- Ectopic fat deposition, zn complex, morphological analysis, animal model, 1145
- EGFR kinase domain, oral and oropharyngeal cancer, mutations, pyrosequencing, review, 23
- Elderly, head and neck cancer, radiotherapy, oropharynx, survival, recurrence, metastasis, outcome, 455
- ELISA, dermatomyositis, interleukin-4, interleukin-17, interferon-gamma, 657
- Embolism, pulmonary, immunocompetent, CMV, nOACs, 1193
- Embryo, proteomics, assisted reproduction, IVF, ICSI, fertility, sperm, oocyte, offspring health, epigenetics, review, 267
- Emergency department, liver transplantation, CRP, PCT, lactate, SAA, IL-6, 1179
- End-stage polycystic kidney, renal transplantation, nephrectomy, review, 307
- End-stage renal disease, cancer, cardiovascular disease, hypothyroidism, thyroid abnormalities, thyroid nodules, waiting list for renal transplant, 1203
- ENDO G, fisetin, mitochondria, DNA damage, AIF, HSC3 cells, 1103
- Endometrial cancer, peritoneal carcinomatosis, debulking surgery, 719
- Endometriosis, ileocecal valve, obstruction, 999
- Endothelial cell, affymetrix GeneChip Array, nd:YAG laser, 51
- Endothelial cells, non-alcoholic steatohepatitis, oxidative stress, silybin, thiobarbituric acid reactive substances, 609
- Environmental chamber, time-lapse videography, live cell imaging, migrating cells, cellular motility, 329
- Epidermal growth factor receptor, lung, carcinoma, chromosome, gene, tissue microarray, 641
- Epigenetics, proteomics, assisted reproduction, IVF, ICSI, fertility, sperm, oocyte, embryo, offspring health, review, 267

- Epithelioid, liver, angiomyolipoma, tumor, laparoscopic surgery, 1169
- Epstein-Barr virus, positron emission tomography, gastric cancer, tumor metabolism, 749
- Esophageal cancer, head and neck cancer, synchronous double cancer, 909
- Esophageal cancer, superdrainage, gastric tube, indocyanine green fluorescence, 1019
- Esophagogastric junction cancer, gastric cancer, brain metastasis, stereotactic radiosurgery, gamma knife, long-term survival, 1209
- Estrous synchronization, miniature pig, prostaglandin F2 $\alpha$ , 1097
- Ethanol-extracted propolis, rat, colon cancer, dimethylhydrazine, dextran sodium sulfate, inflammation, oxidative stress, 187
- Ethyl acetate extraction, mastic, fractionation, antibacterial, anti-HIV, anti-HSV, tumor specificity, CYP3A4 inhibition, 591
- Eugenol-related compounds, antioxidants, RAW264.7 cells, COX-2, NOS2, HO-1, theoretical parameters, 819
- Ewing's sarcoma, neuroblastoma, orthotopic, preclinical model, ultrasound, xenograft, 779
- Ewing's sarcoma, peripheral primitive neuroectodermal tumor, histological features, 481
- Ewing's sarcoma, psychosocial distress, psycho-oncology, crowdsourcing, facebook, osteosarcoma, 443
- Excision, primary, vaginal, melanoma, staging, treatment, prognosis, 133
- Extracorporeal membrane oxygenation therapy, congenital diaphragmatic hernia, pulsed arterial spin labeling, common carotid artery occlusion, cerebral perfusion, 557
- Extravasated platelet aggregation, sepsis, multiple organ failure (MOF), neutrophil extracellular traps (NETs), 1051
- Eyelid ptosis correction, ptosis, blepharoptosis, ptosis surgery outcome, eyelid surgery, 111
- Eyelid surgery, ptosis, blepharoptosis, ptosis surgery outcome, eyelid ptosis correction, 111
- Facebook, psychosocial distress, psycho-oncology, crowdsourcing, osteosarcoma, ewing's sarcoma, 443
- Fanconi anemia, tGF- $\beta$ , total body irradiation, chemotherapy drugs, mouse bone marrow, molecular radiation, mitigators, JP4-039, MMS350, 159
- Fat grafting, adipose-derived stem cells, viability, yield, donor areas, 1229
- Fat tissue addition, nerve, GFAP, NFAP, 649
- Fatty acids, cachexia, sarcopenia, cancer, n-6/n-3, AA/EPA ratio, 1003
- Febrile neutropenia, lipegfilgrastim, myelosuppressive chemotherapy, prophylaxis, review, 303
- Femoral trochlea, cartilage, biomaterial, rabbit, osteochondral defect, tissue regeneration, poly-L/D-lactide, 895
- Fertility, proteomics, assisted reproduction, IVF, ICSI, sperm, oocyte, embryo, offspring health, epigenetics, review, 267
- Fever, cardiotoxicity, clozapine, schizophrenia, case report, 141
- FGF23, calcitriol, phosphorus, sevelamer hydrochloride, healthy adults, 145
- FGR, platelet glycoproteins, sNPs, pyrosequencing, 243
- Fine-needle aspiration cytology, breast cancer, metaplastic carcinoma, case report, 737
- Fisetin, mitochondria, DNA damage, AIF, ENDO G, HSC3 cells, 1103
- Floseal®, gynecologic surgery, intraoperative bleeding, hemostasis, hemostatic matrix, 251
- Fluorescence-activated cell sorting, biliary epithelial cell, isolation, mouse gallbladder, 169
- FoxO, nicotine, renal risk, oxidative stress, resveratrol, mnSOD smoking, 551
- Fractionation, mastic, ethyl acetate extraction, antibacterial, anti-HIV, anti-HSV, tumor specificity, CYP3A4 inhibition, 591
- Friend virus, hematopoietic stem cells, competitive repopulation assay, 313
- Functional end-to-end anastomosis, triangulating anastomosis, colonic resection, 683
- Gamma knife, esophagogastric junction cancer, gastric cancer, brain metastasis, stereotactic radiosurgery, long-term survival, 1209
- Gastric cancer, esophagogastric junction cancer, brain metastasis, stereotactic radiosurgery, gamma knife, long-term survival, 1209
- Gastric cancer, inhibin beta A, adjuvant chemotherapy, 565
- Gastric cancer, KK-LC-1, cancer/testis antigen, *Helicobacter pylori*, carcinogen, 403
- Gastric cancer, positron emission tomography, epstein-Barr virus, tumor metabolism, 749
- Gastric cancer, subserosal invasion, prognosis, 409
- Gastric cancer, tensin 4, TNS4, adjuvant chemotherapy, S-1, prognostic factor, 1065
- Gastric tube, superdrainage, esophageal cancer, indocyanine green fluorescence, 1019
- Gastrointestinal disorder, surgery, stress, rabbits, cortisol, 637
- Gender, age, childhood, genotype, leukemia, MMP-8, polymorphism, 1059
- Gene, lung, carcinoma, epidermal growth factor receptor, chromosome, tissue microarray, 641
- Genotype, age, childhood, gender, leukemia, MMP-8, polymorphism, 1059

- Genotype, *MMP-7*, polymorphism, renal cell cancer, taiwan, 631  
 Genotype, *MMP-8*, oral cancer, polymerase chain reaction, polymorphism, 585  
*GFAP*, nerve, fat tissue addition, NFAP, 649  
*Ghrelin*, obesity, appetite, hormone levels, diet, bariatric surgery, review, 1047  
*Glioblastoma*, oncogenic viruses, neurotropic viruses, serum biomarkers, HSV, VZV, EBV, HCMV, HHV-6, adV, hEV, TBEV, 221  
*Gr/gr*, non-obstructive azoospermia, oligoasthenoteratozoospermia, male infertility, Y chromosome deletion, b1/b3, b2/b3, 365  
 Greek, diabetic neuropathy, vitamin D, bangladeshi, 259  
 Grid climbing, pain behaviour, chronic pain, neuropathic pain, cancer-induced bone pain, 619  
 Grip strength, JAMAR, martin, comparison, conversion factor, 917  
 Growth, nerve cell, culture condition, amino acid consumption, amyloid peptide, 1089  
*GS-nitroxide*, oxidative stress, radiation mitigation, 39  
*Gynecologic surgery*, intraoperative bleeding, hemostasis, hemostatic matrix, floseal®, 251  
 Hair growth, vitamin C, ascorbic acid deficiency, RNA sequencing, skin, 599  
*HCC*, cirrhosis, HCV, PIVKA-II, AFP, 695  
*HCMV*, glioblastoma, oncogenic viruses, neurotropic viruses, serum biomarkers, HSV, VZV, EBV, HHV-6, adV, hEV, TBEV, 221  
*HCV*, CCR5, maraviroc, HIV, atheromasic plaques, 125  
*HCV*, cirrhosis, PIVKA-II, AFP, HCC, 695  
 HDL subfractions, coronary artery disease, SCARB1, polymorphism, 873  
 Head and neck cancer, elderly, radiotherapy, oropharynx, survival, recurrence, metastasis, outcome, 455  
 Head and neck cancer, esophageal cancer, synchronous double cancer, 909  
 Head and neck cancer, radio(chemo)therapy, locally advanced, inoperable, 949  
 Healthy adults, calcitriol, phosphorus, FGF23, sevelamer hydrochloride, 145  
*Helicobacter pylori*, KK-LC-1, cancer/testis antigen, gastric cancer, carcinogen, 403  
 Hematological disorders, laparoscopic splenectomy, laparoscopy, splenectomy, hematology, adults, review, 291  
 Hematology, laparoscopic splenectomy, laparoscopy, splenectomy, hematological disorders, adults, review, 291  
 Hematopoietic stem cells, friend virus, competitive repopulation assay, 313  
 Hemodialysis, reticulocyte hemoglobin content, anemia and iron supplementation, 709  
*Hemostasis*, gynecologic surgery, intraoperative bleeding, hemostatic matrix, floseal®, 251  
*Haemostatic matrix*, gynecologic surgery, intraoperative bleeding, hemostasis, floseal®, 251  
*Hepatic artery aneurysm*, portal embolization, aneurysm resection, 979  
*Hepatic epithelioid haemangioendothelioma*, diagnostic dilemma, treatment options, 763  
*Hepatic fibrosis*, *Antrodia cinnamomea*, carbon tetrachloride, hepatotoxicity, wistar rats, 877  
*Hepatotoxicity*, *Antrodia cinnamomea*, carbon tetrachloride, wistar rats, hepatic fibrosis, 877  
*HER2*, breast cancer, trastuzumab emtansine (T-DM1), anti-HER2 therapy, japanese patients, 493  
*Heterotopic ossification (HO)*, radiation therapy (RT), acetabular fracture, megavoltage photon, split-beam technique, testicular dose, radiation prophylaxis, indomethacin, 461  
*HEV*, glioblastoma, oncogenic viruses, neurotropic viruses, serum biomarkers, HSV, VZV, EBV, HCMV, HHV-6, adV, TBEV, 221  
*HHV-6*, glioblastoma, oncogenic viruses, neurotropic viruses, serum biomarkers, HSV, VZV, EBV, HCMV, adV, hEV, TBEV, 221  
 High-grade gliomas, radiochemotherapy, temozolamide, clinical symptoms, performance status, survival score, 689  
*Histological features*, ewing's sarcoma, peripheral primitive neuroectodermal tumor, 481  
*Histology*, rebiopsy, non-small cell lung cancer, 475  
*HIV*, CCR5, maraviroc, HCV, atheromasic plaques, 125  
*HIV*, multiple sclerosis, antiretroviral therapy, ATRIPLA®, neuroinflammation, 1041  
*HO-1*, eugenol-related compounds, antioxidants, RAW264.7 cells, COX-2, NOS2, theoretical parameters, 819  
*Hormone levels*, ghrelin, obesity, appetite, diet, bariatric surgery, review, 1047  
*HSC3 cells*, fisetin, mitochondria, DNA damage, AIF, ENDO G, 1103  
*HSV*, glioblastoma, oncogenic viruses, neurotropic viruses, serum biomarkers, VZV, EBV, HCMV, HHV-6, adV, hEV, TBEV, 221  
 Hydrogen dioxide, duck-beak, bone, osteogenic, potential, 373  
*Hydroxyapatite*, alveolar socket, bone regeneration, dog, 335  
*Hydroxycarbamide*, hydroxyurea, lung toxicity, interstitial pneumonitis, case report, 1221  
*Hydroxyurea*, hydroxycarbamide, lung toxicity, interstitial pneumonitis, case report, 1221

- Hyperdiploidy, B-ALL, chromosomal abnormalities, centrosome aberrations, polyploidy, prognosis, 215
- Hyperparathyroidism, parathyroid carcinoma, surgery, 925
- Hypothyroidism, cancer, cardiovascular disease, end-stage renal disease, thyroid abnormalities, thyroid nodules, waiting list for renal transplant, 1203
- Hypothyroidism, lung cancer, nivolumab, thyroglobulin, thyroid peroxidase, 1035
- Hypoxia, prenatal, neurogenesis, pax6, immunoreactivity, neural progenitor cell, 1125
- Ica+ strain, osteomyelitis, implant-related infection *Staphylococcus aureus*, immunization, vaccine, ica<sup>-</sup> strain, 45
- Ica- strain, osteomyelitis, implant-related infection *Staphylococcus aureus*, immunization, vaccine, ica<sup>+</sup> strain, 45
- ICSI, proteomics, assisted reproduction, IVF, fertility, sperm, oocyte, embryo, offspring health, epigenetics, review, 267
- Idiopathic pulmonary fibrosis, lung cancer, nintedanib, prognosis, therapy, 773
- IL-6, liver transplantation, emergency department, CRP, PCT, lactate, SAA, 1179
- IL13, knee osteoarthritis, periostin, interleukin-13, signal transducer and activator of transcription 6, STAT6, 79
- IL6, ALT, monoterpenoid alcohol, RT-PCR, tNF $\alpha$ , 209
- Ileocecal valve, endometriosis, obstruction, 999
- Immunization, osteomyelitis, implant-related infection *Staphylococcus aureus*, vaccine, ica<sup>+</sup> strain, ica<sup>-</sup> strain, 45
- Immunocompetent, pulmonary, embolism, CMV, nOACs, 1193
- Immunoreactivity, hypoxia, prenatal, neurogenesis, pax6, neural progenitor cell, 1125
- Immunotherapy, thyroid, nivolumab, 1225
- Implant-associated infection, prosthetic joint infection, tissue biopsy arthroplasty, 937
- Implant-related infection *Staphylococcus aureus*, osteomyelitis, immunization, vaccine, ica<sup>+</sup> strain, ica<sup>-</sup> strain, 45
- Independent predictive factors, carcinoma of the urinary bladder, definitive treatment, irradiation, overall survival, 741
- Indocyanine green fluorescence, superdrainage, gastric tube, esophageal cancer, 1019
- Indomethacin, radiation therapy (RT), acetabular fracture, heterotopic ossification (HO), megavoltage photon, split-beam technique, testicular dose, radiation prophylaxis, 461
- Inerleukin-17, dermatomyositis, interleukin-4, interferon-gamma, ELISA, 657
- Inflammation, aquaporins, ARDS, 885
- Inflammation, chronic hepatitis C, apoptotic microparticles, diabetes, 1027
- Inflammation, ethanol-extracted propolis, rat, colon cancer, dimethylhydrazine, dextran sodium sulfate, oxidative stress, 187
- Inflammation, mesenchymal stem cell, oct4, sox2, lipopolysaccharide, 349
- Inflammation, morphine, adjuvant-induced arthritis, uDP-glucuronosyltransferase, ABCB1, 811
- Inflammation, suPAR, ischemic stroke, mortality, cardioembolic, 381
- Influenza, breast cancer, pulmonary disease, admission, 967
- Infrared spectroscopy, skin cancer, basal cell carcinoma (BCC), melanoma (MM), nevous (NEV), diagnostic bands, 1131
- Inhibin beta A, gastric cancer, adjuvant chemotherapy, 565
- Inoperable, head and neck cancer, radio(chemo)therapy, locally advanced, 949
- Interferon-gamma, dermatomyositis, interleukin-4, inerleukin-17, ELISA, 657
- Interleukin-13, knee osteoarthritis, periostin, IL13, signal transducer and activator of transcription 6, STAT6, 79
- Interleukin-4, dermatomyositis, inerleukin-17, interferon-gamma, ELISA, 657
- Interstitial pneumonitis, hydroxycarbamide, hydroxyurea, lung toxicity, case report, 1221
- Intraoperative bleeding, gynecologic surgery, hemostasis, hemostatic matrix, floseal®, 251
- Intravesical recurrence, bacteruria, pyuria, upper tract urothelial carcinoma, radical nephroureterectomy, 1215
- Irradiation, carcinoma of the urinary bladder, definitive treatment, overall survival, independent predictive factors, 741
- Irradiation, locally recurrent carcinoma of the bladder, pre-treatment factors, predictive score, survival, 435
- Ischemic stroke, suPAR, inflammation, mortality, cardioembolic, 381
- Isolation, biliary epithelial cell, fluorescence-activated cell sorting, mouse gallbladder, 169
- IVF, proteomics, assisted reproduction, ICSI, fertility, sperm, oocyte, embryo, offspring health, epigenetics, review, 267
- JAMAR, martin, grip strength, comparison, conversion factor, 917
- Japanese patients, breast cancer, HER2, trastuzumab emtansine (T-DM1), anti-HER2 therapy, 493
- JP4-039, tGF- $\beta$ , total body irradiation, chemotherapy drugs, fanconi Anemia, mouse bone marrow, molecular radiation, mitigators, MMS350, 159
- K-ras mutation, normal mucosa, benign polyp, biomarker, colorectal cancer, earliest mutation, review, 527
- Ki67 index, neuroendocrine tumors, bronchial neuroendocrine tumors, carcinoid, typical, atypical, 397

- Kidneys, rats, mice, disease, renal function, review, 1
- KK-LC-1, cancer/testis antigen, gastric cancer, *Helicobacter pylori*, carcinogen, 403
- Knee osteoarthritis, dexamethasone, matrix metalloproteinase, periostin, 69
- Knee osteoarthritis, periostin, interleukin-13, IL13, signal transducer and activator of transcription 6, STAT6, 79
- Lactate, liver transplantation, emergency department, CRP, PCT, SAA, IL-6, 1179
- Laparoscopic splenectomy, laparoscopy, splenectomy, hematological disorders, hematology, adults, review, 291
- Laparoscopic surgery, liver, angiomyolipoma, epithelioid, tumor, 1169
- Laparoscopy, laparoscopic splenectomy, splenectomy, hematological disorders, hematology, adults, review, 291
- Laterofixation, vocal fold immobility, vocal fold paralysis, recurrent laryngeal nerve paralysis, dyspnea, 1159
- Leukemia, age, childhood, gender, genotype, MMP-8, polymorphism, 1059
- Lipegfilgrastim, myelosuppressive chemotherapy, febrile neutropenia, prophylaxis, review, 303
- Lipoma, sarcoma, liposarcoma, MRI, 387
- Lipopolysaccharide, brown rice, antibiotics, constipation, 573
- Lipopolysaccharide, inflammation, mesenchymal stem cell, oct4, sox2, 349
- Liposarcoma, sarcoma, lipoma, MRI, 387
- Liquid biopsy, CTC, surgery, metaCell, pancreatic cancer, lung cancer, 1197
- Live cell imaging, time-lapse videography, environmental chamber, migrating cells, cellular motility, 329
- Liver kinase B1, *LKB1*, acute myeloid leukemia, AML, phe354Leu polymorphism, cytogenetically normal, 841
- Liver metastasis, pancreas, prognostic factor, CA19-9, 429
- Liver metastasis, pancreas, prognostic factor, CA19-9, 731
- Liver transplantation, emergency department, CRP, PCT, lactate, SAA, IL-6, 1179
- Liver, angiomyolipoma, epithelioid, tumor, laparoscopic surgery, 1169
- LKB1*, liver kinase B1, acute myeloid leukemia, AML, phe354Leu polymorphism, cytogenetically normal, 841
- Local control, non-metastatic bile duct cancer, concurrent radiochemotherapy, radiotherapy, metastases-free survival, overall survival, 117
- Local control, prostate cancer, metastases to the brain, WBI, survival, 35
- Local recurrence, muscle-invasive bladder cancer, chemoradiation, paclitaxel, outcomes, toxicities, 239
- Locally recurrent carcinoma of the bladder, irradiation, pre-treatment factors, predictive score, survival, 435
- Locally advanced, head and neck cancer, radio(chemo)therapy, inoperable, 949
- Long-term survival, esophagogastric junction cancer, gastric cancer, brain metastasis, stereotactic radiosurgery, gamma knife, 1209
- Lower urinary tract symptoms, brachytherapy, prostate cancer, 755
- Lung cancer cell lines, lung fibroblasts,  $\alpha/\beta$  ratio, 175
- Lung cancer, CTC, surgery, metaCell, pancreatic cancer, liquid biopsy, 1197
- Lung cancer, hypothyroidism, nivolumab, thyroglobulin, thyroid peroxidase, 1035
- Lung cancer, idiopathic pulmonary fibrosis, nintedanib, prognosis, therapy, 773
- Lung fibroblasts, lung cancer cell lines,  $\alpha/\beta$  ratio, 175
- Lung toxicity, hydroxycarbamide, hydroxyurea, interstitial pneumonitis, case report, 1221
- Lung, carcinoma, epidermal growth factor receptor, chromosome, gene, tissue microarray, 641
- Lymph node metastasis, neuroendocrine carcinoma, colorectal, 1011
- Lymphangioma, paediatric, orbital, sclerotherapy, sodium tetradecylsulfate (STS), 263
- MALDI-ToF, mouse hemokinin-1, substance P, tachykinins, N-terminal acetylation, anti-tachykinin antibodies, RP-HPLC, 991
- Male infertility, non-obstructive azoospermia, oligoasthenoteratozoospermia, Y chromosome deletion, gr/gr, b1/b3, b2/b3, 365
- Maraviroc, CCR5, HIV, HCV, atheromasic plaques, 125
- Martin, JAMAR, grip strength, comparison, conversion factor, 917
- Mastic, fractionation, ethyl acetate extraction, antibacterial, anti-HIV, anti-HSV, tumor specificity, CYP3A4 inhibition, 591
- Matrix metalloproteinase, dexamethasone, knee osteoarthritis, periostin, 69
- MDM2, prolactinoma, p16, polymorphism, 357
- MDN, colorectal liver metastases, prognostic factor, 419
- Mediastinal shift, pneumonectomy, tracheal deviation, 1023
- Megavoltage photon, radiation therapy (RT), acetabular fracture, heterotopic ossification (HO), split-beam technique, testicular dose, radiation prophylaxis, indomethacin, 461
- Melanoma (MM), skin cancer, basal cell carcinoma (BCC), nevous (NEV), infrared spectroscopy, diagnostic bands, 1131

- Melanoma, primary, vaginal, excision, staging, treatment, prognosis, 133
- Melatonin, cisplatin, ovarian cancer, chemotherapy, MT1 melatonin receptor, 801
- Mesenchymal stem cell, inflammation, oct4, sox2, lipopolysaccharide, 349
- Mesenchymal stem cells, angiogenesis, bevacizumab, breast cancer, chorioallantoic membrane, 199
- Mesenchymal stem cells, angiogenesis, chorioallantoic membrane, pericyte-like, vasculogenesis, 1139
- MetaCell, CTC, surgery, pancreatic cancer, lung cancer, liquid biopsy, 1197
- Metaplastic carcinoma, breast cancer, fine-needle aspiration cytology, case report, 737
- Metastases to the brain, prostate cancer, WBI, local control, survival, 35
- Metastases-free survival, non-metastatic bile duct cancer, concurrent radiochemotherapy, radiotherapy, local control, overall survival, 117
- Metastasis, head and neck cancer, elderly, radiotherapy, oropharynx, survival, recurrence, outcome, 455
- Metastasis, RUNX3, pancreatic cancer, surgical resection, 833
- Metastasis, RUNX3, pancreatic cancer, surgical resection, 833
- MFF, mitochondrial membrane dynamics, optic neuropathy, OPA1, MFN, DRP1, AFG3L2, SPG7, YME1L, OPA3, SLC25A46, ATAD3A, review, 511
- MFN, mitochondrial membrane dynamics, optic neuropathy, OPA1, DRP1, AFG3L2, SPG7, YME1L, MFF, OPA3, SLC25A46, ATAD3A, review, 511
- Mice, rats, disease, kidneys, renal function, review, 1
- Microalbuminuria, diabetic nephropathy, urinary albumin excretion (UAE), 285
- MicroRNA-1, renal cell carcinoma, microRNA-21, proliferation, 625
- MicroRNA-21, renal cell carcinoma, microRNA-1, proliferation, 625
- Migrating cells, time-lapse videography, environmental chamber, live cell imaging, cellular motility, 329
- Migration, netrin-4, osteoblast, differentiation, 793
- Mild stimulation, controlled ovarian hyperstimulation, poor responders, recombinant FSH, clomiphene citrate, 231
- Miniature pig, estrous synchronization, prostaglandin F2 $\alpha$ , 1097
- Mitigators, tGF- $\beta$ , total body irradiation, chemotherapy drugs, fanconi Anemia, mouse bone marrow, molecular radiation, JP4-039, MMS350, 159
- Mitochondria, fisetin, DNA damage, AIF, ENDO G, HSC3 cells, 1103
- MMP-7*, genotype, polymorphism, renal cell cancer, taiwan, 631
- MMP-8*, age, childhood, gender, genotype, leukemia, polymorphism, 1059
- MMP-8*, genotype, oral cancer, polymerase chain reaction, polymorphism, 585
- MMS350, tGF- $\beta$ , total body irradiation, chemotherapy drugs, Fanconi anemia, mouse bone marrow, molecular radiation, mitigators, JP4-039, 159
- MnSOD smoking, nicotine, renal risk, oxidative stress, resveratrol, foxO, 551
- Molecular radiation, tGF- $\beta$ , total body irradiation, chemotherapy drugs, Fanconi anemia, mouse bone marrow, mitigators, JP4-039, MMS350, 159
- Monoterpene alcohol, ALT, IL6, RT-PCR, tNF $\alpha$ , 209
- Morphine, inflammation, adjuvant-induced arthritis, uDP-glucuronosyltransferase, ABCB1, 811
- Morphological analysis, zn complex, ectopic fat deposition, animal model, 1145
- Mortality, suPAR, ischemic stroke, inflammation, cardioembolic, 381
- Mouse bone marrow, tGF- $\beta$ , total body irradiation, chemotherapy drugs, Fanconi anemia, molecular radiation, mitigators, JP4-039, MMS350, 159
- Mouse gallbladder, biliary epithelial cell, isolation, fluorescence-activated cell sorting, 169
- Mouse hemokinin-1, substance P, tachykinins, n-terminal acetylation, anti-tachykinin antibodies, RP-HPLC, mALDI-ToF, 991
- MRI, sarcoma, liposarcoma, lipoma, 387
- MT1 melatonin receptor, melatonin, cisplatin, ovarian cancer, chemotherapy, 801
- MtDNA, ulcerative colitis, carcinogenesis, digital PCR, 713
- Mucosal ulcers, colon, colectomy specimens, ulcerative colitis crypts, 669
- Multiparametric MRI and prostate cancer, apparent diffusion coefficient (ADC), diffusion-weighted imaging (DWI), 415
- Multiple organ failure (MOF), sepsis, neutrophil extracellular traps (NETs), extravasated platelet aggregation, 1051
- Multiple sclerosis, HIV, antiretroviral therapy, ATRIPLA®, neuroinflammation, 1041
- Muscle-invasive bladder cancer, local recurrence, chemoradiation, paclitaxel, outcomes, toxicities, 239
- Mutations, oral and oropharyngeal cancer, EGFR kinase domain, pyrosequencing, review, 23
- Myelosuppressive chemotherapy, lipegfilgrastim, febrile neutropenia, prophylaxis, review, 303
- Myocardial ischemia, coronary CT angiography, coronary artery disease, myocardial perfusion imaging, dual-energy CT, 1153

- Myocardial perfusion imaging, coronary CT angiography, coronary artery disease, dual-energy CT, myocardial ischemia, 1153
- N-6/n-3, cachexia, sarcopenia, cancer, fatty acids, AA/EPA ratio, 1003
- N-acetylcysteine, breast cancer, cystitis, vaginal atrophy, d-mannose, 931
- N-terminal acetylation, mouse hemokinin-1, substance P, tachykinins, anti-tachykinin antibodies, RP-HPLC, mALDI-ToF, 991
- Nano-bubble water, disinfectant, ozone, 579
- Nd:YAG laser, affymetrix GeneChip Array, endothelial cell, 51
- Neck anatomy, comparative anatomy, blood vessels, rodentia, neck dissection, 861
- Neck dissection, comparative anatomy, blood vessels, rodentia, neck anatomy, 861
- Neoplasm, solid, pseudopapillary, tumor, pancreas, review, 501
- Nephrectomy, end-stage polycystic kidney, renal transplantation, review, 307
- Nerve cell, culture condition, growth, amino acid consumption, amyloid peptide, 1089
- Nerve, fat tissue addition, GFAP, NFAP, 649
- Nervous system, cytomegalovirus, congenital infection, 467
- Netrin-1, osteoblast, differentiation, 321
- Netrin-4, osteoblast, differentiation, migration, 793
- Neural progenitor cell, hypoxia, prenatal, neurogenesis, pax6, immunoreactivity, 1125
- Neuroblastoma, Ewing's sarcoma, orthotopic, preclinical model, ultrasound, xenograft, 779
- Neuroendocrine carcinoma, colorectal, lymph node metastasis, 1011
- Neuroendocrine tumors, bronchial neuroendocrine tumors, carcinoid, typical, atypical, ki67 index, 397
- Neurogenesis, hypoxia, prenatal, pax6, immunoreactivity, neural progenitor cell, 1125
- Neurogenesis, prenatal hypoxia, akt, pAkt, PI3K, 855
- Neuroinflammation, multiple sclerosis, HIV, antiretroviral therapy, ATRIPLA®, 1041
- Neuropathic pain, pain behaviour, chronic pain, cancer-induced bone pain, grid climbing, 619
- Neurotropic viruses, glioblastoma, oncogenic viruses, serum biomarkers, HSV, VZV, EBV, HCMV, HHV-6, adV, hEV, TBEV, 221
- Neutrophil extracellular traps (NETs), sepsis, multiple organ failure (MOF), extravasated platelet aggregation, 1051
- Neutrophil-to-lymphocyte ratio, chronic hepatitis B, cirrhosis, nucleoside analog therapy, 1175
- Neutrophil-to-lymphocyte ratio, chronic hepatitis B, peginterferon, 723
- Nevous (NEV), skin cancer, basal cell carcinoma (BCC), melanoma (MM), infrared spectroscopy, diagnostic bands, 1131
- NFAP, nerve, fat tissue addition, GFAP, 649
- Nicotine, renal risk, oxidative stress, resveratrol, foxO, mnSOD smoking, 551
- Nintedanib, lung cancer, idiopathic pulmonary fibrosis, prognosis, therapy, 773
- Nivolumab, hypothyroidism, lung cancer, thyroglobulin, thyroid peroxidase, 1035
- Nivolumab, thyroid, immunotherapy, 1225
- NOACs, pulmonary, embolism, immunocompetent, CMV, 1193
- Nodal staging, breast cancer, sentinel node, positron-emission tomography (PET) probe, radio-guided surgery, 101
- Non-alcoholic steatohepatitis, endothelial cells, oxidative stress, silybin, thiobarbituric acid reactive substances, 609
- Non-metastatic bile duct cancer, concurrent radiochemotherapy, radiotherapy, local control, metastases-free survival, overall survival, 117
- Non-obstructive azoospermia, oligoasthenoteratozoo-spermia, male infertility, Y chromosome deletion, gr/gr, b1/b3, b2/b3, 365
- Non-small cell lung cancer, adrenal metastasis, brain metastasis, surgery, 451
- Non-small cell lung cancer, rebiopsy, histology, 475
- Normal mucosa, *k-ras* mutation, benign polyp, biomarker, colorectal cancer, earliest mutation, review, 527
- NOS2, eugenol-related compounds, antioxidants, RAW264.7 cells, COX-2, HO-1, theoretical parameters, 819
- Nucleoside analog therapy, chronic hepatitis B, neutrophil-to-lymphocyte ratio, cirrhosis, 1175
- Obesity, diabetes, wound healing, zucker diabetic sprague dawley, rat, 55
- Obesity, ghrelin, appetite, hormone levels, diet, bariatric surgery, review, 1047
- Obstruction, endometriosis, ileocecal valve, 999
- Oct4, inflammation, mesenchymal stem cell, sox2, lipopolysaccharide, 349
- Offspring health, proteomics, assisted reproduction, IVF, ICSI, fertility, sperm, oocyte, embryo, epigenetics, review, 267
- Oligoasthenoteratozoo-spermia, non-obstructive azoospermia, male infertility, Y chromosome deletion, gr/gr, b1/b3, b2/b3, 365
- Oncogenic viruses, glioblastoma, neurotropic viruses, serum biomarkers, HSV, VZV, EBV, HCMV, HHV-6, adV, hEV, TBEV, 221
- Oocyte, proteomics, assisted reproduction, IVF, ICSI, fertility, sperm, embryo, offspring health, epigenetics, review, 267

- OPA1, mitochondrial membrane dynamics, optic neuropathy, MFN, DRP1, AFG3L2, SPG7, YME1L, MFF, OPA3, SLC25A46, ATAD3A, review, 511
- OPA3, mitochondrial membrane dynamics, optic neuropathy, OPA1, MFN, DRP1, AFG3L2, SPG7, YME1L, MFF, SLC25A46, ATAD3A, review, 511
- Open angle glaucoma, confocal microscopy, trans-scleral aqueous humor outflow, trabeculectomy, conjunctival microcysts, three-dimensional analysis, 1081
- Optic neuropathy, mitochondrial membrane dynamics, OPA1, MFN, DRP1, AFG3L2, SPG7, YME1L, MFF, OPA3, SLC25A46, ATAD3A, review, 511
- Oral and oropharyngeal cancer, EGFR kinase domain, mutations, pyrosequencing, review, 23
- Oral cancer, genotype, MMP-8, polymerase chain reaction, polymorphism, 585
- Orbital, paediatric, lymphangioma, sclerotherapy, sodium tetradecylsulfate (STS), 263
- Oropharynx, head and neck cancer, elderly, radiotherapy, survival, recurrence, metastasis, outcome, 455
- Orthotopic, Ewing's sarcoma, neuroblastoma, preclinical model, ultrasound, xenograft, 779
- Osteoblast, netrin-1, differentiation, 321
- Osteoblast, netrin-4, differentiation, migration, 793
- Osteoblast, osteoclast, semaphorin-3A, periostin, osteoporosis, 87
- Osteochondral defect, cartilage, biomaterial, rabbit, tissue regeneration, femoral trochlea, poly-L/D-lactide, 895
- Osteoclast, osteoblast, semaphorin-3A, periostin, osteoporosis, 87
- Osteogenic, duck-beak, bone, potential, hydrogen dioxide, 373
- Osteomyelitis, implant-related infection *Staphylococcus aureus*, immunization, vaccine, ica<sup>+</sup> strain, ica<sup>-</sup> strain, 45
- Osteoporosis, osteoclast, osteoblast, semaphorin-3A, periostin, 87
- Osteosarcoma, PEMF, doxorubicin, cell proliferation, synergistic effect, 61
- Osteosarcoma, psychosocial distress, psycho-oncology, crowdsourcing, facebook, ewing's sarcoma, 443
- Outcome, head and neck cancer, elderly, radiotherapy, oropharynx, survival, recurrence, metastasis, 455
- Outcomes, muscle-invasive bladder cancer, local recurrence, chemoradiation, paclitaxel, toxicities, 239
- Ovarian cancer, melatonin, cisplatin, chemotherapy, MT1 melatonin receptor, 801
- Overall survival, bladder cancer, radiotherapy, transurethral resection, prognostic tool, 745
- Overall survival, carcinoma of the urinary bladder, definitive treatment, irradiation, independent predictive factors, 741
- Overall survival, non-metastatic bile duct cancer, concurrent radiochemotherapy, radiotherapy, local control, metastases-free survival, 117
- Oxidative stress, endothelial cells, non-alcoholic steatohepatitis, silybin, thiobarbituric acid reactive substances, 609
- Oxidative stress, ethanol-extracted propolis, rat, colon cancer, dimethylhydrazine, dextran sodium sulfate, inflammation, 187
- Oxidative stress, gS-nitroxide, radiation mitigation, 39
- Oxidative stress, nicotine, renal risk, resveratrol, foxO, mnSOD smoking, 551
- Ozone, nano-bubble water, disinfectant, 579
- P16, prolactinoma, MDM2, polymorphism, 357
- Paclitaxel, muscle-invasive bladder cancer, local recurrence, chemoradiation, outcomes, toxicities, 239
- Paediatric, orbital, lymphangioma, sclerotherapy, sodium tetradecylsulfate (STS), 263
- Pain behaviour, chronic pain, neuropathic pain, cancer-induced bone pain, grid climbing, 619
- PAkt, prenatal hypoxia, neurogenesis, akt, PI3K, 855
- Pancreas, prognostic factor, liver metastasis, CA19-9, 429
- Pancreas, prognostic factor, liver metastasis, CA19-9, 731
- Pancreas, solid, pseudopapillary, tumor, neoplasm, review, 501
- Pancreatic cancer, CTC, surgery, metaCell, lung cancer, liquid biopsy, 1197
- Pancreatic cancer, RUNX3, metastasis, surgical resection, 833
- Pancreatic cancer, RUNX3, metastasis, surgical resection, 833
- Parathyroid carcinoma, hyperparathyroidism, surgery, 925
- Parvovirus B19, rheumatoid arthritis, treg, CD4<sup>+</sup>CD25<sup>+</sup>, CD8<sup>+</sup>CD25<sup>+</sup>, 181
- Pax6, hypoxia, prenatal, neurogenesis, immunoreactivity, neural progenitor cell, 1125
- PCT, liver transplantation, emergency department, CRP, lactate, SAA, IL-6, 1179
- Peginterferon, neutrophil-to-lymphocyte ratio, chronic hepatitis B, 723
- PEMF, doxorubicin, osteosarcoma, cell proliferation, synergistic effect, 61
- Pemphigus vulgaris*, saliva, desmoglein 1, desmoglein 3, bIOCHIP-based indirect immunofluorescence technique, 97
- Percutaneous arterial embolization, right hepatic artery aneurysm, arteriobiliary fistula, aneurysm resection, portal vein resection and reconstruction with cadaveric allograft, 983
- Performance status, high-grade gliomas, radiochemotherapy, temozolomide, clinical symptoms, survival score, 689
- Perianal ulceration, compound *Sophora flavescens*, topical treatment, cytokine, 543

- Pericyte-like, angiogenesis, chorioallantoic membrane, mesenchymal stem cells, vasculogenesis, 1139
- Periostin, dexamethasone, knee osteoarthritis, matrix metalloproteinase, 69
- Periostin, knee osteoarthritis, interleukin-13, IL13, signal transducer and activator of transcription 6, STAT6, 79
- Periostin, osteoclast, osteoblast, semaphorin-3A, osteoporosis, 87
- Peripheral primitive neuroectodermal tumor, ewing's sarcoma, histological features, 481
- Peritoneal carcinomatosis, endometrial cancer, debulking surgery, 719
- Peritonectomy, advanced stage ovarian cancer, rectosigmoidian loop, resection, 973
- Phe354Leu polymorphism, liver kinase B1, *LKB1*, acute myeloid leukemia, AML, cytogenetically normal, 841
- Phosphorus, calcitriol, FGF23, sevelamer hydrochloride, healthy adults, 145
- Photodynamic diagnosis, 5-aminolevulinic acid, biliary tract cancer, 905
- Physical activity, sports, screening, cancer, 1187
- PI3K, prenatal hypoxia, neurogenesis, akt, pAkt, 855
- PIVKA-II, cirrhosis, HCV, AFP, HCC, 695
- Platelet glycoproteins, FGR, sNPs, pyrosequencing, 243
- PN0-N1, breast cancer, pT1-T2, adjuvant radiotherapy, conservative surgery, 151
- Pneumonectomy, mediastinal shift, tracheal deviation, 1023
- Poly-L/D-lactide, cartilage, biomaterial, rabbit, osteochondral defect, tissue regeneration, femoral trochlea, 895
- Polymerase chain reaction, genotype, *MMP-8*, oral cancer, polymorphism, 585
- Polymorphism, age, childhood, gender, genotype, leukemia, *MMP-8*, 1059
- Polymorphism, coronary artery disease, HDL subfractions, SCARB1, 873
- Polymorphism, genotype, *MMP-7*, renal cell cancer, taiwan, 631
- Polymorphism, genotype, *MMP-8*, oral cancer, polymerase chain reaction, 585
- Polymorphism, prolactinoma, p16, MDM2, 357
- Polymorphism, prostate cancer, caspase 9, rs1052576, 205
- Polypliody, B-ALL, chromosomal abnormalities, centrosome aberrations, hyperdiploidy, prognosis, 215
- Poor responders, controlled ovarian hyperstimulation, recombinant FSH, mild stimulation, clomiphene citrate, 231
- Portal embolization, hepatic artery aneurysm, aneurysm resection, 979
- Portal vein resection and reconstruction with cadaveric allograft, right hepatic artery aneurysm, percutaneous arterial embolization, arteriobiliary fistula, aneurysm resection, 983
- Positron emission tomography, gastric cancer, epstein-Barr virus, tumor metabolism, 749
- Positron-emission tomography (PET) probe, breast cancer, nodal staging, sentinel node, radio-guided surgery, 101
- Potential, duck-beak, bone, osteogenic, hydrogen dioxide, 373
- Pre-treatment factors, locally recurrent carcinoma of the bladder, irradiation, predictive score, survival, 435
- Preclinical model, Ewing's sarcoma, neuroblastoma, orthotopic, ultrasound, xenograft, 779
- Predictive score, locally recurrent carcinoma of the bladder, irradiation, pre-treatment factors, survival, 435
- Prenatal hypoxia, neurogenesis, akt, pAkt, PI3K, 855
- Prenatal, hypoxia, neurogenesis, pax6, immunoreactivity, neural progenitor cell, 1125
- Primary, vaginal, melanoma, excision, staging, treatment, prognosis, 133
- Prognosis, B-ALL, chromosomal abnormalities, centrosome aberrations, hyperdiploidy, polyploidy, 215
- Prognosis, breast cancer, african-American, 661
- Prognosis, gastric cancer, subserosal invasion, 409
- Prognosis, lung cancer, idiopathic pulmonary fibrosis, nintedanib, therapy, 773
- Prognosis, primary, vaginal, melanoma, excision, staging, treatment, 133
- Prognostic factor, colorectal liver metastases, MDN, 419
- Prognostic factor, pancreas, liver metastasis, CA19-9, 429
- Prognostic factor, pancreas, liver metastasis, CA19-9, 731
- Prognostic factor, tensin 4, *TNS4*, gastric cancer, adjuvant chemotherapy, S-1, 1065
- Prognostic tool, bladder cancer, radiotherapy, transurethral resection, overall survival, 745
- Programmed cell death 1 ligand 1, central nervous system, disease progression, renal cell carcinoma, 769
- Prolactinoma, p16, MDM2, polymorphism, 357
- Proliferation, renal cell carcinoma, microRNA-1, microRNA-21, 625
- Prophylaxis, lipegfilgrastim, myelosuppressive chemotherapy, febrile neutropenia, review, 303
- Prostaglandin F2 $\alpha$ , miniature pig, estrous synchronization, 1097
- Prostate cancer radiotherapy, rectal toxicity, radiation-induced GI toxicity, 961
- Prostate cancer, brachytherapy, lower urinary tract symptoms, 755
- Prostate cancer, caspase 9, rs1052576, polymorphism, 205
- Prostate cancer, metastases to the brain, WBI, local control, survival, 35
- Prosthetic joint infection, antimicrobial prophylaxis, coagulase-negative *Staphylococci*, 673

- Prosthetic joint infection, tissue biopsy arthroplasty, implant-associated infection, 937
- Proteomics, assisted reproduction, IVF, ICSI, fertility, sperm, oocyte, embryo, offspring health, epigenetics, review, 267
- Pseudopapillary, solid, tumor, neoplasm, pancreas, review, 501
- Psoriasis, rehabilitation, balneotherapy, 11631179
- Psycho-oncology, psychosocial distress, crowdsourcing, facebook, osteosarcoma, ewing's sarcoma, 443
- Psychosocial distress, psycho-oncology, crowdsourcing, facebook, osteosarcoma, ewing's sarcoma, 443
- PT1-T2, breast cancer, pN0-N1, adjuvant radiotherapy, conservative surgery, 151
- Ptosis surgery outcome, ptosis, blepharoptosis, eyelid surgery, eyelid ptosis correction, 111
- Ptosis, blepharoptosis, ptosis surgery outcome, eyelid surgery, eyelid ptosis correction, 111
- Pulmonary disease, influenza, breast cancer, admission, 967
- Pulmonary, embolism, immunocompetent, CMV, nOACs, 1193
- Pulsed arterial spin labeling, congenital diaphragmatic hernia, extracorporeal membrane oxygenation therapy, common carotid artery occlusion, cerebral perfusion, 557
- Pyrosequencing, FGR, platelet glycoproteins, sNPs, 243
- Pyrosequencing, oral and oropharyngeal cancer, *EGFR* kinase domain, mutations, review, 23
- Pyuria, bacteriuria, upper tract urothelial carcinoma, radical nephroureterectomy, intravesical recurrence, 1215
- Rabbit, cartilage, biomaterial, osteochondral defect, tissue regeneration, femoral trochlea, poly-L/D-lactide, 895
- Rabbits, gastrointestinal disorder, surgery, stress, cortisol, 637
- Radiation mitigation, oxidative stress, gS-nitroxide, 39
- Radiation prophylaxis, radiation therapy (RT), acetabular fracture, heterotopic ossification (HO), megavoltage photon, split-beam technique, testicular dose, indomethacin, 461
- Radiation therapy (RT), acetabular fracture, heterotopic ossification (HO), megavoltage photon, split-beam technique, testicular dose, radiation prophylaxis, indomethacin, 461
- Radiation-induced GI toxicity, rectal toxicity, prostate cancer radiotherapy, 961
- Radical nephroureterectomy, bacteriuria, pyuria, upper tract urothelial carcinoma, intravesical recurrence, 1215
- Radio-guided surgery, breast cancer, nodal staging, sentinel node, positron-emission tomography (PET) probe, 101
- Radio(chemo)therapy, head and neck cancer, locally advanced, inoperable, 949
- Radiochemotherapy, high-grade gliomas, temozolomide, clinical symptoms, performance status, survival score, 689
- Radiosurgery, brain stem gliomas, rotating gamma system, treatment outcomes, adverse events, 957
- Radiotherapy, bladder cancer, transurethral resection, overall survival, prognostic tool, 745
- Radiotherapy, head and neck cancer, elderly, oropharynx, survival, recurrence, metastasis, outcome, 455
- Radiotherapy, non-metastatic bile duct cancer, concurrent radiochemotherapy, local control, metastases-free survival, overall survival, 117
- Rat, diabetes, obesity, wound healing, zucker diabetic sprague dawley, 55
- Rat, ethanol-extracted propolis, colon cancer, dimethylhydrazine, dextran sodium sulfate, inflammation, oxidative stress, 187
- Rats, mice, disease, kidneys, renal function, review, 1
- RAW264.7 cells, eugenol-related compounds, antioxidants, COX-2, NOS2, HO-1, theoretical parameters, 819
- Rebiopsy, histology, non-small cell lung cancer, 475
- Recombinant FSH, controlled ovarian hyperstimulation, poor responders, mild stimulation, clomiphene citrate, 231
- Reconstruction, breast cancer, acellular dermal matrix, ADM, tutomesh, surgiMend, 677
- Rectal toxicity, prostate cancer radiotherapy, radiation-induced GI toxicity, 961
- Rectosigmoidian loop, advanced stage ovarian cancer, resection, peritonectomy, 973
- Recurrence, head and neck cancer, elderly, radiotherapy, oropharynx, survival, metastasis, outcome, 455
- Recurrent laryngeal nerve paralysis, laterofixation, vocal fold immobility, vocal fold paralysis, dyspnea, 1159
- Rehabilitation, psoriasis, balneotherapy, 1163
- Renal cell cancer, genotype, *MMP-7*, polymorphism, taiwan, 631
- Renal cell carcinoma, central nervous system, disease progression, programmed cell death 1 ligand 1, 769
- Renal cell carcinoma, microRNA-1, microRNA-21, proliferation, 625
- Renal function, rats, mice, disease, kidneys, review, 1
- Renal risk, nicotine, oxidative stress, resveratrol, foxO, mnSOD smoking, 551
- Renal transplantation, end-stage polycystic kidney, nephrectomy, review, 307
- Resection, advanced stage ovarian cancer, rectosigmoidian loop, peritonectomy, 973
- Resveratrol, nicotine, renal risk, oxidative stress, foxO, mnSOD smoking, 551
- Reticulocyte hemoglobin content, anemia and iron supplementation, hemodialysis, 709
- Review, end-stage polycystic kidney, renal transplantation, nephrectomy, 307
- Review, ghrelin, obesity, appetite, hormone levels, diet, bariatric surgery, 1047

- Review, *k-ras* mutation, normal mucosa, benign polyp, biomarker, colorectal cancer, earliest mutation, 527
- Review, laparoscopic splenectomy, laparoscopy, splenectomy, hematological holds disorders, hematology, adults, 291
- Review, lipegfilgrastim, myelosuppressive chemotherapy, febrile neutropenia, prophylaxis, 303
- Review, oral and oropharyngeal cancer, *EGFR* kinase domain, mutations, pyrosequencing, 23
- Review, proteomics, assisted reproduction, IVF, ICSI, fertility, sperm, oocyte, embryo, offspring health, epigenetics, 267
- Review, rats, mice, disease, kidneys, renal function, 1
- Review, solid, pseudopapillary, tumor, neoplasm, pancreas, 501
- Review, mitochondrial membrane dynamics, optic neuropathy, OPA1, MFN, DRP1, AFG3L2, SPG7, YME1L, MFF, OPA3, SLC25A46, ATAD3A, 511
- Rheumatoid arthritis, parvovirus B19, treg, CD4<sup>+</sup>CD25<sup>+</sup>, CD8<sup>+</sup>CD25<sup>+</sup>, 181
- Right hepatic artery aneurysm, percutaneous arterial embolization, arteriobiliary fistula, aneurysm resection, portal vein resection and reconstruction with cadaveric allograft, 983
- RNA sequencing, vitamin C, ascorbic acid deficiency, skin, hair growth, 599
- Rodentia, comparative anatomy, blood vessels, neck dissection, neck anatomy, 861
- Rodents, BBN, animal models, animal welfare, 1073
- Rotating gamma system, brain stem gliomas, radiosurgery, treatment outcomes, adverse events, 957
- RP-HPLC, mouse hemokinin-1, substance P, tachykinins, n-terminal acetylation, anti-tachykinin antibodies, mALDI-ToF, 991
- Rs1052576, prostate cancer, caspase 9, polymorphism, 205
- RT-PCR, ALT, IL6, monoterpenoid alcohol, tNF $\alpha$ , 209
- RUNX3, pancreatic cancer, metastasis, surgical resection, 833
- RUNX3, pancreatic cancer, metastasis, surgical resection, 833
- S-1, tensin 4, *TNS4*, gastric cancer, adjuvant chemotherapy, prognostic factor, 1065
- S-1, thrombotic microangiopathy, thrombotic thrombocytic purpura, cisplatin, 439
- SAA, liver transplantation, emergency department, CRP, PCT, lactate, IL-6, 1179
- Saliva, *Pemphigus vulgaris*, desmoglein 1, desmoglein 3, bIOPCHIP-based indirect immunofluorescence technique, 97
- Sarcoma, liposarcoma, lipoma, MRI, 387
- Sarcopenia, cachexia, cancer, fatty acids, n-6/n-3, AA/EPA ratio, 1003
- SCARB1, coronary artery disease, HDL subfractions, polymorphism, 873
- Schizophrenia, cardiotoxicity, fever, clozapine, case report, 141
- Sclerotherapy, paediatric, orbital, lymphangioma, sodium tetradecylsulfate (STS), 263
- Screening, sports, physical activity, cancer, 1187
- Semaphorin-3A, osteoclast, osteoblast, periostin, osteoporosis, 87
- Sentinel node, breast cancer, nodal staging, positron-emission tomography (PET) probe, radio-guided surgery, 101
- Sepsis, multiple organ failure (MOF), neutrophil extracellular traps (NETs), extravasated platelet aggregation, 1051
- Serum biomarkers, glioblastoma, oncogenic viruses, neurotropic viruses, HSV, VZV, EBV, HCMV, HHV-6, adV, hEV, TBEV, 221
- Sevelamer hydrochloride, calcitriol, phosphorus, FGF23, healthy adults, 145
- Signal transducer and activator of transcription 6, knee osteoarthritis, periostin, interleukin-13, IL13, STAT6, 79
- Signet ring cell carcinoma, cecum, distal intramural spread, 705
- Silybin, endothelial cells, non-alcoholic steatohepatitis, oxidative stress, thiobarbituric acid reactive substances, 609
- Skin cancer, basal cell carcinoma (BCC), melanoma (MM), nevous (NEV), infrared spectroscopy, diagnostic bands, 1131
- Skin, vitamin C, ascorbic acid deficiency, RNA sequencing, hair growth, 599
- SLC25A46, mitochondrial membrane dynamics, optic neuropathy, OPA1, MFN, DRP1, AFG3L2, SPG7, YME1L, MFF, OPA3, ATAD3A, review, 511
- SMP30-KO mouse, tendonitis, vitamin C, adipose-derived stem cell, stem cell therapy, 343
- SNPs, FGR, platelet glycoproteins, pyrosequencing, 243
- Sodium tetradecylsulfate (STS), paediatric, orbital, lymphangioma, sclerotherapy, 263
- Solid, pseudopapillary, tumor, neoplasm, pancreas, review, 501
- Sox2, inflammation, mesenchymal stem cell, oct4, lipopolysaccharide, 349
- Sperm, proteomics, assisted reproduction, IVF, ICSI, fertility, oocyte, embryo, offspring health, epigenetics, review, 267
- SPG7, mitochondrial membrane dynamics, optic neuropathy, OPA1, MFN, DRP1, AFG3L2, YME1L, MFF, OPA3, SLC25A46, ATAD3A, review, 511
- Splenectomy, laparoscopic splenectomy, laparoscopy, hematological holds disorders, hematology, adults, review, 291
- Split-beam technique, radiation therapy (RT), acetabular fracture, heterotopic ossification (HO), megavoltage photon, testicular dose, radiation prophylaxis, indomethacin, 461

- Sports, physical activity, screening, cancer, 1187
- Staging, primary, vaginal, melanoma, excision, treatment, prognosis, 133
- STAT6, knee osteoarthritis, periostin, interleukin-13, IL13, signal transducer and activator of transcription 6, 79
- Stem cell therapy, tendonitis, vitamin C, adipose-derived stem cell, SMP30-KO mouse, 343
- Stereotactic radiosurgery, esophagogastric junction cancer, gastric cancer, brain metastasis, gamma knife, long-term survival, 1209
- Stomach, anaplastic large cell lymphoma, aLK-negative, eBV-negative, 701
- Stress, gastrointestinal disorder, surgery, rabbits, cortisol, 637
- Subserosal invasion, gastric cancer, prognosis, 409
- Substance P, mouse hemokinin-1, tachykinins, n-terminal acetylation, anti-tachykinin antibodies, RP-HPLC, mALDI-ToF, 991
- SuPAR, ischemic stroke, inflammation, mortality, cardioembolic, 381
- Superdrainage, gastric tube, esophageal cancer, indocyanine green fluorescence, 1019
- Surgery, adrenal metastasis, brain metastasis, non-small cell lung cancer, 451
- Surgery, CTC, metaCell, pancreatic cancer, lung cancer, liquid biopsy, 1197
- Surgery, gastrointestinal disorder, stress, rabbits, cortisol, 637
- Surgery, parathyroid carcinoma, hyperparathyroidism, 925
- Surgical resection, RUNX3, pancreatic cancer, metastasis, 833
- Surgical resection, RUNX3, pancreatic cancer, metastasis, 833
- SurgiMend, breast cancer, acellular dermal matrix, ADM, tutomesh, reconstruction, 677
- Survival score, high-grade gliomas, radiochemotherapy, temozolamide, clinical symptoms, performance status, 689
- Survival, head and neck cancer, elderly, radiotherapy, oropharynx, recurrence, metastasis, outcome, 455
- Survival, locally recurrent carcinoma of the bladder, irradiation, pre-treatment factors, predictive score, 435
- Survival, prostate cancer, metastases to the brain, WBI, local control, 35
- Synchronous double cancer, esophageal cancer, head and neck cancer, 909
- Synergistic effect, PEMF, doxorubicin, osteosarcoma, cell proliferation, 61
- Tachykinins, mouse hemokinin-1, substance P, n-terminal acetylation, anti-tachykinin antibodies, RP-HPLC, mALDI-ToF, 991
- Taiwan, genotype, *MMP-7*, polymorphism, renal cell cancer, 631
- TBEV, glioblastoma, oncogenic viruses, neurotropic viruses, serum biomarkers, HSV, VZV, EBV, HCMV, HHV-6, adV, hEV, 221
- Temozolomide, high-grade gliomas, radiochemotherapy, clinical symptoms, performance status, survival score, 689
- Tendonitis, vitamin C, adipose-derived stem cell, SMP30-KO mouse, stem cell therapy, 343
- Tensin 4, *TNS4*, gastric cancer, adjuvant chemotherapy, S-1, prognostic factor, 1065
- Testicular dose, radiation therapy (RT), acetabular fracture, heterotopic ossification (HO), megavoltage photon, split-beam technique, radiation prophylaxis, indomethacin, 461
- TGF- $\beta$ , total body irradiation, chemotherapy drugs, fanconi Anemia, mouse bone marrow, molecular radiation, mitigators, JP4-039, MMS350, 159
- Theoretical parameters, eugenol-related compounds, antioxidants, RAW264.7 cells, COX-2, NOS2, HO-1, 819
- Therapy, lung cancer, idiopathic pulmonary fibrosis, nintedanib, prognosis, 773
- Thiamine, vitamin B1, Wernicke's encephalopathy, alcohol, 121
- Thiobarbituric acid reactive substances, endothelial cells, non-alcoholic steatohepatitis, oxidative stress, silybin, 609
- Three-dimensional analysis, confocal microscopy, open angle glaucoma, trans-scleral aqueous humor outflow, trabeculectomy, conjunctival microcysts, 1081
- Thrombotic microangiopathy, thrombotic thrombocytic purpura, S-1, cisplatin, 439
- Thrombotic thrombocytic purpura, thrombotic microangiopathy, S-1, cisplatin, 439
- Thyroglobulin, hypothyroidism, lung cancer, nivolumab, thyroid peroxidase, 1035
- Thyroid abnormalities, cancer, cardiovascular disease, end-stage renal disease, hypothyroidism, thyroid nodules, waiting list for renal transplant, 1203
- Thyroid nodules, cancer, cardiovascular disease, end-stage renal disease, hypothyroidism, thyroid abnormalities, waiting list for renal transplant, 1203
- Thyroid peroxidase, hypothyroidism, lung cancer, nivolumab, thyroglobulin, 1035
- Thyroid, nivolumab, immunotherapy, 1225
- Time-lapse videography, environmental chamber, live cell imaging, migrating cells, cellular motility, 329
- Tissue biopsy arthroplasty, prosthetic joint infection, implant-associated infection, 937
- Tissue microarray, lung, carcinoma, epidermal growth factor receptor, chromosome, gene, 641
- Tissue regeneration, cartilage, biomaterial, rabbit, osteochondral defect, femoral trochlea, poly-L/D-lactide, 895

- Titanium implants, direct laser interference, cytocompatibility, 849
- TNF $\alpha$ , ALT, IL6, monoterpenoid alcohol, RT-PCR, 209
- TNS4, tensin 4, gastric cancer, adjuvant chemotherapy, S-1, prognostic factor, 1065
- Topical treatment, compound *Sophora flavescens*, cytokine, perianal ulceration, 543
- Total body irradiation, tGF- $\beta$ , chemotherapy drugs, Fanconi anemia, mouse bone marrow, molecular radiation, mitigators, JP4-039, MMS350, 159
- Toxicities, muscle-invasive bladder cancer, local recurrence, chemoradiation, paclitaxel, outcomes, 239
- Trabeculectomy, confocal microscopy, open angle glaucoma, trans-scleral aqueous humor outflow, conjunctival microcysts, three-dimensional analysis, 1081
- Tracheal deviation, pneumonectomy, mediastinal shift, 1023
- Trans-scleral aqueous humor outflow, confocal microscopy, open angle glaucoma, trabeculectomy, conjunctival microcysts, three-dimensional analysis, 1081
- Transumbilical, complication, wound, 943
- Transurethral resection, bladder cancer, radiotherapy, overall survival, prognostic tool, 745
- Trastuzumab emtansine (T-DM1), breast cancer, HER2, anti-HER2 therapy, japanese patients, 493
- Treatment options, hepatic epithelioid haemangiendothelioma, diagnostic dilemma, 763
- Treatment outcomes, brain stem gliomas, radiosurgery, rotating gamma system, adverse events, 957
- Treatment, primary, vaginal, melanoma, excision, staging, prognosis, 133
- Treg, parvovirus B19, rheumatoid arthritis, CD4 $^+$ CD25 $^+$ , CD8 $^+$ CD25 $^+$ , 181
- Triangulating anastomosis, functional end-to-end anastomosis, colonic resection, 683
- Tumor metabolism, positron emission tomography, gastric cancer, epstein-Barr virus, 749
- Tumor specificity, mastic, fractionation, ethyl acetate extraction, antibacterial, anti-HIV, anti-HSV, CYP3A4 inhibition, 591
- Tumor, liver, angiomyolipoma, epithelioid, laparoscopic surgery, 1169
- Tumor, solid, pseudopapillary, neoplasm, pancreas, review, 501
- Tutomesh, breast cancer, acellular dermal matrix, ADM, surgiMend, reconstruction, 677
- Typical, neuroendocrine tumors, bronchial neuroendocrine tumors, carcinoid, atypical, ki67 index, 397
- UDP-glucuronosyltransferase, morphine, inflammation, adjuvant-induced arthritis, ABCB1, 811
- Ulcerative colitis crypts, colon, colectomy specimens, mucosal ulcers, 669
- Ulcerative colitis, carcinogenesis, mtDNA, digital PCR, 713
- Ultrasound, Ewing's sarcoma, neuroblastoma, orthotopic, preclinical model, xenograft, 779
- Upper tract urothelial carcinoma, bacteriuria, pyuria, radical nephroureterectomy, intravesical recurrence, 1215
- Urinary albumin excretion (UAE), diabetic nephropathy, microalbuminuria, 285
- Vaccine, osteomyelitis, implant-related infection *Staphylococcus aureus*, immunization, ica $^+$  strain, ica $^-$  strain, 45
- Vaginal atrophy, breast cancer, cystitis, n-acetylcysteine, d-mannose, 931
- Vaginal, primary, melanoma, excision, staging, treatment, prognosis, 133
- Vasculogenesis, angiogenesis, chorioallantoic membrane, mesenchymal stem cells, pericyte-like, 1139
- Viability, fat grafting, adipose-derived stem cells, yield, donor areas, 1229
- Vitamin B1, thiamine, wernicke's encephalopathy, alcohol, 121
- Vitamin C, ascorbic acid deficiency, RNA sequencing, skin, hair growth, 599
- Vitamin C, tendonitis, adipose-derived stem cell, SMP30-KO mouse, stem cell therapy, 343
- Vitamin D, diabetic neuropathy, greek, bangladeshi, 259
- Vocal fold immobility, laterofixation, vocal fold paralysis, recurrent laryngeal nerve paralysis, dyspnea, 1159
- Vocal fold paralysis, laterofixation, vocal fold immobility, recurrent laryngeal nerve paralysis, dyspnea, 1159
- VZV, glioblastoma, oncogenic viruses, neurotropic viruses, serum biomarkers, HSV, EBV, HCMV, HHV-6, adV, hEV, TBEV, 221
- Waiting list for renal transplant, cancer, cardiovascular disease, end-stage renal disease, hypothyroidism, thyroid abnormalities, thyroid nodules, 1203
- WBI, prostate cancer, metastases to the brain, local control, survival, 35
- Wernicke's encephalopathy, thiamine, vitamin B1, alcohol, 121
- Wistar rats, *Antrodia cinnamomea*, carbon tetrachloride, hepatotoxicity, hepatic fibrosis, 877
- Wound healing, diabetes, obesity, zucker diabetic sprague dawley, rat, 55
- Wound, transumbilical, complication, 943
- Xenograft, Ewing's sarcoma, neuroblastoma, orthotopic, preclinical model, ultrasound, 779
- Y chromosome deletion, non-obstructive azoospermia, oligoasthenoteratozoospermia, male infertility, gr/gr, b1/b3, b2/b3, 365

- Yield, fat grafting, adipose-derived stem cells, viability, donor areas, 1229
- YME1L, mitochondrial membrane dynamics, optic neuropathy, OPA1, MFN, DRP1, AFG3L2, SPG7, MFF, OPA3, SLC25A46, ATAD3A, review, 511
- Zn complex, morphological analysis, ectopic fat deposition, animal model, 1145
- Zucker diabetic sprague dawley, diabetes, obesity, wound healing, rat, 55
- A/β ratio, lung cancer cell lines, lung fibroblasts, 175
- Mitochondrial membrane dynamics, optic neuropathy, OPA1, MFN, DRP1, AFG3L2, SPG7, YME1L, MFF, OPA3, SLC25A46, ATAD3A, review, 511

## Authors Index

(Figures refer to page numbers)

Abate G, 455	Bacalbasa N, 429, 719, 973, 979, 983, 999	Bremer M, 949	Choi M, 1175
Abdallah LE, 461	Bagalà C, 833	Brezean I, 979, 983	Choi SH, 335, 373, 637
Abeln T, 329	Bagli E, 511	Broulík P, 925	Chou J, 877
Adachi T, 169	Bajrovic A, 35	Brunelli C, 833	Christiansen H, 949
Adámek S, 925	Bakopoulos A, 737	Brunnert K, 677	Chrouzos GP, 267
Adamietz IA, 329	Baldini C, 731	Bruno G, 125	Chukkapalli S, 779
Adamietz R, 329	Balescu I, 429, 719, 973, 979, 983, 999	Bubba L, 467	Chun M, 967
Agnantis N, 511	Banke IJ, 937	Buhler H, 329	Chung J-G, 877, 1103
Agnifili L, 1081	Baraldi O, 1203	Bulzonetti N, 455	Chung M-J, 343
Ahn J-O, 1115	Barbu I, 979, 983	Büntzel J, 1187	Chung Y, 855, 1125
Ahrend HS, 625	Bargagli E, 773, 1215	Buonomo AR, 695	Ciancaglini M, 1081
Ajtay Z, 425, 1163	Barmayoun A, 649	Buonomo OC, 101	Ciancio F, 111
Akin I, 1153	Barone C, 833	Burchardt M, 625	Cianciolo G, 1203
Alaibac M, 97	Barretta L, 709	Burton S, 701	Cilla S, 961
Alberioli E, 387	Barretta S, 709	Buwenge M, 961	Cimpean AM, 199, 1139
Alexandrou A, 1047	Bartolucci M, 773	Canbek M, 209	Climastone H, 1081
Alitto AR, 961	Barton S, 991	Canbek S, 209	Comai G, 1203
Amagai T, 1003	Bartscht T, 117	Cao S, 159	Comşa §, 199, 1139
Amano S, 591	Basios G, 231	Capelli I, 1203	Conti V, 609
Anagnostopoulos AK, 267	Basso M, 833	Capone D, 709	Copeland Jr RL, 661
Anagnostouli M, 1041	Bau D-T, 585, 631, 1059	Cappuccilli M, 1203	Coran A, 387
Anastassopoulou J, 1131	Baumann S, 1153	Caraglia M, 609	Crăiniceanu Z, 649
Andreatos N, 501, 1169	Baxa J, 763	Caravatta L, 151	Createsas G, 243
Angarano G, 125	Bayindir Y, 1179	Carriero C, 695	Cucchi D, 961
Anghel C, 979, 983	Becher T, 1153	Casaroto AR, 481	Cuna V, 1203
Antoniou EA, 501, 1169	Beyaz CC, 365	Cassano A, 833	D'Urso D, 415
Antunes L, 1073	Beyene D, 661	Cataldi M, 709	Da Silva Sampieri MB, 481
Aoki T, 705, 943	Bhang D-H, 1115	Cattan S, 731	Da Silva Santos PS, 481
Aoki Y, 1209	Bin D, 543	Cavalcanti E, 695	Dafopoulos K, 231
Aoyama T, 565, 1065	Binda S, 467	Ceauşu RA, 199, 649, 1139	Dahlke S, 949
Arai H, 1209	Bindi A, 773, 1221	Cefalogli C, 151	Daizumoto K, 755
Arai K, 811	Bloancă V, 649	Cerasuolo D, 695	Dallio M, 609
Arantes-Rodrigues R, 1073	Bobek V, 925, 1197	Ceyhan E, 209	Dam G, 397
Arany I, 551	Bolm L, 117	Chang BY, 263	Damante JH, 481
Arcelli A, 961	Boncz I, 425, 1163	Chang J, 861	Damaskos C, 133, 501, 1169
Argyrou C, 307	Bonti V, 773	Chang M-L, 723	Danieli R, 101
Ariyoshi W, 793	Borggrefe M, 1153	Chang W-S, 585, 631, 1059	Daum O, 763
Arponen O, 381	Borgia G, 467, 695	Chao JR, 861	De Felice F, 455
Asano K, 69, 79	Bountouris I, 1193	Chen D, 543	Deie M, 61
Asci R, 365	Brandenburg L-O, 625	Chen Y-C, 723	Deiss L, 673
Atagi S, 1035	Brasoveanu V, 979, 983	Chen Y-L, 1103	Deliconstantinos G, 991
Athanasiou A, 451	Bratu T, 649	Chen Y-Y, 585	Deng Q, 543
Attar S, 387	Bravaccio C, 467	Cheng S-P, 1059	Deodato F, 961
Avram §, 199		Chiara M, 773	Dewitty Jr RL, 661
Ayhan H, 873		Chiaravalloti A, 101	Di Carlo C, 151

- Di Gregorio A, 1081  
 Di Nicola M, 151  
 Di Staso S, 1081  
 Diaz-Carballo D, 329  
 Dillman JR, 779  
 Dima S, 973  
 Dimitriou N, 291  
 Dimitroulis D, 451  
 Dixit M, 551  
 Dixon T, 159  
 Dogkas N, 259  
 Doi K, 187  
 Donati G, 1203  
 Dontas I, 145  
 Douzenis A, 141  
 Dreassi E, 111  
 Duh D, 221  
 Durisin M, 949  
 Durmus B, 209  
 Durmuş H, 657  
 Dzięgiel P, 801  
 Dziggel L, 35  
 Ebihara Y, 905  
 Eckardt A, 949  
 Economou E, 243  
 Efremova J, 677  
 Egashira A, 909  
 Eguchi S, 169  
 Eichler C, 677  
 El-Hindy N, 263  
 Enoki Y, 321, 793  
 Epperly MW, 39, 159, 313  
 Ersan V, 1179  
 Eto K, 683  
 Falk S, 619  
 Faria Yaedu RY, 481  
 Farioli A, 961  
 Fasanella V, 1081  
 Faustino-Rocha AI, 1073  
 Federico A, 609  
 Ferda J, 763  
 Ferrari K, 773  
 Ferreira R, 1073  
 Fialová M, 925  
 Filipescu A, 719, 999  
 Filippelli A, 609  
 Fiorentini A, 101  
 Fisher R, 39, 313  
 Forster J, 251  
 Fotiades PP, 641  
 Fraggetta F, 415  
 Franicola D, 159, 313  
 Frazzoni L, 961  
 Friedrich RE, 849  
 Fuccio L, 961  
 Fujimori A, 705, 943  
 Fujioka M, 187  
 Fujisawa S, 819  
 Fujita I, 1209  
 Fujita T, 285  
 Fukawa T, 755  
 Fukuchi K, 591  
 Fukumori T, 755  
 Fukushima H, 1215  
 Fukuyama T, 403  
 Furutani S, 755  
 Fushida S, 1051  
 Futawatari N, 403  
 Galanos A, 145  
 Galassi E, 1081  
 Galdieri A, 455  
 Galia A, 415  
 Gallego-Pedersen S, 619  
 Garmpi A, 501, 1169  
 Garmpis N, 501, 1169  
 Garufi A, 415  
 Gaskins M, 661  
 Gaulke R, 917  
 Genovesi D, 151  
 Gentile I, 467, 695  
 Georgiadou E, 145  
 Georgiannos SN, 641  
 Gerasimou C, 141  
 Ghosh K, 215  
 Gi M, 187  
 Giaccherini L, 961  
 Giriş M, 657  
 Girkontaite I, 181  
 Gluz O, 677  
 Gobbett TA, 55  
 Gollwitzer H, 673  
 Gong C-L, 1059  
 Gontika M, 1041  
 Gormus U, 873  
 Goto S, 943  
 Grammatico F, 1203  
 Granai AV, 101  
 Greenberger JS, 39, 169, 313  
 Grill R, 1197  
 Griniatsos J, 291  
 Grivas A, 1169  
 Gronbek H, 397  
 Grzegorek I, 801  
 Guerron AD, 1047  
 Guido A, 961  
 Gulow N, 849  
 Gunes S, 365  
 Guo S, 87  
 Gür A, 1179  
 Gurbuz S, 1179  
 Hagiwara N, 1209  
 Haji S, 1003  
 Hall S, 551  
 Han S-M, 349, 1115  
 Han TS, 335  
 Hanazaki K, 1019  
 Hanken H, 849  
 Hankey-Giblin P, 313  
 Hanschmann H, 1159  
 Hara T, 169  
 Harada K, 1051  
 Harmon JW, 1051  
 Harrasser N, 673, 937  
 Hartjen P, 849  
 Hashizume R, 683  
 Hata A, 475  
 Hata K, 713, 1011  
 Haubenreisser H, 1153  
 Hayashi H, 1051  
 Hayashi N, 321, 793  
 He R, 461  
 Hebbar M, 731  
 Hedman M, 381  
 Heiland M, 849  
 Henningsen A, 849  
 Henzler C, 557  
 Henzler T, 1153  
 Heo J, 967  
 Hero T, 329  
 Herschbach P, 443  
 Hidaka M, 169  
 Higashi H, 439  
 Higashijima J, 419  
 Hirano S, 905  
 Hirata M, 1097  
 Hisamitsu T, 69, 79, 87  
 Hladik P, 1197  
 Hoenerhoff MJ, 779  
 Hoffman RM, 543  
 Holthaus MG, 849  
 Holubec L, 303  
 Hontani K, 905  
 Hou W, 313  
 Hsiao H-H, 841  
 Hsu C-M, 841  
 Hsu C-W, 723  
 Hsu P-C, 1059  
 Hsu S-W, 631  
 Hu P-S, 631  
 Huang Y-P, 877  
 Hübner J, 1187  
 Hung F-M, 1103  
 Hung H-S, 585, 631  
 Hung NQ, 957  
 Hung Y-W, 585, 1059  
 Hwang S-K, 343  
 Ichiki Y, 403  
 Ikebe M, 909  
 Ikegami N, 1035  
 Ikemoto H, 87  
 Ikemoto T, 419  
 Ikushima H, 755  
 Ilhan M, 357  
 Imada T, 565, 1065  
 Imai Y, 475  
 Imamura H, 169  
 Imura S, 419  
 Inagawa H, 573  
 Inagawa T, 87  
 Ince V, 1179  
 Ingrosso M, 961  
 Innocenti A, 111  
 Innocenti M, 111  
 Inoue Y, 909  
 Inzani F, 833  
 Ippolito E, 961  
 Isbir S, 873  
 Isbir T, 205, 873  
 Ishihara S, 713  
 Ishikawa D, 419  
 Ishikawa S, 69, 79, 87  
 Ishikawa T, 579  
 Ishizuka M, 905  
 Ito Y, 493  
 Iwabu J, 1019  
 Iwahashi S, 419

- Iwama S, 1089  
 Iwasaki H, 1225  
 Iwata T, 793  
 Izzo F, 695  
 Jabłońska K, 801  
 Jäger C, 251  
 Jagicza A, 1163  
 Jäkälä P, 381  
 Jang SJ, 335, 373, 637  
 Janssen S, 239, 435, 741, 745  
 Jarosz Ł, 895  
 Jencsik T, 425  
 Jensen AL, 45  
 Jensen NV, 45  
 Jeong K-S, 343  
 Jitariu AA, 649  
 Johansen HK, 45  
 Jun Y, 855, 1125  
 Jung O, 849  
 Kaesmann L, 117  
 Kagawa M, 909  
 Kaizuka Y, 439  
 Kaji R, 475  
 Kakehashi A, 187  
 Kakinuma D, 1209  
 Kalampokas E, 133  
 Kalampokas T, 133  
 Kalantzis G, 263  
 Kanaan YM, 661  
 Kanada Y, 79  
 Kanaka-Gantenbein C, 267  
 Kanamoto T, 591  
 Kanatani K, 493  
 Kanayama H-O, 755  
 Kanazawa Y, 1209  
 Kang K-K, 343  
 Kang K-S, 1115  
 Kang SS, 335, 373, 637  
 Kang TC, 861  
 Kanno H, 1209  
 Karagkiouzis G, 451  
 Karagounis IV, 175  
 Karaman O, 357  
 Karameris A, 641  
 Karandreas N, 259  
 Karaolanis G, 1193  
 Karathanasis I, 451  
 Kardara M, 885  
 Käsmann L, 239  
 Katakami N, 475  
 Katayama Y, 565  
 Kato S, 1209  
 Katsavos S, 1041  
 Kaul A, 625  
 Kavantzas N, 641  
 Kawaguchi H, 1097  
 Kawai K, 713, 1011  
 Kawanaka T, 755  
 Kawano K, 1215  
 Kawata A, 819  
 Kerketta LS, 215  
 Khoa MT, 689, 957  
 Kim G, 637  
 Kim J-H, 373  
 Kim J-Y, 343  
 Kim L, 967  
 Kim MJ, 861  
 Kim SE, 335, 373  
 Kim SH, 749  
 Kim S-Y, 343  
 Kim Y-D, 343  
 Kim YY, 861  
 Kimura Y, 811, 1035  
 Kinjo M, 439  
 Kinoshita J, 1051  
 Kishihara F, 439  
 Kishimoto H, 439  
 Kiss I, 425, 1163  
 Kitagawa H, 1019  
 Kitagawa M, 1003  
 Kitasato A, 169  
 Kitsos G, 511  
 Kiyomatsu T, 713, 1011  
 Knebel C, 443, 937  
 Kobari Y, 769  
 Kobayashi M, 1215  
 Kobayashi N, 403  
 Kobayashi T, 1035  
 Kobunai T, 713  
 Koch J, 45  
 Kohagura K, 1225  
 Kohchi C, 573  
 Koizumi T, 943  
 Kokabu S, 321, 793  
 Kokoris SI, 141  
 Kokotis P, 259  
 Kolostova K, 1197  
 Komatsu K-I, 599  
 Kondo T, 769  
 Konstantinou F, 451  
 Kontos M, 1229  
 Kontzoglou K, 501, 1169  
 Korhonen M, 381  
 Kornerup LS, 397  
 Köse A, 1179  
 Kosteria I, 267  
 Kosuge M, 683  
 Koszegi T, 425  
 Kotanidou A, 885  
 Kouerinis IA, 451  
 Kou M, 1131  
 Koukourakis MI, 175  
 Kouloudoussa M, 527  
 Kouraklis G, 501  
 Kouskouni E, 243  
 Krainz T, 39  
 Kreska Z, 425  
 Krettek C, 917  
 Kritikou G, 1193  
 Krook M, 779  
 Kubikova T, 303  
 Kubin T, 1187  
 Kubinyi J, 925  
 Kubo A, 755  
 Kucukhuseyin O, 357  
 Kulac T, 365  
 Kumada K, 187  
 Kunitake N, 909  
 Kurbacher CM, 677  
 Kuroki T, 169  
 Kushibiki T, 905  
 Kustán P, 425, 1163  
 Kusterer I, 1187  
 Kusuhara Y, 755  
 Kuwabara S, 905  
 Kwisda S, 917  
 Kykalos S, 501  
 Kyriakidou M, 1125  
 La Manna G, 1203  
 Laczo A, 425  
 Ladisa N, 125  
 Lah TT, 221  
 Lahanis S, 501  
 Lai J-P, 701  
 Lai M-W, 723  
 Łaćut M, 895  
 Lanza P, 833  
 Laoutaris G, 1193  
 Lara VS, 481  
 Lawlor ER, 779  
 Le P-H, 723  
 Lee C-H, 877, 1103  
 Lee E-J, 343  
 Lee JH, 861  
 Lee JJ, 861  
 Lee JY, 373, 637  
 Lee M-H, 1103  
 Lee S-J, 1115  
 Lee SY, 749  
 Lefas AY, 641  
 Lenze F, 937  
 Lenze FW, 443  
 Lenze U, 443, 673, 937  
 Leoncini E, 833  
 Li Q, 349  
 Li S, 39  
 Li X, 543  
 Liang K-H, 723  
 Liang M, 39  
 Liao C-H, 631  
 Liao N-C, 877  
 Liappas I, 141  
 Libánský P, 925  
 Lin C-L, 723  
 Lin P-M, 841  
 Lin S-F, 841  
 Lin W-R, 723  
 Liousia MV, 175  
 Lischke R, 925, 1197  
 Liska V, 763  
 Lisnerova L, 303  
 Liu J-Y, 877, 1103  
 Liu S-P, 631  
 Liu Y-C, 841  
 Liu Y-F, 585, 631  
 Liu Z, 543  
 Loguercio C, 609  
 Lossnitzer D, 1153  
 Lu H-F, 877, 1103  
 Ma JK, 461  
 Macchia G, 961  
 Maciunaite G, 181  
 Madkaikar M, 215  
 Maekura T, 1035

- Maggi P, 125  
 Magkouti E, 1169  
 Makino I, 1051  
 Makris K, 145  
 Makris MC, 1047  
 Malietzis G, 1047  
 Maniatis NA, 885  
 Manig L, 239, 435, 741, 745  
 Manitsopoulos N, 885  
 Mantas D, 1229  
 Mantini G, 961  
 Manzo V, 609  
 Marallag M, 1175  
 Marchan EM, 461  
 Marchiori D, 931  
 Margari L, 467  
 Margetis N, 527  
 Margonis G-A, 501, 1169  
 Mariolisis-Sapsakos T, 527  
 Marketou H, 145  
 Masarone M, 609  
 Mastronikolis NS, 641  
 Masuda Munetaka, 565,  
     1065, 1225  
 Masuda Muneyuki 909  
 Masuda N, 493  
 Masuda Y, 51, 591  
 Masudo K, 565, 1225  
 Masutomi H, 599  
 Matahira Y, 591  
 Matsui T, 61  
 Matsumoto M, 321, 793  
 Matsuno K, 1209  
 Matsutani T, 1209  
 Mattiucci GC, 833  
 Mauricas M, 181  
 Mayer-Kuckuk P, 673  
 Melita D, 111  
 Menghi V, 1203  
 Merando A, 701  
 Meyer A, 949  
 Michelotto A, 97  
 Micke O, 1187  
 Mieliuskaite D, 181  
 Minomo S, 1035  
 Miseta A, 425  
 Mitsumori N, 683  
 Miyashita T, 1051  
 Mobit PN, 461
- Montesco MC, 387  
 Morganti AG, 961  
 Mori F, 111  
 Mori H, 755  
 Morimoto S, 1215  
 Morine Y, 419  
 Moris D, 291, 307, 451, 737,  
     1023, 1047, 1193, 1229  
 Morita M, 909  
 Moş R, 649  
 Mosca T, 709  
 Moue T, 69, 79  
 Mourad WF, 461  
 Muhlhofer HML, 443, 673,  
     937  
 Murakami M, 705, 943  
 Murakami R, 285  
 Murakami Y, 819  
 Muramatsu Y, 61  
 Murawska-Cialowicz E, 1027  
 Murono K, 713, 1011  
 Murovska M, 181  
 Musio D, 455  
 Mustea A, 625  
 Mustonen P, 381  
 Muto J, 439  
 Muuronen A, 381  
 Na SJ, 749  
 Nabeshima K, 409  
 Naciute M, 181  
 Nada O, 849  
 Nadkarni A, 215  
 Nagashima T, 599  
 Naito M, 1035  
 Naito Y, 1145  
 Naito Z, 1209  
 Nakagami K, 493  
 Nakagawa M, 1089  
 Nakagawa S, 493  
 Nakahira M, 321  
 Nakaji Y, 909  
 Nakamura K, 409, 1051  
 Nakamura M, 285  
 Nakamura N, 285  
 Nakamura T, 905  
 Nakanuma S, 1051  
 Nakashima H, 591  
 Nakata A, 599  
 Nakayama H, 1225
- Nakayama T, 493  
 Nakazawa H, 769  
 Nam LV, 689  
 Namikawa T, 1019  
 Nanjo S, 475  
 Naňka O, 925  
 Narita I, 285  
 Nascimento-Gonçalves E,  
     1073  
 Nashimoto M, 579  
 Nassar S, 737  
 Natsuda K, 169  
 Neff KW, 557  
 Neki K, 683  
 Németh B, 425, 1163  
 Neumann S, 917  
 Newman EA, 779  
 Ngoc TB, 957  
 Nguemgo-Kouam P, 329  
 Ninomiya I, 1051  
 Nishi Y, 403  
 Nishihara T, 793  
 Nishikawa T, 713, 1011  
 Nishimoto A, 121  
 Nishiyama N, 573  
 Nisizawa T, 573  
 Noguchi M, 1097  
 Nogueira A, 1  
 Noh OK, 967  
 Noji T, 905  
 Nomura E, 409  
 Nomura T, 1209  
 Nonni A, 1169  
 Nonoguchi H, 403  
 Nozawa H, 713, 1011  
 Ntanasis-Stathopoulos I, 737,  
     1023  
 Nuzzo M, 151, 961  
 O JH, 749  
 Oguzturk H, 1179  
 Oh D, 861  
 Oh Y-T, 967  
 Ohbatake Y, 1051  
 Ohnishi M, 187  
 Ohta T, 1051  
 Okamoto K, 1051  
 Okamura K, 905  
 Okawara M, 591  
 Okazaki M, 1051
- Okuda C, 475  
 Okumo T, 69, 79  
 Okumura K, 285  
 Oliveira M, 1073  
 Oliveira PA, 1, 1073  
 Omae K, 769  
 Onatsu J, 381  
 Onem K, 365  
 Ono K, 705  
 Ono M, 905  
 Ono S, 169  
 Oporto F, 467  
 Opipari VP, 779  
 Orfanos SE, 885  
 Orsaria P, 101  
 Ortolan P, 387  
 Osawa H, 285  
 Oshima T, 565, 1065  
 Ota M, 909  
 Otani K, 713, 1011  
 Otsuka K, 705, 943  
 Owrang M, 661  
 Oyama K, 1051  
 Ozaki N, 811  
 Ozen A, 209  
 Packianathan S, 461  
 Pafko P, 925  
 Page N, 991  
 Palazzi M, 1215  
 Palla V-V, 1193  
 Pamio A, 151  
 Pan Y, 543  
 Panagiotopoulos N, 1023  
 Papadakis G, 259  
 Papageorgiou C, 141  
 Papaioannou N, 145  
 Papantonio N, 231  
 Papatsoutsos EG, 1047  
 Papavassiliou A, 145  
 Park HL, 749  
 Park HS, 861  
 Park M-H, 373  
 Park S-B, 1115  
 Park S-C, 349  
 Parman Y, 657  
 Patel A, 1175  
 Patel KC, 263  
 Patrini D, 1023  
 Patsouras D, 451, 501

Patsouris E, 641	Rhieu B-H, 159	Schinzari G, 833	Stanc G-M, 737
Pautov M, 979, 983	Riccio MP, 467	Schizas D, 737, 1169	Steinmann D, 949
Pavlou K, 527	Ricks-Santi LJ, 661	Schoenberg SO, 557, 1153	Stiuso P, 609
Pawlik TM, 501	Rindi G, 833	Schoenike CA, 1153	Stodolak-Zych E, 895
Pazgan-Simon M, 1027	Rino Y, 565, 1065, 1225	Schroeder K, 701	Stopa MB, 625
Pei J-S, 1059	Rizos E, 141	Schutzner J, 1197	Stramare R, 387
Pellegrinelli L, 467	Rizzo M, 695	Scognamiglio D, 467	Strojnik T, 221
Pennisi M, 415	Rosi E, 773, 1221	Scotto R, 695	Suckow MA, 55
Pepe P, 415	Rossi CR, 387	Šedý J, 925	Suganuma N, 1225
Perilli F, 125	Rossi E, 833	Seetharam AB, 1175	Sugasawa M, 321
Perisanidis C, 23	Różański P, 895	Seki M, 579	Sugiyama M, 909
Perissinotto E, 387	Rubio CA, 669	Seo M-S, 1115	Suh J-G, 861
Perri F, 1215	Rudolph Y, 1187	Shaaban SG, 461	Sun Y, 543
Perrotti F, 151	Rugiene R, 181	Shen M-Y, 585	Sunaga K, 591
Persico M, 609	Russo G, 415	Shibata M, 811	Sunagawa M, 87
Peschos D, 641	Russo I, 97	Shida A, 403	Suren C, 673, 937
Péter I, 425, 1163	Russomanno G, 609	Shields D, 159, 313	Suzuki H, 1089
Petersen NC, 619	Rutsch M, 1153	Shih L-C, 585	Suzuki R, 591, 1089
Peterson RG, 55	Ryu M-O, 349, 1115	Shih Y-L, 877, 1103	Svajdler M, 763
Petrella G, 101	Rzechonek A, 1197	Shimada M, 285, 419	Syrigos K, 641
Phuong PC, 689, 957	Sabini MG, 415	Shimoda T, 1209	Szendi K, 1163
Piccirillo M, 695	Sacher JR, 39	Shiozawa M, 565, 1065	Szponder T, 895
Pier GB, 45	Saeki T, 493	Shirataki Y, 591, 1089	Tahara M, 1035
Piessen G, 731	Safanda M, 303	Shulberg M, 701	Taina M, 381
Pires MJ, 1	Saika T, 573	Silmanowicz P, 895	Tajika Y, 69, 79
Pistolese C, 101	Saito Y, 419	Silva J, 1073	Tajima H, 1051
Pistolesi M, 1221	Sakagami H, 51, 591, 1089	Silva TG, 849	Takagi H, 69
Ploquin A, 731	Sakai S, 1051	Simon K, 1027	Takagi T, 769
Pohlig F, 443, 673, 937	Sakai Y, 169	Simonek J, 1197	Takaguri A, 599
Polivka J, 303	Sakamaki K, 565, 1065	Simou M, 243	Takahashi M, 755
Polkowska I, 895	Sakellariou S, 1169	Siristatidis C, 231	Takahashi Y, 403
Popescu R, 199, 1139	Sakurai K, 1051	Skarlis C, 1041	Takamura H, 1051
Potaris K, 451	Salakos C, 501	Skourtis EK, 175	Takano T, 493
Poulsen SS, 45	Salamalekis G, 231	Smeets R, 849	Takao S, 493
Precht C, 849	Salla C, 737	So K, 1125	Takasaki H, 1209
Priolo G, 415	Santoro C, 125	Soares CT, 481	Takasu C, 419
Prodinger P, 673	Saponeri A, 97	Sobczyńska-Rak A, 895	Takatsuki M, 169
Pulkki K, 381	Saracino A, 125	Søe NH, 45	Takeda M, 683
Puppe J, 677	Sasaki K, 1011	Sokuza Y, 187	Takenouchi A, 1145
Qian X, 701	Sato K, 61, 599	Soloviev M, 991	Takeshima H, 1089
Quickel M, 313	Sato Tsutomu, 565, 1065	Soma G-I, 573	Takeshita M, 187
Rades D, 35, 117, 239, 435, 689, 741, 745, 957	Sato Tsuyoshi, 321, 793	Son JS, 335, 373	Takimoto M, 705
Ragos V, 641	Sawazaki S, 1065	Son SJ, 373, 637	Tamada M, 811
Ragosta A, 709	Schaible T, 557	Song KY, 749	Tamiya A, 1035
Raica M, 199, 1139	Schauwecker J, 443, 673, 937	Song W-J, 349	Tamura N, 1089
Raimondi C, 1203	Schild SE, 35, 117, 435, 689, 741, 745	Sonobe S, 1035	Tanabe K, 769
Rajeh MN, 701	Schillaci O, 101	Sorrentino A, 709	Tanaka K, 1089
Rastrelli M, 387		Soyama A, 169	Tanaka T, 713, 1011
		Spartalis E, 451, 501, 1169	Tanimoto A, 1097

- Tarantino G, 709  
 Tasan E, 357  
 Taşlı H, 657  
 Tentolouris A, 737  
 Terada H, 579  
 Terakubo S, 591  
 Teraoku H, 419  
 Teymoortash A, 1159  
 Theophanides T, 1131  
 Thomas T, 779  
 Toh Y, 909  
 Tombolini V, 455  
 Tomioka K, 943  
 Tomioku M, 409  
 Tomoda T, 793  
 Tomomura A, 591  
 Tomomura M, 591  
 Tomori K, 683  
 Tomos P, 451  
 Torricelli E, 1221  
 Tosi AL, 387  
 Toulas P, 1041  
 Treska V, 763  
 Trignani M, 151  
 Tropea S, 387  
 Trovas G, 145  
 Truant S, 731  
 Tsai C-W, 585, 631, 1059  
 Tsakiris A, 1131  
 Tsangaris GT, 267  
 Tsekouras A, 1229  
 Tsiambas E, 641  
 Tsilimigras DI, 737, 1023,  
     1047, 1193, 1229  
 Tsoukalas N, 641  
 Tsuchikawa T, 905  
 Tsuda M, 755  
 Tsugawa K, 493  
 Tsuji T, 1035  
 Tuccillo C, 609  
 Turan S, 357
- Turgak O, 209  
 Turgut S, 357  
 Turtay MG, 1179  
 Tüzün E, 657  
 Twilla J, 121  
 Uchida E, 1209  
 Uchiyama H, 599  
 Uenobe M, 573  
 Ursini LA, 151  
 Usery J, 121  
 Usui M, 793  
 Uyanoglu M, 209  
 Valastro LM, 415  
 Valentini V, 961  
 Van Noord RA, 779  
 Vanni G, 101  
 Vanninen R, 381  
 Varvaras D, 101  
 Vassiliou AG, 885  
 Vavougios GD, 141  
 Vecchione A, 709  
 Velonakis G, 1041  
 Veninga T, 35  
 Vernadakis S, 307  
 Verveniotis A, 451  
 Vijayakumar S, 461  
 Villiotou V, 259  
 Vinciguerra M, 709  
 Vitali GP, 141  
 Vitoratos N, 243  
 Vogiatzi P, 231  
 Vogler N, 1153  
 Volpe A, 125  
 Voltolini L, 773, 1221  
 Von Eisenhart-Rothe R, 673,  
     937  
 Vrakas S, 527  
 Vuagnat P, 731  
 Vundinti BR, 215  
 Wakame K, 599  
 Wang Hong, 39, 159, 313
- Wang Huisun, 855  
 Wanibuchi H, 187  
 Warm M, 677  
 Watanabe H, 591  
 Watanabe J, 493  
 Watanabe M, 705, 943  
 Watanabe T, 713, 1011  
 Watrowski R, 251  
 Wegener G, 949  
 Weis M, 557  
 Weiss MJ, 1169  
 Wiegand S, 1159  
 Winton JC, 121  
 Wipf P, 39, 159  
 Wong MN, 1175  
 Wu C-N, 585  
 Wu H-C, 631  
 Wu M-F, 877  
 Wu S, 701  
 Xu X, 543  
 Yamabe H, 285  
 Yamada S, 419  
 Yamada T, 1209  
 Yamaguchi K, 755  
 Yamaguchi T, 1051  
 Yamamoto Y, 713, 755  
 Yamashita T, 1225  
 Yamato M, 793  
 Yamazaki H, 403, 1225  
 Yamazaki T, 403  
 Yamochi-Onizuka T, 705  
 Yan W, 461  
 Yanaga K, 683  
 Yang C, 461  
 Yang M-Y, 841  
 Yang Z, 543  
 Yasuda K, 713  
 Yasui H, 1145  
 Yaylim I, 357  
 Yeh C-T, 723
- Yeh M-Y, 877, 1103  
 Yencilek E, 205  
 Yencilek F, 205  
 Yetimler B, 657  
 Yildirim A, 205  
 Yilmaz SG, 205, 873  
 Yoda T, 321, 793  
 Yokose S, 51, 591  
 Yoshida D, 909  
 Yoshida T, 1225  
 Yoshikawa M, 419  
 Yoshikawa T, 565, 1065  
 Yoshikawa Y, 1145  
 Yoshimoto T, 419  
 Yoshizawa K, 1145  
 Youn H-Y, 349, 1115  
 Yu S-K, 855, 1125  
 Yuan H, 543  
 Yucel N, 1179  
 Zahn K, 557  
 Zambelis T, 259  
 Zanello PP, 931  
 Zappulo E, 467, 695  
 Zemła A, 801  
 Zhang L, 543  
 Zhang M, 87  
 Zhang W, 701  
 Zhang X, 39, 159, 313  
 Ziegler P, 625  
 Ziegler S, 625  
 Zikou AK, 511  
 Zimmer F, 557  
 Zimmermann T, 443  
 Zimmermann U, 625  
 Zinkeviciene A, 181  
 Zografos GC, 1229  
 Zöllner FG, 557  
 Zuwala-Jagiello J, 1027  
 Zwahr C, 849  
 Źylińska B, 895

## **Instructions for Authors 2017**

**General Policy.** IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research. The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to peer-review, when appropriate, by two members of the Editorial Board. All manuscripts submitted to IN VIVO are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

**Open Access Policy.** IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of USD 575.00 for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 58.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO online will keep the volume and issue numbers, as well as page numbering.

**Copyright.** Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of IN VIVO articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and html files of all articles published in IN VIVO are the property of the publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear **at the end** of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are not subject to color charges.

**Tables.** All tables should appear **at the end** of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of “Index Medicus” and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. Anticancer Res 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: Receptors for Reproductive Hormones (O’ Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergery’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “NCT”). Please note that there is no space between the prefix “NCT” and the number. Example: NCT00001789.

**Ethical Policies and Standards.** IN VIVO agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html> In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iilar-anticancer.org](mailto:journals@iilar-anticancer.org)

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Galley proofs should be returned corrected to the Editorial Office by email within two days.

### **Specific information and additional instructions for Authors**

1. In Vivo (IV) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.
3. Each manuscript submitted to IV is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to IV, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

4. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
5. Authors should pay attention to the following points when writing an article for IN VIVO:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
8. Articles submitted to IN VIVO may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions for authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to IV.
  - plagiarism is detected by plagiarism screening services.(Rejection rate (2016): 59%).
9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to [journals@iilar-anticancer.org](mailto:journals@iilar-anticancer.org).
11. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.  
(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of IV).

**Copyright© 2017 – International Institute of Anticancer Research (G.J. Delinasios).** All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

**General Policy:** IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of human physiology, pathology and disease management. The special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models for biomedical research. The principle aim of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports (a) the aims and research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

**Publication Data:** IN VIVO is published bimonthly online-only and open access by the International Institute of Anticancer Research. Each annual volume comprises six issues. Annual Author and Subject Indexes are included in the sixth issue of each volume. IN VIVO Vol. 18 (2004) and onwards appears online with Stanford University HighWire Press. All published articles are deposited in PubMed Central.

**Copyright:** Once a manuscript has been published in IN VIVO, the legal ownership of all published parts of the paper has passed from the Author to the Journal.

**Open Access Policy:** Open Access Policy: IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to contribute an online publication fee of US\$ 575 for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged US\$ 58,00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO online will keep the volume, issue, and page numbering.

Articles in IN VIVO are regularly indexed in bibliographic services, including PubMed, Index Medicus, MEDLINE, Biological Abstracts, BIOSIS, Chemical Abstracts, Excerpta Medica, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, CANCER-LIT Database, University of Sheffield Biomedical Information Service (SUBIS), Current Clinical Cancer, AIDS Abstracts, Progress in Palliative Care, Update-Research Information Systems Inc., Inpharma-Reactions Datastar, BRS, Reference Update (I.S.I.), Research Alert (I.S.I.), Google Scholar, BioBase, MedBase, Investigational Drugs Database, VINITI Abstracts Journal, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Databases.

The Editors and Publisher of the journal IN VIVO accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing herein.

**All correspondence** (status of submitted manuscripts, change of address, general editorial matters, advertising rate requests) should be addressed to the Editorial Office, e-mail: [journals@iilar-anticancer.org](mailto:journals@iilar-anticancer.org). Articles should be submitted only through our online submission system ([www.iiar-submissions.com](http://www.iiar-submissions.com)).

**Editorial Office:** International Institute of Anticancer Research (IIAR), 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O.B. 22, Attiki 19014, Greece. Tel & Fax: +30-22950-53389.

**U.S. Branch:** Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ, 07732, USA. e-mail: [journals@iilar-anticancer.org](mailto:journals@iilar-anticancer.org).

**E-mails:**

**Editorial Office:** [journals@iilar-anticancer.org](mailto:journals@iilar-anticancer.org)

**Managing Editor:** [editor@iilar-anticancer.org](mailto:editor@iilar-anticancer.org)

For more information about IN VIVO and the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, please visit the IIAR website: [www.iilar-anticancer.org](http://www.iilar-anticancer.org); [www.iv.iilarjournals.org](http://www.iv.iilarjournals.org)

Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved